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Ovarian carcinoma is one of the most common types of gynecological cancer and the one 
with the highest mortality. It was diagnosed in 1288 women in The Netherlands in 2012, while 
1028 women died from this disease1. It is often already in an advanced stage at diagnosis, 
as symptoms of disease are non-specific and knowledge of the origin of ovarian carcinoma 
is poor. Ovarian carcinoma is a collective term for carcinomas with different histological 
subtypes, differentiation grades, clinicopathological characteristics and prognosis. The four 
main histological subtypes of ovarian carcinoma are serous, endometrioid, clear cell and 
mucinous carcinomas, accounting for 70%, 10%, 10% and 5%, respectively2.
Although, improvements have been made in debulking surgery and chemotherapeutic 
options, estimated overall survival of these women has improved only minimally. Overall five-
year relative survival in women diagnosed with ovarian carcinoma increased from 36% in 
1989-1993 to 42% in 2004-2009, and for advanced stage patients from 18% to 28%1,3. To 
accomplish a significant improvement in overall survival, it is essential to determine the route 
of tumor development in order to be able to diagnose these women in an earlier stage of 
disease. 
Traditional View on the Origin of Ovarian Carcinoma and Recent Ideas
Traditionally, all ovarian carcinomas were expected to arise from the ovarian surface 
epithelium (mesothelial lining). Fathalla described in 1971 the ‘incessant ovulation hypothesis’ 
that proposes that constant damage and repair by numerous ovulations makes the ovarian 
surface epithelium vulnerable to malignant transformation4. This theory was strengthened 
by Cramer and Welch, suggesting that damaged ovarian surface epithelium is vulnerable 
to transformation as it is surrounded by an excess of gonadotrophins5. The ovarian surface 
epithelium is thought to undergo invagination into the underlying ovarian stroma at the time 
of ovulation and forms ovarian inclusion cysts (OIC). A process of “metaplasia”, followed 
by malignant transformation, is thought to be responsible for the development of different 
histological tumor types. However, OICs are invariably present in women at high risk of 
developing ovarian carcinoma and in controls, and metaplastic changes specific for the 
different histological tumor types have not been found6-8. Decades of diligent examination 
could not reveal other potential precursor lesions in the ovaries9,10. 
Remnants of the Müllerian ducts are also suggested as a putative source of origin for 
ovarian carcinoma as they can explain for the typical Müllerian phenotype of most ovarian 
carcinomas. These remnants, or the “secondary Müllerian system”, include a variety of 
epithelial structures such as paraovarian and paratubal cysts, or endosalpingiosis. However, 
ovarian carcinomas are rarely seen restricted to these anatomic areas and precursor lesions 
Introduction
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have not been found here.
Nowadays, it is thought that ovarian carcinomas arise from tissues that are embryologically 
derived from the Müllerian ducts (paramesonephros), instead of the Wollfian ducts 
(mesonephros) that form the gonads, developing into the ovary11. The Müllerian ducts are 
derived from the intermediate mesoderm of the urogenital ridge, as an evagination of the 
peritoneum, and arise adjacent to the gonads (Figure 1). Müllerian ducts develop in early 
embryogenesis into the upper part of the vagina, uterus and fallopian tubes12,13. The normal 
epithelial lining of these Müllerian derived tissues resemble histological characteristics of 
the main subtypes of ovarian carcinoma: the serous subtype resembles the tubal fallopian 
epithelial cells, the endometrioid and clear cell subtypes show similarities with the endometrial 
cells, and the mucinous subtype with the endocervical cells. The association of ovarian 
carcinoma and Müllerian derived epithelium is confirmed with correlating gene expression 
patterns14. As a result, ovarian carcinoma is described to have a Müllerian phenotype, and it 
is no longer thought that all ovarian carcinomas develop following one and the same pathway, 
but that histological tumor types originate from different carcinogenic routes. 
Different routes of carcinogenesis is supported by the different degrees of risk reduction 
to develop ovarian carcinoma after tubal ligation and/or hysterectomy for the four main 
histological subtypes of ovarian carcinoma. Compared with women who did not have a tubal 
ligation, women who underwent the procedure had a reduced risk of 52% for endometrioid 
carcinoma, 48% for clear cell carcinoma, 32% for mucinous carcinoma, and 19% for serous 
carcinoma15. 
Recent View on the Origin of Serous Ovarian Carcinoma
High-grade serous ovarian carcinoma concerns the vast majority of ovarian carcinomas 
and is the subtype on which this thesis focuses2,16. High-grade serous carcinomas harbor 
a p53 mutation in 70-97% and a BRCA1 or BRCA2 mutation in approximately 10-20%17-20. 
The origin of serous ovarian carcinoma is subject of discussion. The fallopian tubes were 
suggested as a likely source of origin, as their Müllerian derived epithelium has direct contact 
with the ovaries, and the secretory cells of the normal tubal epithelium are morphologically 
and genetically associated with serous cancer cells14,21,22. Piek et al., extensively screened the 
tubal epithelium of BRCA-mutation carriers at risk of developing ovarian carcinoma showing 
dysplastic epithelial changes23. These dysplastic epithelial changes were defined as serous 
tubal intraepithelial carcinoma (STIC), and described as non-invasive serous carcinoma24. 
STIC is hypothesized to develop in serous ovarian carcinoma by exfoliation of loose cohesive 
cells that migrate and implant onto the peritoneum or ovarian surface21,25-27. It is predominantly 
identified in the plicae of the fimbrial end22,24. In order to maximize exposure and to enable 
optimal microscopic view of the plicae, the SEE-FIM (Sectioning and Extensive Examination of 
the FIMbria) protocol was introduced28. Following the protocol, the fimbriated end is amputated 
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at the infundibulum and cut longitudinally in four sections, after which the fallopian tube is 
cross-sectioned at 2-3 mm intervals (Figure 2)28. An overview of studies investigating the tubal 
epithelium for STIC in serous ovarian cancer patients after embedding tissue in accordance 
with the SEE-FIM protocol is shown in Table 1. These studies reported a prevalence of STIC 
in 19-61% (Table 1)29-32. 
Figure 1: Development of the female  
genital system. 
A) The paramesonephric (Müllerian) ducts (1) 
arise during the sixth week of embryogenesis by 
invagination of a ribbon of thickened coelomic 
epithelium, just lateral to the  
mesonephric (Wolffian) ducts (2). Following, the 
mesonephric ducts degenerate in absence of testis 
determining factor12,13.
3. Gonad.
4. Mesonephros.
The caudal parts of the paramesonephric ducts 
(5) fuse with the sinus tubercle to form a tube with 
a single lumen, developing into the uterus and 
superior part of the vagina.
B) 
1. The unfused, superior part of the 
paramesonephric duct develops into the  
fimbria (infundibulum of the oviduct) 12,13. 
2. After the mesonephric ducts are degenerated 
remnants can be seen, such as the epoophoron, 
paroophoron, and Gartner’s cysts.
3. The oviduct (fallopian tube).
4. Ovary.
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There is no direct evidence that all serous ovarian carcinomas arise from the fallopian 
tubes, and/or from STIC. Several additional pathways have been proposed for the tumor 
development of serous ovarian carcinoma in tubal epithelium. Both ‘p53 signatures’ and benign 
secretory cell outgrowth (SCOUT) have been proposed to represent putative steps in serous 
carcinogenesis occurring prior to or in parallel with STIC. A ‘p53 signature’ is defined as an 
area with strong immunohistochemical expression of p53 for at least twelve consecutive nuclei 
of the tubal epithelium33,34. The SCOUTs represent linear arrays of at least 30 consecutive 
secretory cells with absent or reduced PAX2 expression and are found in the distal tubal 
epithelium35,36. If ‘p53 signatures’ and/or SCOUTS have indeed a role in the carcinogenesis 
of serous ovarian cancer is not yet known, as they are also commonly identified in controls 
36,38. Others used the term ‘serous tubal intraepithelial lesions’(STILS) to describe a spectrum 
of epithelial changes ranging from normal appearing tubal epithelium, expressing p53, to 
lesions with increasing degrees of cytologic atypia that fall short of STIC39. Additional gene 
alterations need to be identified to differentiate precursors form normal variations of disturbed 
epithelium. 
It has been hypothesized that premalignant cells do not develop in the fallopian tube in 
general, but in the fallopian tube-peritoneal junction41,42. This junction is a transformation 
zone of tubal mesothelial serosa and tubal epithelium, and is located in the outer edge of the 
fimbria41,42. Transitional epithelial junctions in general are prone to malignant transformation, 
Figure 2: The SEE-FIM (Sectioning and Extensively Examining of the Fimbriated end) protocol. The fimbriated end was 
amputated at the infundibulum and cut longitudinally in four sections to maximize exposure en optimized histological 
view of the tubal plicae. The fallopian tube was cross-sectioned at intervals of 2-3 mm. (Adapted from Crum CP, et al. 
The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007 Feb;19: 3-9)
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as for example cervical carcinoma develops in the cervical squamocolumnar junction. 
Some high-grade serous ovarian carcinoma might originate from low grade serous 
carcinomas, developing from borderline tumors43. Another proposed pathway is that normal 
tubal epithelium could implant on the ovary to form ovarian inclusion cysts lined with tubal 
epithelium at the time of ovulation when the surface ovarian epithelium is ruptured43. This 
hypothesis follows the same route as described earlier for ovarian inclusion cysts (OIC), but 
with the invagination of tubal epithelium instead of ovarian epithelium. However, this would 
imply the identification of inclusion cyst lined with tubal epithelium in women at risk of ovarian 
carcinoma, but to our knowledge these inclusion cysts are not regularly identified.
Our research group recently suggested that the endometrium might be a potential source 
of a proportion of serous ovarian carcinomas44,45. Uterine papillary serous carcinoma (UPSC) 
is thought to develop from a carcinoma in situ termed endometrial intraepithelial carcinoma 
(EIC), that was introduced by Sherman in 1992 and formalized by Ambros in 199546,47. 
Occasionally, EIC is seen without concordant invasive endometrial carcinoma, but with foci of 
extra uterine disease, including foci on the ovarian surface, tubal epithelium or peritoneum48,49. 
It is hypothesized that EIC may also be a precursor lesion for serous ovarian carcinoma in a 
proportion of casus. However, knowledge on the prevalence of endometrial pathology, other 
than the prevalence of double primary endometrial carcinomas, is limited in ovarian cancer 
patients. 
Serous ovarian carcinoma
Study Year *SEE-Fim protocol N STIC
N (%)
Tang et al. (32) 2012 Yes 32 6 (19)
Przybycin et al. (30) 2010 Yes 33 20 (61)
Roh et al. (40) 2009/2010 Yes 56 20 (36)
Kindelberger et al. (29) 2007 Yes 43 20 (47)
Salvador et al. (31) 2008 **No, total 16 7 (44)
Overall 2007-2012 180 73/180 (41)
* SEE-Fim protocol (Sectioning and Extensive Examining of the Fimbriated end). 
**The fallopian tubes are embedded in total for histological examination.
Table 1: Frequency of serous tubal intraepithelial carcinoma (STIC) in women diagnosed with 
serous ovarian carcinoma, provided that tissue is embedded in accordance with the SEE-Fim 
protocol.
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Common Denominators between Serous Ovarian Carcinomas and Serous Uterine 
Carcinomas 
The serous histology type represents the majority of the ovarian carcinomas, but serous 
carcinomas can also occur in the tubes, the peritoneum, the endometrium and rarely even in 
the cervix. The carcinogenesis of serous ovarian carcinomas is still widely discussed. Yet, the 
carcinogenetic route of serous endometrial carcinoma, UPSC, is much more accepted. UPSC 
accounts for 10% of endometrial carcinomas. Just like serous ovarian carcinoma, UPSC 
exhibits an aggressive behavior and has a propensity of spreading to other sites in the pelvis 
in an early stage of disease. The intraepithelial carcinoma, EIC, is defined as noninvasive 
serous carcinoma with malignant transformation of the surface epithelium or endometrial 
glands, without myometrial invasion, and can be found in up to 90% of UPSC cases46,50,51. 
Characteristics of women with serous ovarian carcinoma and UPSC are almost identical. 
Although, UPSC cases tend to be slightly older with an average age of seventy compared to a 
median age of sixty for women diagnosed with serous ovarian carcinoma52. Adjuvant treatment 
management for women diagnosed with serous endometrial carcinoma used to consist of 
radiotherapy. However, the high frequency of extra-uterine disease, high recurrence rates 
and similar histological and biological tumor characteristics as serous ovarian carcinoma led 
to a change in treatment protocol. Treatment for serous endometrial carcinomas is nowadays 
more and more comparable to the treatment for serous ovarian carcinoma, with adjuvant 
or neoadjuvant chemotherapy consisting of a combination of carboplatin and paclitaxel. 
Although, less sensitivity of serous endometrial carcinoma has been mentioned for platinum 
based chemotherapy53,54.
Morphologically, UPSCs and serous ovarian carcinomas cannot be distinguished and 
recent studies showed that they also share their molecular denominators. The most typical 
characteristic is that they harbor a TP53 mutation in 70-97%18-20,55. Whole genome sequencing 
showed similar molecular profiles for UPSC and high-grade serous ovarian carcinomas with 
low mutation ratios in comparison to other histology subtypes19,55. 
Serous ovarian carcinomas and UPSC are often already broadly distributed at diagnosis, 
which makes it difficult or even impossible to determine their primary location. In routine 
practice, determination of the primary site is largely based on the location of the bulk of the 
carcinoma and can be supported by the presence of a carcinoma in situ specific for that 
tumor site. Though, this method has not been validated, is often arbitrary and susceptible for 
misclassification. 
Occasionally, EIC is seen concordant to serous ovarian carcinoma without concordant 
invasive endometrial carcinoma, and our research group hypothesized that EIC may be a 
precursor lesion for serous ovarian carcinoma in a proportion of casus56. Others postulated 
that STIC might represent a potential precursor for a proportion of UPSC cases48. Among 
others, the role of these intraepithelial carcinomas concordant to serous ovarian carcinoma 
1G
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and UPSC needs further clarification before we are able to determine their primary location. 
The clinical value of accurate differentiation of primary sites of serous carcinomas can be 
questioned as they are to a greater extent treated similarly. Nevertheless, it is of importance 
to discriminate UPSC from serous ovarian carcinoma in order to enable accurate analysis of 
their carcinoma characteristics, optimal treatment management, prognosis, and to improve 
insight into their route of tumor development.
Tools with Potential to Discriminate Serous Carcinomas
Some differences have been reported for UPSC and serous ovarian carcinoma, like 
immunohistochemical expression of Wilms tumor 1 protein (WT1). Yet, they have not been 
thoroughly analyzed for their discriminative value between different primaries of serous 
carcinomas. Expression of WT1 has been suggested to show noticeable differences between 
UPSC and serous ovarian carcinomas, and could be an important tool in their discrimination. 
WT1 is a mesothelial marker, showing strong, nuclear expression in the normal ovarian 
surface epithelium compared to no expression in the normal endometrium57,58.
Apart from genetic characteristics, epigenetic characteristics can be analyzed to compare 
UPSC and serous ovarian carcinoma, as they are supposed to be tumor type specific59. 
Most epithelial malignancies result from the accumulation of several genetic and epigenetic 
alterations in oncogenes, tumor suppressor genes, or genes involved in DNA repair60. 
Epigenetic alterations are changes in the gene expression that are not due to alterations in 
the DNA sequence. DNA methylation is a way of epigenetic alteration, defined as the addition 
of a methyl group to the DNA. Methylation of normally unmethylated CpG islands in the gene 
promoter regions may cause progressive epigenetic inactivation of growth-inhibitory genes, 
such as tumor suppressor genes or genes involved in DNA repair. The studies reporting on 
methylation levels in UPSC or serous ovarian carcinoma showed that serous carcinomas 
can be differentiated from other histology subtypes of carcinoma based on their methylation 
profiles19,55,61-67. However, these studies did not compare methylation profiles of different 
primaries of serous carcinoma. 
Aims of the Thesis
The origin of serous ovarian carcinoma has not been clarified yet. The fallopian tubes 
originating from the Müllerian ducts in early embryogenesis are thought to represent the 
primary origin of at least a part of the serous carcinomas. Müllerian derived epithelium will be 
extensively analyzed in women diagnosed with (serous) ovarian carcinoma and in controls. In 
this thesis we focused on the following themes;
• To accurately determine the prevalence of tubal intraepithelial carcinoma in BRCA 
mutation carriers and their location in the tubes.
• To gain more insight into normal tubal epithelial and endometrial variation in asymptomatic 
18
women.
• To improve knowledge on endometrial and tubal intraepithelial carcinomas in women 
diagnosed with (serous) ovarian carcinoma, when meticulously examining the entire 
endometrium.
• To identify tools to differentiate primary serous ovarian carcinoma from UPSC, including 
WT1 immunohistochemistry and methylation profiles.
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Outline of the Thesis
In this thesis the Müllerian derived epithelium was meticulously assessed for (potential) 
precursor lesions in women at high risk of developing serous ovarian carcinoma and women 
diagnosed with (serous) ovarian carcinoma, and in controls.
The tubal epithelium is thought of as a plausible source of serous carcinoma as it shows 
strong resemblance with the serous carcinoma type and a precursor has been identified. 
In chapter 2 we histologically examined the tubal epithelium of a large cohort of BRCA-
mutation carriers to determine the prevalence of tubal intraepithelial carcinoma, minor atypia 
and hyperplasia in these women, at increased risk of developing serous ovarian carcinoma. 
In chapter 5 this examination was carried out for a prospective cohort of serous ovarian 
carcinomas. Knowledge of normal tubal epithelial variation is poor. To gain insight into this 
variation, we performed identical analyses in control cases from patients who underwent 
bilateral salpingo-oophorectomy for benign reasons.
There is no direct evidence that the tubal epithelium accounts for all serous carcinomas. 
Apart from research of the fallopian tubes and ovaries, extensive research of remaining 
Müllerian derived tissues in ovarian cancer patients is lacking. In chapter 3 the endometrium 
was extensively studied in a large cohort of ovarian carcinomas and the prevalence of 
identified endometrial lesions was compared between the four main histological subtypes of 
ovarian carcinoma. 
Routine endometrial sampling includes the embedding of one or two endometrial sections 
if the endometrium is macroscopically non-suspect for endometrial cancer. Although, 
endometrial intraepithelial carcinomas or other lesions are not always diffusely present or 
they occur in a restricted area of the endometrium. A sampling method was developed, the 
SEE-End (Sectioning and Extensive Examination of the Endometrium) protocol, to enable 
structural embedding of the endometrium in total. Following, the entire endometrium was 
microscopically examined in a cohort of asymptomatic women who underwent hysterectomy 
because of uterovaginal prolapse and in a cohort of women who underwent debulking surgery 
because of serous ovarian carcinoma (chapter 4 and 5).
Determining the primary location of serous carcinoma can be challenging in case of 
coexistence of (non)invasive serous ovarian and endometrial carcinoma. Efforts need to be 
made to develop classification methods for serous carcinomas in order to personalize treatment 
management and to elucidate the biology of these carcinomas. Immunohistochemical 
20
expression of Wilms tumor 1 is suggested to be of value in differentiating serous endometrial 
from serous ovarian carcinoma. Further, DNA-methylation levels of different primary locations 
of serous carcinoma have not yet been compared. We analyzed the discriminative capability 
of WT1 and methylation levels of a selection of tumor suppressor genes in a cohort of serous 
ovarian carcinoma, UPSC and in cases with widespread serous carcinomas involving both the 
endometrium and ovaries (chapter 6 and 7). 
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Abstract
Objective: A precursor lesion for ovarian carcinoma, tubal intraepithelial carcinoma (TIC), has 
been identified in BRCA-mutation carriers undergoing prophylactic bilateral salpingo-oophorectomy 
(pBSO). Other lesions were also identified in fallopian tubes, but different terminology, interpretation, 
and lack of knowledge of normal epithelium, have hampered to unravel their possible role in 
carcinogenesis. The aim of this study is to classify tubal epithelial lesions in BRCA-mutation carriers 
and controls to enable comparison of prevalence, area of localization, and possible malignant 
potential.
Materials and Methods: Two hundred twenty-six BRCA1/2-mutation carriers were included; ovaries 
and fallopian tubes, embedded completely, were reviewed. Controls included 105 women who 
underwent BSO for non-malignant reasons. Tubal epithelial lesions included the following categories: 
hyperplasia, minor epithelial atypia, TIC, and invasive carcinoma.
Results: Tubal neoplasia was identified in 7.1% (invasive carcinoma, 0.9%; TIC, 6.2%) of BRCA-
mutation carriers compared to none in controls (p=0.004, Fisher’s exact test). Hyperplasia and minor 
epithelial atypia were identified in 41.6% BRCA-mutation carriers and compared to 58.1% in controls 
(p=0.005, Pearson’s Chi square). Invasive carcinoma and TIC showed preference for the fimbrial 
ends (p=0.027, Pearson’s Chi square), while hyperplasia and minor epithelial atypia displayed more 
variation in localization. 
Conclusions: Invasive tubal carcinoma and TIC were limited to BRCA-mutation carriers, whereas 
hyperplasia and minor epithelial atypia were commonly found in both BRCA-mutation carriers 
and controls. It is suggested that hyperplasia and minor atypia represent variations of normal 
tubal epithelium instead of premalignant lesions. Furthermore, total salpingectomy is strongly 
recommended as most but not all TIC occurred in the fimbriae. 
2Tubal epithelial lesions in salpingo-oophorectom
y specim
ens of B
R
C
A
-m
utation carriers and controls
29
Introduction
Ovarian carcinoma is a highly aggressive disease which is most often diagnosed in an 
advanced stage. The majority of cases exhibit serous histology which can either be ovarian, 
fallopian tube, or peritoneal in origin1. Until now these three localizations of serous carcinomas 
are considered as a single disease entity (“ovarian carcinomas”) with respect to treatment and 
prognosis. Over the last decades the pathogenesis of ovarian carcinoma has been subject 
to debate. The traditional view of ovarian carcinogenesis assumes that ovarian carcinoma 
originates from the ovarian surface epithelium (mesothelium), which invaginates into the 
underlying stroma, resulting in epithelial inclusion cysts that eventually undergo malignant 
transformation2. However, these epithelial inclusion cysts were invariably present in both high 
risk cases and controls3-5. Recently, a predisposition for ovarian carcinoma was discovered 
in the fallopian tubes of women with a germline BRCA-mutation6,7. Prophylactic bilateral 
salpingooophorectomy (pBSO) is performed in the majority of BRCA-mutation carriers, 
which reduces the risk of ovarian carcinoma by 80%8,9. Incidental findings of occult invasive 
carcinoma and precursor lesions such as serous tubal intraepithelial carcinoma (TIC) were 
found in prophylactically removed fallopian tubes from women with a BRCA-mutation6,7. 
Recent studies have established that TIC is present in 1–17% of these women10-17. 
Histopathological investigation of fallopian tube specimens of women diagnosed with serous 
ovarian carcinomas reported the presence of TIC in up to 50% of these women11,18,19. Recent 
morphologic and molecular genetic studies provided compelling evidence that a proportion 
of primary serous ovarian tumors actually arise from these precursor lesions; unique and 
identical p53 mutations were found in both the serous ovarian carcinoma and corresponding 
TIC, indicating a monoclonal relation20-22. It is hypothesized that (pre)malignant cells of the 
tubal epithelium may exfoliate into the tubal lumen and migrate by retrograde flow to the 
abdominal cavity; implantation of these cells onto the peritoneum or ovarian surface might 
result in the development of serous carcinomas8,20,23. 
Histological entities other than TIC were also described in the tubal epithelium, for which 
various terminologies were used such as dysplasia, atypical hyperplasia or mucosal epithelial 
proliferations15. Because of difficulties in interpretation it is still unclear whether all these 
subtypes have a causal role in the development of tubal or ovarian carcinoma. Furthermore, 
because most studies did not include a proper control group of healthy women without a BRCA-
mutation, knowledge of normal tubal epithelium is poor. This knowledge of tubal epithelial 
lesions in the general population is essential to enable differentiation of true premalignant 
lesions from lesions representing variants of normal tubal epithelium. 
In this study, we report on tubal epithelial lesions in the largest cohort to date of women with 
a confirmed BRCA1/2 mutation who underwent pBSO, in comparison to a large control group 
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of women that underwent BSO for non-malignant reasons. Identified prevalences and areas 
of localization in the tubes will be compared between both groups to enable identification of 
lesions representing possible premalignancies and lesions that are most likely variations of 
normal tubal epithelium. In addition, a scheme for classification of tubal epithelial lesions is 
suggested. 
Materials and Methods
Clinical Data
Between January 1996 and December 2009, all women with a known germline BRCA1/2 
mutation opted for pBSO at the Radboud University Nijmegen Medical Centre (RUNMC), 
The Netherlands, were identified. Patients with surgery for preoperatively suspected ovarian 
or tubal lesions were not included in this study. The Dutch nation-wide pathology database 
(PALGA) was used to identify a control group of women who underwent BSO at the RUNMC 
between 1999 and 2009. The control group included specimens of 105 women who underwent 
hysterectomy and/or salpingo-oophorectomy with a non-malignant diagnosis: uterine 
leiomyomatosis (n=42), mucinous cystadenoma (n=19), serous cystadenoma (n=14), fibroma 
(n=6), endometrial hyperplasia with or without atypia (n=6), mature teratoma (n=5), ovarian 
torsion (n=4), endometriosis (n=3), uterovaginal prolapse (n=3) or gynecological complaints 
such as meno- or metrorhagia without a distinct histopathologic diagnosis (n=3). 
Clinical and histopathological data were collected for each patient using a standardized 
form. Data collected included the BRCA-mutation status, age, menopausal status, presence 
of earlier breast carcinoma and management of the breast carcinoma. On behalf of the 
research ethics committee of the RUNMC, the study has been carried out in accordance 
with the applicable rules concerning the review of research ethics committees and informed 
consent.
Pathology
All pBSO specimens of BRCA-mutation carriers were completely embedded, according to 
standard protocol. The fallopian tubes were cross sectioned at 3 mm interval, except for the 
fimbrial ends that were sectioned longitudinally to enable maximum exposure of the tubal 
plicae. One haematoxylin and eosin stained section was produced from each paraffin block. 
Fallopian tube specimens of control cases were not completely embedded. From these 
fallopian tubes representative sections of the fimbria, ampulla and/or isthmus were selected 
and embedded for histological examination. All available tubal sections were reviewed by 
two pathologists (MB, JB) with ample experience in gynecological pathology, being blinded 
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for clinical patient characteristics. Tubal or ovarian epithelial lesions and their locations were 
recorded. Consensus was reached concerning the criteria for tubal epithelial lesions before 
the start of the present study. In case of discrepant diagnoses consensus was reached 
between both pathologists. In the present study, the following entities were distinguished 
in the fallopian tubes: benign epithelium, hyperplasia, minor epithelial atypia, TIC (tubal 
intraepithelial carcinoma, non invasive severe dysplasia and carcinoma in situ), and (occult) 
tubal invasive carcinoma. 
Benign fallopian tube 
The normal fallopian tube is lined by non stratified epithelium with a mixture of three cell types 
(Figure 1). Ninety percent of the tubal mucosa is layered by secretory and ciliated cells. The 
third cell type is the intercalated cell, which is inconspicuous and considered to be a secretory 
cell as well.
Hyperplasia
Tubal hyperplasia is defined as cellular crowding, stratification, occasional tufting of cells, 
some loss of nuclear polarity, but the absence of nuclear atypia. Cellular crowding is visible 
when the number of secretory cells exceeds the number of ciliated cells (Figure 2A).
Minor epithelial atypia
Features for histological diagnosis of minor epithelial atypia are slightly enlarged, rounded nuclei 
Figure 1: 
Benign fallopian 
tube epithelium 
with secretory and 
ciliated cells (level of 
magnification: 200x; 
level of magnification 
of inset: x400)
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with irregular cell membrane outlines, slightly enlarged nuclear/cytoplasm ratio, nuclei with slight 
loss of polarity and inconspicuous nucleoli (Figure 2B). Minor epithelial atypia is not visible at low 
power magnification. It comprises epithelial lesions that fulfill some but not all of the criteria for TIC. 
Tubal intraepithelial carcinoma (TIC)
Tubal intraepithelial carcinoma is identifiable at low power magnification, displaying a row 
of dark and thickened epithelium. It is characterized by disorganized cellular crowding and 
nuclear stratification, and consists of secretory cells in absence of ciliated cells. Other features 
include mitotic figures, high nuclear/cytoplasm-ratio, nuclear pleomorphism with loss of 
polarity and prominent nucleoli (Figure 2C).
Figure 2: Tubal epithelial lesions (level of magnification: x200)
A) Fallopian tube epithelium with hyperplasia, showing cellular crowding, but without atypical nuclei (arrow: mitotic 
figure). 
B) Minor epithelial atypia in the fallopian tube showing cellular crowding, slight cellular atypia and nuclei with small 
nucleoli, but without loss of polarity of the epithelial cells (arrows). 
C) Tubal intraepithelial carcinoma (TIC) with cellular crowding, stratification of nuclei, loss of polarity and severe 
atypia of the nuclei.
D) Fallopian tube carcinoma, including overlying atypical epithelium.
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Tubal invasive carcinoma
Histological features of tubal invasive carcinoma are identical to TIC, but with the addition of 
an invasive component (Figure 2D). 
Statistical Analysis
Pearson’s Chi square and, if appropriate, the Fisher’s exact test were used to test 
associations between categoric variables. The Kruskal–Wallis and Mann–Whitney U test were 
used to compare medians between different independent samples. All statistical analyses 
were performed using SPSS software version 18.0 (SPSS Inc., Chicago, IL) and p<0.05 (two-
sided test) was considered statistically significant.
Results
A total number of 226 women with a confirmed BRCA-mutation were included in the current 
study (149 BRCA1 and 77 BRCA2 mutations). Also, 105 controls were included. Women with 
a BRCA-mutation had a median age of 44 years (range 24–70) compared to controls with a 
median age of 48 years (range 22–60) (p=0.04, Mann–Whitney U test; Table 1). The median 
age specified for type of BRCA-mutation was 42 years for the BRCA1 mutation carriers and 
48 years for the BRCA2 mutation carriers. Distribution of menopausal status was comparable 
for both groups; 40% of the BRCA-mutation carriers were postmenopausal and 32% of the 
controls (85 of 212 vs 33 of 103; p=0.17, Pearson’s Chi square; Table 1). Median number of 
parity was two for both BRCA-mutation carriers and controls, but the BRCA-mutation carriers 
had more often three or more children compared to controls (Table 1). Breast carcinoma 
prior to BSO was significantly more often diagnosed in BRCA-mutation carriers compared to 
controls (81 of 226 (36%) vs 1 of 105 (1%); p<0.001, Pearson’s Chi square; Table 1).
Tubal Epithelial Lesions
The median number of sections reviewed from the fallopian tubes was 17 (range 2–33) 
for BRCA-mutation carriers and six (range 1–20) for controls (p<0.001, Mann–Whitney U 
test). Of the 226 women with a BRCA-mutation, 116 (51%) were diagnosed with benign tubal 
epithelium and in 110 (49%) a tubal epithelial lesion was detected: 43 (19%) cases showed 
hyperplasia, 51 (23%) minor epithelial atypia, 14 (6%) a TIC, and two (1%) an invasive tubal 
carcinoma (Table 2). In seven cases TIC was identified bilaterally and in another seven cases 
unilaterally. Of the seven cases with unilateral TIC, the contralateral tubal epithelium showed 
benign epithelium in three cases, hyperplasia in one, and minor epithelial atypia in three. 
Two cases were identified with invasive tubal carcinoma which occurred unilaterally with 
contralaterally benign tubal epithelium in one case and occult ovarian carcinoma in the other. 
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In the control group the tubal epithelium was benign in 44 (42%) cases, showed hyperplasia 
in 37 (35%) and minor epithelial atypia in 24 (23%) cases. No tubal neoplasia (TIC or invasive 
carcinoma) was found in controls, which was significantly different from the BRCA-mutation 
carriers (zero of 105 vs 16 of 226 (7%); p=0.004, Fisher’s exact test). The less severe lesions, 
hyperplasia and minor epithelial atypia were commonly identified in both BRCA-mutation 
carriers and controls, although more often in controls (94 of 226 (42%) vs 61 of 105 (58%); 
p=0.005, Pearson’s Chi square; Table 2). Furthermore, severity of tubal epithelial lesions in 
women with a BRCA-mutation was significantly associated with higher age (p<0.001, Kruskal–
Wallis test; Table 3). Controls revealed no significant difference in age distribution for tubal 
epithelial lesions (Table 3).
Topographic Characteristics of Tubal Epithelial Lesions
In the majority of cases, invasive tubal carcinoma and TIC were identified in the distal 
fimbria: invasive tubal carcinomas in 100% and TICs in 64% of the cases (Table 4). Tubal 
neoplasia (invasive carcinoma or TIC) was significantly more often localized in the fimbriae 
compared to hyperplasia and minor epithelial atypia (11 of 16 (69%) vs 62 of 155 (40%); 
p=0.027, Pearson’s Chi square; Table 4). As mentioned previously, invasive tubal carcinoma 
and TIC were only identified in BRCA-mutation carriers and not in the controls. In the BRCA-
mutation carriers hyperplasia was seen in the fimbriae in 35% and minor epithelial atypia in 
Population characteristics BRCA 1/2 Controls p value
N (%) N (%)
Median age (range) 44 (24-70) 48 (22-60) 0.04a
Menopausal status 0.17b
Premenopausal 127 (60%) 70 (68%)
Postmenopausal 85 (40%) 33 (32%)
Missing 14 2
Parity 0.001b
No children 34 (16%) 23 (24%)
1-2 children 110 (50%) 60 (62%)
3+ children 75 (34%) 14 (14%)
Missing 7 8
History of breast carcinoma 81 (36%) 1 (1%) <0.00b
Sterilization 23 (10%) 17 (16%) 0.11b
Table 1: Population characteristics of BRCA-mutation carriers (N=226) and controls (N=105)
a Mann Whitney U test. b Pearson’s Chi square.
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Tubal epithelium BRCA1 BRCA2 BRCA 1/2 Controls
(N=149) (N=77) (N=226) (N=105)
N % N % N % N %
Benign 80 53.7 36 46.8 116 51.3 44 41.9
Hyperplasia 29 19.5 14 18.2 43 19.0 37 35.2
Minor atypia 31 20.8 20 26.0 51 22.6 24 22.9
TIC 9 6.0 5 6.5 14 6.2 0 0.0
Invasive carcinoma 0 0.0 2 2.5 2 0.9 0 0.0
Abbreviation: TIC, tubal intraepithelial carcinoma. 
Tubal epithelium BRCA 1/2 Controls
N Median age (range) N Median age (range)
Benign 116 41.5 (24-70) 44 48.0 (28-59)
Hyperplasia 43 45.0 (36-70) 37 48.0 (35-60)
Minor atypia 51 48.0 (35-69) 24 51.0 (22-59)
TIC 14 53.0 (35-63) -
Invasive carcinoma 2 57.5 (55-60) -
p<0.001 (Kruskal-Wallis test) p=0.14 (Kruskal-Wallis test)
Table 3: Tubal epithelial lesions in BRCA-mutation carriers and controls in relation to age
Abbreviation: TIC, tubal intraepithelial carcinoma. 
Tubal epithelium BRCA 1/2 Controls
Fimbrial Non-fimbrial Fimbrial Non-fimbrial
(N=50) (N=60) (N=23) (N=38)
N % N % N % N %
Hyperplasia 15 34.9 28 65.1 10 27.0 27 73.0
Minor atypia 24 47.1 27 52.9 13 54.2 11 45.8
TIC 9 64.3 5 35.7 - - - -
Invasive carcinoma 2 100.0 0 0.0 - - - -
Table 4: Tubal epithelial lesions in BRCA-mutation carriers located in the fimbria or in the isthmus and ampullary 
region of the tube (non-fimbrial)
Abbreviation: TIC, tubal intraepithelial carcinoma. 
Table 2: Histopathologic findings in the epithelium of the fallopian tubes from both BRCA-mutation carriers and controls 
that received bilateral salpingo-oophorectomy
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47%, versus 27% and 54% in the controls, respectively. Hyperplasia and minor epithelial 
atypia, did not occur significantly more often in the fimbriae but displayed more variation in 
localization (39 of 94 (41%) vs 23 of 61 (38%); p=0.64, Pearson’s Chi square; Table 4).
Ovarian Occult Carcinoma
An occult ovarian carcinoma of 5.8 mm was identified in a 60 year old woman with a BRCA2 
mutation, with an occult invasive carcinoma in one of the adjacent tubes. All other cases, from 
both the BRCA-mutation and control group, showed only benign ovarian pathology. 
Of  BRCA-mutation carriers, 81 (36%) were diagnosed with breast carcinoma 
prior to pBSO. In these 81 BRCA-mutation carriers TIC was present in 5% and 
invasive tubal carcinoma in 2%, compared to respectively 7% and 0% in the 133 
BRCA-mutation carriers without prior breast carcinoma. The presence of tubal 
neoplasia (TIC and invasive carcinoma) was not significantly different for cases with 
or without a previous breast carcinoma (six of 81(7%) vs nine of 133 (7%); p=0.86, 
Pearson’s Chi square). Treatment for breast carcinoma was surgery (36%), or in addition 
either adjuvant chemotherapy (49%) or adjuvant chemotherapy with tamoxifen (15%). No 
significant difference was seen between treatment management of breast carcinoma and 
prevalence of tubal neoplasia (tamoxifen, p=0.58 (0/12 vs 6/69); chemotherapy, p=0.18 (2/52 
vs 4/29), Fisher’s exact test).
Discussion
Our study has identified significant differences in the prevalence and preferred localization 
of tubal epithelial lesions in a large cohort of 226 BRCA-mutation carriers versus 105 controls. 
Occult invasive tubal carcinoma and TIC were present in 7.1% of the BRCA-mutation carriers 
but were absent in control cases. In contrast, tubal hyperplasia and minor epithelial atypia 
were commonly identified in both BRCA-mutation carriers and controls, although more often in 
controls. An association was found between increasing age and the presence of more severe 
tubal epithelial lesions in BRCA-mutation carriers. Furthermore, invasive tubal carcinomas 
and TICs had a marked preference for the distal fimbrial end, which was not seen for tubal 
hyperplasia and minor epithelial atypia.
Our divergent results for the different categories of tubal epithelial lesions lead to the 
suggestion that hyperplasia and minor epithelial atypia do not represent precursor lesions of 
invasive carcinomas and/or TICs. Previously, it has been suggested that a stepwise epithelial 
carcinoma progression model can be applied to the tubes11. According to this model, occult 
carcinoma and TIC are preceded by atypic and/or hyperplastic tubal lesions. However, 
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according to the results of the present study the accurateness of this stepwise progression 
model seems controversial, as prevalence of the specific tubal lesions as well as areas of 
localization are different for BRCA-mutation carriers and controls. The association found 
between increasing age and severity of tubal epithelial lesions in BRCA-mutation carriers 
might be suggestive for the stepwise progression model, but as the less severe lesions 
are more often identified in controls it seems unlikely that they are part of the oncogenic 
pathway. It is more likely that the less severe tubal lesions, as hyperplasia, represent normal 
proliferation of the tubal epithelium. Tubal hyperplasia is more common in younger women, 
as was suggested by Norquist et al24. The fact that invasive carcinomas and TICs were not 
identified in controls marks their uniqueness for women at high risk for ovarian carcinoma 
and therefore their suggested role in carcinogenesis. Especially, since controls were older 
and therefore more TICs and carcinomas would be expected. In addition, histological findings 
of hyperplasia and minor atypia were not identified in close proximity with occult invasive 
carcinoma and TIC25.
The incidence of invasive tubal carcinoma and TIC in BRCA-mutation carriers in the present 
study was comparable with other studies including relatively large populations, with a mean 
overall prevalence of 5.2% for TIC and 6.7% for tubal neoplasia (TIC and invasive carcinoma) 
(Table 5). Comparing the prevalence of hyperplasia and minor epithelial atypia with previous 
reports entails more obstacles. Various terminologies have been used by different authors, or 
only distinct lesions such as occult carcinoma and TIC were recorded. Some extent of tubal 
epithelial proliferation has been seen in women, mostly premenopausal, without an increased 
risk of ovarian or tubal carcinoma, and are considered within normal limits of epithelial 
variation26. However, the extent of this normal variation is still somewhat unclear as most 
studies did not include a control group. The current study provided the first large control group 
consisting of patients that were operated for various non-malignant reasons. Only two previous 
studies on epithelial lesions of the fallopian tubes included a control group (Table 5)25,27. The 
study of Shaw et al. included 64 controls who underwent BSO and reported TIC in 3% of 
their control cases27. However, 22% of their controls underwent surgery for synchronously 
diagnosed carcinoma of the cervix or endometrium which could have biased their results27. 
In our own control group all patients receiving BSO for malignancy were excluded to rule out 
possible intrusion.
A limitation of the current study is its retrospective nature leading to less extensive sampling 
of tubal tissue of controls. Therefore, median number of tubal slides available for review in 
BRCA-mutation carriers versus controls differed, resulting in an inability of completely blinding 
the pathologist for BRCA status. Tubal epithelial lesions are quite small and the use of a 
pathological protocol to embed the fallopian tubes in toto is preferred in further prospective 
research in order not to overlook putative precursor lesions. One of the strengths of our 
study is that it included the largest cohort of both BRCA-mutation carriers and controls. Age 
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distribution of the cohort was comparable with other studies12,17,27, both groups were identified 
in one single institution and all sections were reviewed by the same two gyneco-pathologists. 
Before starting this study, a classification scheme for tubal epithelial lesions was developed 
and consensus was reached on definitions of these epithelial tubal lesions. 
Although, various epithelial tubal lesions in women at high risk for ovarian carcinoma were 
described previously, the diagnosis of tubal epithelial lesions is still subject to many difficulties 
as outlined in a recent report by Visvanathan et al28. They analyzed inter- and intraobserver 
reproducibility between gynecologic pathologists in diagnosing tubal epithelial lesions which 
showed to be fair to moderate for TIC, but poor for other tubal epithelial lesions28. To bypass 
definition issues several reports combined terms as occult carcinoma and TIC in their reported 
incidence number, which further complicates comparison of studies8,13,27. The difficulties in 
interpretation of results stress the importance of a generally used morphologic classification 
for future research. Our proposed classification scheme could overcome these interpretation 
difficulties when generally used.
The BRCA-mutation carriers also have an increased risk of developing breast carcinoma 
which often occurs at an earlier age than ovarian carcinoma29. Literature shows some 
controversy on the influence of prior breast carcinoma and the risk of identifying occult tubal 
carcinoma in pBSO tissue8,16. In the current study prior breast carcinoma did not influence the 
presence of tubal epithelial lesions, nor did different treatment protocols for breast carcinoma. 
It is recommended to perform a pBSO in women with a confirmed BRCA-mutation at the age 
of about 40 years, which is based on the increased prevalence of tubal or ovarian carcinoma 
in these women30. This is supported by the present study as both identified invasive tubal 
carcinomas occurred at the age of 55 and 60, respectively. However, in the current study, 
the precursor lesion, TIC, was identified in two women before reaching the age of 40 years. 
The median age of TIC was 53 years (range 35–63) and age distribution of identified TIC 
Abbreviation: TIC, tubal intraepithelial carcinoma. 
TIC BRCA1 (N=149) BRCA2 (N=77) BRCA1/2 (N=226)
N (total N) N (total N) N (total N)
Age category (years)
<35 0 (9) 0 (1) 0 (10)
35-40 2 (57) 0 (17) 2 (74)
41-50 2 (42) 2 (26) 4 (68)
50+ 5 (41) 3 (33) 8 (74)
Table 6: Age distribution of TIC in women with a confirmed BRCA-mutation
Abbreviation: TIC, tubal intraepithelial carcinoma. 
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was shown in Table 6. Whether the identification of TIC before reaching the age of 40 years 
is a reason to perform pBSO at a younger age needs further investigation. More research is 
needed on the prevalence of TIC before the age of 40, on the possibility of TIC metastasizing 
before developing towards carcinoma and, if so, if this is an indication for adjuvant treatment 
in these women. Recently, ‘radical fimbriectomy’ was suggested as an alternative solution for 
prevention of tubal or ovarian carcinoma instead of pBSO31. However, our study contradicts 
that only fimbriectomy would be sufficient in preventing these malignancies. We identified 
only two-thirds of TICs in the fimbrial end while one-third occurred in the ampulla or isthmus of 
the tubes. Removal of the total fallopian tubes after completion of childbearing with a second 
step removal of the ovaries at a higher age might be a more suitable alternative for pBSO 
that needs further investigation32. In addition, this method could be more safely performed 
before the age of 40 years as recommended for pBSO, without the adverse effects of early 
menopause.
In conclusion, the results of the present study emphasize the essence of removing the 
fallopian tubes in total, as one-third of the identified TICs did not occur in the fimbrial end. 
Furthermore, the classification scheme used in this study appears to be useful as it differentiates 
between equivocal tubal epithelial lesions (hyperplasia and minor epithelial atypia) that are 
commonly present in the general population, from premalignant lesions with an already 
established role in carcinoma development (TIC and invasive carcinoma). Occult invasive 
carcinoma and TIC were only identified in BRCA-mutation carriers, whereas hyperplasia and 
minor epithelial atypia were more often identified in controls. Therefore, it seems unlikely that 
hyperplasia and minor epithelial atypia are also precursor lesions of ovarian carcinoma. We 
suggest to interpret tubal hyperplasia and minor epithelial atypia as variants of normal tubal 
epithelial proliferation.
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Abstract
Objective: Routine hysterectomy is part of surgical management of epithelial ovarian cancer (EOC), 
because the serosa is a common area of metastases and, occasionally, double primary carcinoma 
occurs. Knowledge of endometrial premalignancies in these women is poor. The aim of the present 
study was to review the endometrium of EOC patients to determine the prevalence of endometrial 
lesions. 
Materials and Methods: Endometrial and ovarian specimens of 186 EOC patients were 
retrospectively selected using the nationwide pathology network and registry. All sections were 
comprehensively reviewed and 136 (73%) carcinomas were diagnosed as serous carcinoma, 
19 (10%) endometrioid, 15 (8%) mucinous, 7 (4%) clear cell, and 9 (5%) were undifferentiated. 
Immunohistochemical staining with p53, Ki-67, ER and PR was performed for serous EOC patients 
with concurrent endometrial pathology. 
Results: In 31% of EOC patients an endometrial (pre)malignancy was found: carcinoma in 3%, EIC 
in 4%, and atypical hyperplasia in 24%. Concurrent to endometrioid EOC, atypical hyperplasia was 
found in 47%, whereas in other histological subtypes in 7-33%. Body mass index was significantly 
higher in patients diagnosed with atypical hyperplasia, compared to normal endometrium (p=0.001). 
Immunohistochemical expression patterns of serous EOC and EIC were almost identical, whereas 
atypical hyperplasia expressed differently. 
Conclusions: Atypical hyperplasia was commonly seen in patients diagnosed with EOC, with the 
highest prevalence in endometrioid EOC patients with 47%. Apart from synchronous endometrial 
carcinoma, endometrial premalignancies should be taken into account when determining optimal 
treatment for women diagnosed with ovarian cancer. 
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Introduction
Epithelial ovarian cancer (EOC) is a highly aggressive and rapidly progressive tumor. 
Surgical management of EOC includes primary debulking or interval debulking after 
neoadjuvant chemotherapy. All international guidelines recommend a hysterectomy in these 
women to accomplish complete debulking, since the serosa of the uterus is one of the 
most frequent sites of peritoneal spread and complete debulking surgery is associated with 
improved overall survival1,2. Another justification to perform routine hysterectomy in patients 
with EOC includes the presence of a double primary carcinoma in the endometrium in 10% 
of endometrioid ovarian carcinomas and in 2% to 5% of serous, clear cell, and mucinous 
carcinomas3-5. Knowledge of the prevalence of synchronous endometrial premalignancies in 
these women is nevertheless poor. 
In studies reporting on EOC and concurrent endometrial carcinomas, no additional 
information is given on the prevalence of endometrial premalignancies. One study investigated 
a small cohort of extraovarian carcinomas and reported endometrial hyperplasia in 13% of 
cases, in addition to synchronous endometrial carcinoma in 6%1. The few studies analyzing 
the endometrium in general (asymptomatic) populations reported a much lower prevalence 
of endometrial lesions, with hyperplasia found in 1% to 2%, atypical hyperplasia in 1%, and 
carcinoma in 0.5%6-10.
The aim of this study was to extensively review the endometrium of a large cohort of patients 
with EOC to assess the prevalence of endometrial pathology in these women. Correlations 
were analyzed between endometrial lesions and clinical risk factors that are known to influence 
endometrial proliferation. Furthermore, immunohistochemical expression patterns of the most 
common type of ovarian carcinomas, serous ovarian carcinomas, and concurrent endometrial 
lesions were analyzed.
Materials and Methods
Patients and Samples
All patients surgically treated for EOC in the Radboud University Nijmegen Medical Centre 
(RUNMC) from April 1996 through December 2010 were selected. The search term ovarian 
carcinoma was entered in the Dutch nationwide network and registry of histopathology and 
cytopathology (PALGA), yielding 311 patients satisfying these constraints. In total, 108 patients 
were excluded because hysterectomy was not performed at the RUNMC; in 34 patients, 
hysterectomy already had been performed for benign reasons or at primary incomplete 
debulking in another institution, and in 48 patients, the uterus remained in situ because of 
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an inability to achieve complete debulking or uterus preservation. Twenty-six patients visited 
our institution only for a second opinion on treatment management and revision of pathologic 
diagnosis. For the remaining 203 patients, all available H&E-stained endometrial and ovarian 
sections were retrieved from the pathology archive of the RUNMC. Embedding of endometrial 
tissue was performed according to routine protocol. Seventeen patients had to be excluded 
because not all sections were available for review. Therefore, the final study population 
contained 186 patients with EOC: 136 (73%) women diagnosed with serous carcinoma, 19 
(10%) with endometrioid carcinoma, 15 (8%) with mucinous carcinoma, seven (4%) with clear 
cell carcinoma, and nine (5%) with undifferentiated carcinoma.
Medical records and surgical and pathology reports were retrieved to determine pertinent 
clinical and pathologic data. Data obtained included age, menopausal status, BRCA-
mutation status, International Federation of Gynecology and Obstetrics (FIGO) stage, and 
treatment management. Patients were staged in accordance with the FIGO surgical staging 
adopted in 198811. Conditions that are able to cause unopposed estrogen stimulation were 
retrieved from medical records: late menopause, high body mass index (BMI; by peripheral 
conversion of androstenedione to estrogen in adipose tissue of obese women), or an 
estrogen-producing tumor.
On behalf of the research ethics committee of the RUNMC, the study was carried out in 
accordance with the applicable rules concerning the review of research ethics committees 
and informed consent.
Histopathology
All ovarian and endometrial sections were reviewed by two pathologists with extensive 
experience in gynecopathology. In case of a discrepancy in diagnosis, consensus was reached 
between both pathologists. The following endometrial entities were scored in the endometrium: 
normal endometrium, hyperplasia, atypical hyperplasia, endometrial intraepithelial carcinoma 
(EIC), and invasive carcinoma (Figure 1). A classification scheme developed by Kurman et al.12 
and adapted by the World Health Organization was used to interpret endometrial hyperplasia 
with or without atypia. For the identification of EIC, previously published criteria were used 
that define EIC morphologically as the replacement of endometrial surface epithelium and 
glands, without myometrial or stromal invasion, by malignant cells that are identical to serous 
carcinoma cells12-14.
Immunohistochemical Analysis
Immunohistochemical stainings were performed on sections from formalin-fixed, paraffin-
embedded samples in which endometrial atypical hyperplasia or EIC was identified in patients 
diagnosed with serous EOC. A representative sample of the ovarian carcinoma was added in 
each case. Sections of 5 μm were sliced and incubated with monoclonal antibodies against 
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Figure 1: 
A) Normal endometrial epithelium (level of magnification: x200). Endometrial lesions identified in the 
endometrium of women with ovarian carcinoma: 
B) Endometrial simple hyperplasia (x200).
C) Endometrial atypical hyperplasia (x100).
D) Endometrial atypical hyperplasia (x200).
E) Endometrial intraepithelial carcinoma (EIC) (x200).
F) Synchronous primary endometrial carcinoma (x200).
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p53 (dilution 1:250, clone DO-7; Neomarkers, Fremont, CA), WT1 monoclonal antibody 
(dilution 1:20, clone 49, NCL-L-WT1-562; Leica Biosystems, Newcastle Upon Tyne, UK), 
Ki-67 (dilution 1:100, clone MIB-1; DAKO, Glostrup, Denmark), estrogen receptor (ER) 
(dilution 1:100, clone SP-1; Thermo Scientific, Fremont, CA), progesterone receptor (PR) 
(dilution 1:500, clone PgR636; DAKO), and p16 (dilution 1:500, clone 16PO4; Neomarkers). 
Antigen retrieval was processed according to the manufacturers’ guidelines, and antigen-
antibody complexes were localized using the standard streptavidin-biotin technique (Vector 
Laboratories, Burlingame, CA) with diaminobenzidine as chromogen. Normal endometrial 
tissue was used as a control in each case, and a positive control was included in each batch 
of staining. Immunohistochemical stainings were interpreted by two authors (JB and MJJMM). 
Expression of nuclear staining for p53, p16, and WT1 was scored as the percentage of positive 
stained tumor cells and classified as follows: 1% to 50%, 51% to 75%, more than 75%, or 
complete absence of expression. Intense expression of p53 in more than 75% of tumor cells 
or complete absence of expression was considered strongly correlated with the presence of 
a TP53 mutation15. Expression of nuclear staining for Ki-67, ER, and PR was scored as the 
percentage of positive stained cells and classified as follows: less than 5% (–, negative), 5% 
to 20% (+, weak), more than 20% to 50% (++, moderate), and more than 50% (+++, strong). 
Membranous and/or cytoplasmic expression was not considered positive.
Statistics
Analyses were performed to compare the prevalence of endometrial entities and their 
clinicopathologic characteristics for the different histologic subtypes of EOC. Furthermore, the 
prevalence of risk factors for endometrial proliferation was compared between the group of 
patients diagnosed with an atypical hyperplastic endometrium and the group diagnosed with 
normal endometrium. Variables were expressed as frequencies and percentages for discrete 
data and as median and 25th to 75th quartiles for continuous data. Statistical comparison 
of medians from independent samples was performed using the Kruskal-Wallis and Mann-
Whitney U tests. Pearson’s Chi square and, if appropriate, the Fisher’s exact test were used 
to test associations between categorical variables. All statistical analyses were performed 
using SPSS software version 18.0 (SPSS Inc., Chicago, IL), and p<0.05 (two-sided test) was 
considered statistically significant.
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Results
Clinical data were analyzed for 186 patients with EOC included in the study (Table 1). 
The median age at diagnosis was 60 years, median BMI was 24.6 kg/m², and 71% were 
postmenopausal (Table 1). Most patients had an advanced stage of disease at diagnosis, with 
a FIGO stage IV in 29 (16%) patients, stage III in 114 (63%), stage II in nine (5%), and stage 
I in 29 (16%). Median age at diagnosis, menopausal state, and FIGO stage were significantly 
different for histologic subtypes of EOC (p= 0.009, p=0.007, and p<0.001, respectively; Table 
1). Patients diagnosed with serous or clear cell carcinomas had a median age of 60 years, 
whereas patients with endometrioid and mucinous carcinomas were younger and more often 
premenopausal.
Results of histologic assessment of the endometrium are shown in Table 2. In 105 (56%) 
patients, the endometrium was without abnormalities. In 81 (44%) patients, an endometrial 
lesion was identified, and in 58 (31%) patients, this lesion was (pre)malignant. The latter 
included a double primary endometrial carcinoma in six (3%) patients, EIC in seven (4%), and 
atypical hyperplasia in 45 (24%). In two patients diagnosed with double primary endometrioid 
carcinoma, atypical hyperplasia also was found in the preexistent endometrium. In all cases, 
the background endometrium was assessed to confirm that endometrial lesions arise from 
the endometrial tissue instead of representing detached fragments of the concurrent ovarian 
carcinoma.
Atypical hyperplasia was frequently identified in all histologic subtypes of EOC but 
most common in concurrence with endometrioid cancers (Table 2). In patients with 
endometrioid EOC, atypical hyperplasia was found in nine (47%) of 19 patients. In other 
histologic subtypes of EOC, the prevalence of atypical hyperplasia was three (33%) 
of nine for undifferentiated carcinomas, two (29%) of seven for clear cell carcinomas, 
32 (24%) of 136 for serous carcinomas, and one (7%) of 15 for mucinous carcinomas. 
Furthermore, EIC was found in seven (5%) of 136 patients with serous EOCs and was limited 
to the serous histology type. Double primary endometrial carcinomas were identified in four 
(3%) of 136 patients with serous EOC and in two (11%) of 19 with endometrioid EOC but in 
none of the other histologic subtypes.
Higher BMI in Patients Identified with Atypical Hyperplasia
The prevalence of conditions known to influence the development of endometrial proliferation 
was compared between patients diagnosed with an atypical hyperplastic endometrium and 
those with a normal endometrium. Patients identified with endometrial atypical hyperplasia 
had a significantly higher BMI than those with a normal endometrium (p=0.001, Mann-
Whitney U test) (Table 3). Other analyzed conditions, including treatment with neoadjuvant 
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Population characteristics Normal endometrium Atypical hyperplasia
N (%)/Median (Quartiles) N (%)/Median (Quartiles)
No. Cases (%) 105 (60%) 47 (25%)* p value
Age at diagnosis, median, y 58 (49-65) 60 (49-70) 0.157a
Menopausal state
     Premenopausal 29 (30%) 11 (24%) 0.479b
     Postmenopausal 67 (70%) 34 (76%)
     Missing 9 2
Age at menopause, median, y 50 (46-52) 50 (45-54) 0.276a
Parity, median 2 (0.8-3.0) 2 (0.3-2.0) 0.821a
FIGO stage
     I 19 (18%) 8 (18%) 0.931b
     II 4 (4%) 2 (4%)
     III 65 (64%) 27(60%)
     IV 14 (14%) 8 (18%)
     Unknown 3 2
Neoadjuvant chemotherapy
     No 48 (48%) 22 (49%) 0.921b
     Yes 52 (52%) 23 (51%)
     Missing 5 2
BMI, median (kg/m2) 23.4 (21.3-26.1) 27.4 (23.1-32.7) 0.001a
Table 3: Potential endometrial proliferation risk factors and population characteristics analyzed in patients with 
epithelial ovarian cancer with a normal endometrium or an atypical endometrium
*Total number of patients with endometrial atypical hyperplasia:45 with atypical hyperplasia and two with atypical 
hyperplasia adjacent to the double primary endometrioid endometrial carcinoma.
aMann-Whitney U test, bPearson’s Chi square
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chemotherapy, revealed no significant difference between these two groups (Table 3). Of 
those who were genetically tested, BRCA-mutation carriers were identified equally in both 
groups, and Lynch syndrome was not identified in any patient.
Signs of abnormal vaginal bleeding were reported in three (6%) of 47 patients with EOC 
who had concurrent atypical hyperplasia and in three (3%) of 105 patients with a normal 
endometrium. Of the three patients diagnosed with a normal endometrium and abnormal 
vaginal bleeding, the endometrium was diagnosed in two patients as disordered proliferative 
and in one as atrophic.
Distinct Expression Pattern of Atypical Hyperplasia vs EIC and Concurrent Serous 
EOC
In patients diagnosed with serous EOC, the concurrent presence of EIC or atypical 
hyperplasia was identified. Immunohistochemical staining was analyzed for 27 patients with 
serous EOC and concurrent endometrial pathology: 20 patients with atypical hyperplasia and 
seven with EIC (Table 4 and Table 5). In one patient, the paraffin block of the EOC was not 
available for immunohistochemical staining.
Most patients with serous EOC and concurrent EIC showed a strong exhibition for Ki-67 
and ER but a weak exhibition for PR (Table 4). Furthermore, p53 was strongly positive or 
completely negative in 80% of patients with serous EOC and in 71% of those with EIC (Table 
5).
Atypical hyperplastic lesions had a different expression pattern compared with the concurrent 
serous EOC. In atypical hyperplastic lesions, Ki-67 showed most often weak expression, while 
ER and PR stained strongly positive in almost all cases. Furthermore, p53 immunostaining 
was weakly positive in 65% of the atypical hyperplastic lesions, completely negative in 35%, 
and strongly positive in none (Table 5). Immunohistochemical staining with p16 supports 
the finding that distinct endometrial lesions (EIC, atypical hyperplasia, and endometrioid 
endometrial carcinoma) are found concurrent to serous ovarian carcinoma. In five (83%) of 
six patients, the EIC showed strong expression of p16 in more than 75% of tumor cells. In one 
patient, the EIC tissue was insufficient to perform p16 staining. Atypical hyperplasia showed 
no expression for p16 in two (10%) of 20 patients, expression in 1% to 50% of hyperplastic 
cells in 11 (55%) of 20, and expression in 51% to 75% of hyperplastic cells in seven (35%) 
of 20. Endometrioid endometrial carcinomas showed in all cases (two of two) expression of 
p16 in 1% to 50% of the tumor cells. In conclusion, almost all EICs showed strong and diffuse 
expression of p16, whereas atypical hyperplasia and endometrioid endometrial carcinoma 
showed focal and irregular expression in most cases.
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WT1 Expression in Serous EOC and Concurrent EIC
Results of immunohistochemical WT1 staining for women diagnosed with serous EOC and 
concurrent EIC are shown in (Table 6). In one patient, tissue was not sufficient for additional 
WT1 staining. Four patients showed a comparable expression pattern for WT1 in the serous 
EOC and concurrent EIC, whereas in two patients, the serous EOC was strongly positive and 
the EIC completely negative for WT1.
Discussion
In this study, an endometrial (pre)malignancy was identified in one-third of patients diagnosed 
with EOC. Atypical hyperplasia was found in half of endometrioid ovarian carcinomas and in 
7% to 33% of other histology types. Endometrial intraepithelial carcinoma was found only 
synchronous to serous EOC. Synchronous endometrial carcinomas were identified in patients 
with endometrioid and serous ovarian cancer, in 11% and 3% respectively.
The prevalence of synchronous endometrial carcinomas is comparable to other studies 
reporting on endometrial carcinomas in patients diagnosed with EOC3-5. Synchronous atypical 
hyperplasia was common in patients with EOC, and similar to the prevalence of synchronous 
endometrial carcinoma, atypical hyperplasia has the highest prevalence in patients with 
endometrioid EOC. Atypical hyperplasia is known as a premalignancy of endometrioid 
Table 6: Serous EOC and concurrent EIC with their respective WT1 im-
munohistochemical staining patterns (N=7)*
WT1 expression
Patient No. Serous EOC, % EIC, %
1 51-75 51-75
2 - -
3 >75 >75
4 0 0
5 51-75 51-75
6 51-75 0
7 51-75 0
Abbreviations: EOC, epithelial ovarian cancer; EIC, endometrial intraepithelial 
carcinoma.
*WT1 expression: 0%, 1 to 50%, 51 to 75% ,or more than 75%
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endometrial carcinoma16. It is thought that endometrial atypical hyperplasia progresses to 
endometrial carcinoma in 23% of patients, and if so, progression occurs over a mean duration 
of four years17-18.
The development of atypical hyperplasia is thought to be influenced by unopposed 
estrogens16,19. In the present study, BMI was the only clinical variable that was significantly 
higher in women diagnosed with endometrial atypical hyperplasia than in those diagnosed 
with a normal endometrium. Other variables, including neoadjuvant chemotherapy, did not 
differ between both groups of women.
Atypical hyperplasia could represent an adverse effect of increased estrogen production by 
the EOC itself. Normal ovarian surface epithelial cells and/or ovarian tumors are capable of 
the production of steroids, and occasionally EOC has been reported to produce high estrogen 
levels20-25. However, this is a retrospective study and we were not informed on estrogen levels 
of the included cases. Furthermore, most reported estrogen-producing ovarian tumors are of 
endometrioid histology, and estrogen production is only very rarely described for the more 
common serous EOC19-21,23,24. Still, in the current study atypical hyperplasia was also identified 
in one-fourth of patients with serous EOC.
None but two (4%) patients diagnosed with EOC and concurrent atypical hyperplasia 
did report signs of abnormal vaginal bleeding at presentation. Eleven patients diagnosed 
with atypical hyperplasia were premenopausal, and none of them showed specific signs of 
endometrial disease at presentation.
Preoperative ultrasound on endometrial thickness could not always be retrieved from 
the medical records of included cases. If a suspective ovarian tumor is identified, probably 
less focus is given to describing the endometrial thickness. Furthermore, neoadjuvant 
chemotherapy often had been started before preoperative ultrasound was performed at the 
RUNMC. Other limitations of the current study are that clinical variables could not always 
be retrieved from the medical records, and no follow-up was available on the endometrial 
pathology of patients without a hysterectomy. Genetic counseling for a BRCA-mutation or 
Lynch syndrome was offered to women with a family history at risk of hereditary cancer 
syndrome. However, results were not always available in the medical records, or genetic 
counseling was not or had not been performed because of refusal by the patient or rapid 
progression of the disease. Furthermore, the cohorts of nonserous EOC were relatively small 
and the endometrium was embedded according to routine protocol. Therefore, only a part of 
the endometrium was available for histologic assessment.
Endometrial intraepithelial carcinomas (EICs) were limited to the serous subtype of EOC and 
identified in 5% of this group. It is known as a precursor of serous endometrial carcinoma and 
defined as noninvasive serous endometrial carcinoma16,26. Recently, EIC in the endometrium 
was suggested as a potential source for a limited proportion of serous EOC27,28. A more and 
more accepted source of serous ovarian carcinoma is serous tubal intraepithelial carcinoma 
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(STIC) and can be found in the fallopian tubes of 19% to 61% of these women29-33. STIC has 
also been suggested as a putative precursor of tubal and primary peritoneal serous carcinoma 
and rarely of serous endometrial carcinoma34.
WT1 staining is thought to be able to discriminate between primary serous EOC and serous 
endometrial carcinoma35. Half of the analyzed cases showed strong expression for WT1 in 
both the serous EOC and concurrent EIC, which is suggestive of a primary serous EOC. 
One patient showed negative expression in both lesions, suggestive of primary endometrial 
carcinoma. In two patients the WT1 staining was suggestive of a primary serous EOC as well 
as a primary endometrial carcinoma. In the latter, the EIC showed no expression of WT1, 
whereas the concurrent serous EOC showed strong and diffuse WT1 expression.
Immunohistochemical staining showed comparable expression patterns for EIC and 
concurrent serous EOC. The expression pattern of atypical endometrial hyperplasia was more 
distinct. It showed strong exhibition of ER and PR, as well as negative to moderate Ki-67 and 
p53 staining. This expression pattern of atypical hyperplasia is comparable to the expression 
pattern known for endometrioid endometrial carcinoma36. Therefore, atypical hyperplasia and 
concurrent serous EOC are most likely two independent lesions.
Prevalence of endometrial pathology seemed significantly higher concurrent to endometrioid 
EOC in comparison with other histologic subtypes. To confirm this finding in a larger cohort, 
we selected patients with endometrioid EOC operated on at the Canisius Wilhelmina Hospital 
from 1996 through 2010 (unpublished data). Twenty-two women diagnosed with endometrioid 
EOC could be identified, and sections were retrieved from the pathology archives to review 
the endometrium and confirm tumor histology. In six (27%) patients, a benign endometrium 
was found, whereas 11 (50%) had atypical hyperplasia and five (23%) had endometrioid 
endometrial carcinoma. The high prevalence of atypical hyperplasia concurrent to endometrioid 
EOC was confirmed in these additionally selected cases and did not differ from findings in the 
initial cohort (nine [47%] of 19 vs 11 [50%] of 22).
In patients diagnosed with EOC, the presence of a concurrent endometrial premalignancy 
has to be taken into account. However, the clinical importance of these often asymptomatic 
endometrial lesions has not yet been clarified. Most likely, concurrent atypical hyperplasia 
represents a premalignant stage of synchronous endometrioid endometrial carcinoma. 
Presence of Lynch syndrome, as in families with hereditary nonpolyposis colorectal cancer, 
could explain for the frequent presence of an endometrial (pre)malignancy as well as ovarian 
carcinoma. However, the chance that these women develop colorectal cancer or endometrial 
carcinoma as their first malignancy is much higher compared with ovarian carcinoma, with a 
40% to 60% chance of developing endometrial carcinoma first37.
Occasionally, conservative surgery is performed in women diagnosed with early stage EOC, 
sparing the uterus and contralateral ovary38. Studies investigating recurrence risk in these 
women showed that a recurrence was mostly found in the contralateral ovary, and in only 0% 
60
to 3% of cases did carcinoma recur in the endometrium39-41. However, all women included in 
these studies were aged 40 years or younger. Women investigated in the current study had a 
median age of 60 years. This is comparable to the median age in which EOC is diagnosed36. 
Therefore, the cohorts included in studies analyzing conservative surgery are not comparable 
to the current study. Though, we support their recommendation of performing endometrial 
sampling at the time of conservative surgery, since endometrial atypical hyperplasia was 
also found in patients with early stage disease41,42. In the current study, eight patients with a 
FIGO stage I EOC were diagnosed with atypical hyperplasia, and three of them (38%) were 
premenopausal.
In conclusion, in 31% of women diagnosed with EOC, the endometrium showed a (pre)
malignant endometrial lesion. In patients with endometrioid EOC, atypical hyperplasia 
occurred in half. Identified endometrial premalignancies are vital when considering treatment 
options for these women. If conservative surgery is considered with preservation of the uterus, 
attention should be given to the possibility of concurrent endometrial pathology.
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Abstract
Knowledge on the nature of the endometrium in women without symptoms of endometrial 
disease is poor. Therefore, the aim of this prospective study was to describe the endometrium of 
a cohort of asymptomatic women. The entire endometrium of pre- and postmenopausal women 
was embedded for histological examination. All included patients underwent a hysterectomy on 
indication of uterovaginal prolapse, from July 2011 to October 2012, in three hospitals in the South 
of The Netherlands. Exclusion criteria were symptoms of postmenopausal vaginal blood loss, or 
premenopausal disordered vaginal bleeding. As a result, sixty-eight women were included in the 
study, 48 women were postmenopausal and 20 were premenopausal. In the endometrium of ten 
women simple hyperplasia was found (15%), in one complex hyperplasia (2%), in two simple atypical 
hyperplasia (3%), in two complex atypical hyperplasia (3%), and in two a small focus of intramucosal 
endometrioid endometrial carcinoma (3%). In general, the endometrium was heterogeneous 
and the majority of the lesions were not present in the entire endometrium. In conclusion, after 
examining the entire endometrium, a remarkable high prevalence of endometrial pathology was 
found in asymptomatic women. The clinical meaning of these lesions is not yet clear, but endometrial 
pathology may frequently exist without symptoms.
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Introduction
Endometrial carcinoma is the most common gynecologic malignancy in the Western 
population1. Endometrial carcinogenesis is thought to be a combination of genetic
predisposition and environmental influences2. Most of endometrioid histology arises in a 
hyperplastic endometrium. In this type of endometrial carcinoma, unopposed estrogenic 
stimulation leads to orderly progression from endometrial proliferation to hyperplasia, atypical 
hyperplasia, and, finally, endometrioid endometrial carcinoma3. In about a quarter of women 
diagnosed as having endometrial atypical hyperplasia, development into endometrioid 
endometrial carcinoma occurs, within a period of around 4 years4,5. 
During the reproductive years, the endometrium is dynamic and undergoes hundreds 
of cycles of proliferation, differentiation, and shedding. In premenopausal women, the 
endometrium is expected to be proliferative or secretory, depending on the phase of the 
menstrual cycle. However, in postmenopausal women, it is expected that the decline of 
estrogen production of the ovaries will result in an atrophic endometrium6. However, excessive 
and unopposed estrogenic stimulation after menopause is described, and an unspecified 
proportion of menopausal women retain a weak proliferative pattern for many years7.
So far, the prevalence of endometrial lesions is mainly investigated in symptomatic 
women with abnormal bleeding. A limited number of studies investigated endometrial tissue 
in asymptomatic women. Based on review of biopsies, dilatation and curettage tissues, or 
pathology reports from hysterectomies, hyperplasia was reported in 0.6% to 5.5%, atypical 
hyperplasia was reported in 0.5% to 1.1%, and carcinoma was reported in 0.3% to 0.5% 
of the reviewed cases8-13. However, these studies are limited by the fact that endometrial 
sections of the hysterectomies were not reviewed, and embedding of the endometrium was 
performed according to routine protocol, including only 1 or 2 sections of the endometrium. 
It is known from the literature that endometrial pathology can present focally and is therefore 
easily missed if the entire endometrium is not embedded and reviewed14. Hence, routine 
sampling leaves the possibility that endometrial pathology will be missed. 
The aim of the current study is to improve knowledge on the nature of the endometrium 
in premenopausal and postmenopausal women without symptoms of endometrial disease. 
Therefore, the prevalence of endometrial pathology is determined in asymptomatic patients 
who received a hysterectomy for uterovaginal prolapse. The endometrium was entirely 
embedded in all cases for extensive histologic assessment.
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Materials and Methods
Patient Selection
In this prospective, multicenter study, women who were treated for uterovaginal prolapse 
with a vaginal, laparoscopically assisted, or abdominal hysterectomy were included. All women 
were treated in the Radboud University Nijmegen Medical Centre from July 2011 to October 
2012 or in TweeSteden Hospital and St Elisabeth Hospital, Tilburg, from February 2012 to 
October 2012. Exclusion criteria were uterus myomatosus, abdominal pain, or any signs or 
symptoms of endometrial disease (menorrhagia, metrorrhagia, or postmenopausal vaginal 
bleeding). Of the included women, clinical data including age, body mass index, menopausal 
status, parity, medical history, and use of hormone replacement therapy were extracted from 
the medical records.
Sampling of the Endometrium
After formalin fixation overnight, the uterus was sectioned for diagnostic purposes following 
routine protocol, including 1 or 2 endometrial sections for histologic assessment. The 
diagnostic process was completed by a pathologist, before the remaining endometrium was 
entirely sampled according to the Sectioning and Extensively Examining the Endometrium 
(SEE-End) protocol shown in Figure 1. The endometrium was cut transversely at 2-mm 
intervals before embedding in paraffin. All sections were stained with hematoxylin and eosin 
for histologic examination.
Viewing and Reviewing of the Endometrium
All endometrial sections were reviewed blindly by 3 of the authors (MM, YG, JB). In case of 
discrepancies, the case was discussed by all 3 authors, and consensus was reached. Review 
was performed systematically by checking the following items: the nature of the endometrium, 
the presence of additional pathology in the endometrium (eg, polyp, endometrial intraepithelial 
carcinoma, or carcinoma), the presence of adenomyosis or leiomyomas, and measurement 
of endometrial and myometrial thickness. The endometrium was grouped in 8 categories: 
proliferative endometrium, secretory endometrium, atrophy, disordered proliferative 
endometrium, simple hyperplasia (SH), complex hyperplasia (CH), simple atypical hyperplasia 
(SAH), complex atypical hyperplasia (CAH), and endometrial carcinoma. The categories SH 
and CH, SAH and CAH, and carcinoma were considered as endometrial pathology. 
Atrophic endometrium was defined as shallow endometrium with a thin basalis and with 
a few tubular glands lined by inactive epithelium6. Proliferative or secretory endometrium 
was defined as widely spread, sometimes tortuous, tubular glands that show mitotic activity, 
pseudostratification of the nuclei, and abundant stroma6. Proliferation in the endometrium 
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Figure 1: The endometrium was embedded enitrely following the SEE-
End protocol. After completing the diagnostic process, the remaining 
endometrium was sectioned in transverse direction with intervals of 2 mm. 
Redundant myometrium was removed to enable the display of several 
endometrial section in 1 section.
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of postmenopausal patients is defined as disordered proliferative. This diagnosis was 
considered when some of the glands showed proliferative activity, and the gland/stroma 
ratio was slightly increased but did not meet the criteria for hyperplasia14,15. Endometrial 
hyperplasia was defined as proliferation of glands with an increase in gland/stroma ratio of 3:1 
and a variety of abnormal architectural patterns14. Cytologic atypia was defined as enlarged, 
rounded, polymorphic nuclei with loss of polarity, prominent nucleoli, chromatin clumping, and 
an increased nuclear-to-cytoplasmic ratio15. Hyperplasia was categorized according to the 
World Health Organization classification system for hyperplasia, which is based on the study 
of Kurman and colleagues4. When focal areas of hyperplasia or disordered proliferation were 
identified, the percentages of the entire endometrium containing this pathologic feature were 
estimated. The diagnosis of hyperplasia was only made when present in more than 10% of 
the total endometrial surface. Endometrial thickness was measured in all areas containing 
pathologic lesions and in all areas with a nonpathologic diagnosis of the endometrium to 
enable comparison. At least 2 measurements were performed for each specific area of the 
endometrium.
Statistical Analysis
For comparisons between the groups of women with or without endometrial pathology, the 
Pearson’s χ2 test or the Fisher’s exact test, when appropriate, was used. For comparison of 
continuous variables between both groups, the Mann-Whitney U test was used.
Ethical Committee Approval
The study protocol was approved to be in accordance with the applicable rules concerning 
the review of research ethics committees and informed consent by the Research Ethics 
Committee of Radboud University Nijmegen Medical Centre and the Medical Ethical Test 
Committee of both St. Elisabeth Hospital and TweeSteden Hospital, Tilburg. 
Results
Patient Characteristics
A total of 68 women who underwent a hysterectomy for uterovaginal prolapse were included 
in the study. Clinical characteristics are shown in Table 1. The mean age was 61 years (range, 
33-89 years), and 71% (48/68) were postmenopausal. In most women, a vaginal hysterectomy 
was performed, and in a few women, an abdominal hysterectomy was performed. The mean 
body mass index of these women was 25.9 kg/m2 (range, 19.6-39.8 kg/m2), and a minority 
had comorbidity-like diabetes mellitus or hypertension. Twelve percent (8/68) used hormone 
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replacement therapy, estrogen supplementation opposed with progesterone, for menopausal 
complaints.None of the women had a history of tamoxifen use. Furthermore, 9% (6/68) of the 
women used contraceptives; 3 used an intrauterine device, and 3 used oral contraceptives. 
The mean number of deliveries in the studied group was 2.7 (range, 1-8). None of the women 
were diagnosed as having a malignancy or premalignancy in the past.
Table 1: Clinical characteristics of all included women (N=68)
Characteristic N/mean (%/range)
Age (y) (N=68) 60.5 (33-89)
BMI (kg/m2) (N=41) 25.9 (19.6-39.8)
Parity (N=47) 2.7 (1.0-8.0)
Menopausal status
     Premenopausal 20 (29.4)
     Postmenopausal 48 (70.6)
Diabetes mellitus
     No 58 (85.3)
     Yes 6 (8.8)
     Unknown 4 (5.9)
Hypertension
     No 49 (72.1)
     Yes 15 (22.1)
     Unknown 4 (5.8)
Use contraceptives
     Oral 3 (4.4)
     Intrauterine device 3 (4.4)
     No or unknown 62 (91.2)
Use HRT
     No 56 (83.3)
     Yes 8 (11.8)
     Unknown 4 (5.9)
Type of operation
     Vaginal hysterectomy 62 (91.3)
     Laparoscopic-assisted hysterectomy 2 (2.9)
     Abdominal hysterectomy 2 (2.9)
     Unknown    2 (2.9)
Abbreviations: BMI, body mass index; HRT, hormone replacement 
therapy.
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Histology
The mean number of endometrial sections available for review, after applying the SEE-End 
protocol, was 6, including a mean number of 2 sections embedded for standard diagnostic 
examination. (Sections contained several small areas with endometrial tissue for histologic 
examination.) Results of assessment of the endometrial sections are shown in Table 2. 
Examples of all diagnosed categories in the endometrium are shown in Figure 2. Endometrial 
pathology was observed in 25% (17/68) of the reviewed cases: SH in 15% (10/68), CH in 
2% (1/68), SAH in 3% (2/68), CAH in 3% (2/68), and endometrioid endometrial carcinoma 
in 3% (2/68). The remaining 75% of cases were diagnosed without endometrial pathology. 
Proliferative endometrium was found in 15% (10/68) of cases, secretory endometrium in 7% 
(5/68), and atrophic in 46% (31/68). Furthermore, in 17 (25%) cases, a polyp was found in the 
endometrium. One of these polyps was diagnosed with atypical hyperplasia that was located 
both in the polyp as well as in the adjacent endometrial tissue. In all other polyps, no atypical 
hyperplasia was identified.
Results were specified for premenopausal and postmenopausal women (Table 2). In the 
postmenopausal women, 10% (5/48) showed disordered proliferative endometrium. Of the 
premenopausal women, 20% (4/20) had atrophic endometrium, and all 4 used contraceptives.
The prevalence of endometrial pathology was significantly different in postmenopausal 
and premenopausal women, 33% and 5%, respectively. Furthermore, in the group of women 
with endometrial pathology, 13% (2/15) used hormone replacement therapy. One of these 
2 women had SH, and 1 had CAH. In the group of women without endometrial pathology, 
also 12% (6/49) used hormone replacement therapy. In addition, the presence of additional 
endometrial and myometrial pathology is shown in Table 2. 
In a significant percentage of the women, the endometrium was heterogeneous. In Table 3, 
an overview is given of what percentage of endometrial pathology covered the endometrial 
surface. In 2 women, a focal area was identified with intramucosal endometrioid endometrial 
carcinoma. Both were located in a background of atypical hyperplasia, and only a small area 
was diagnosed as atrophic in one case and disordered proliferative in the other (Table 3).
Changes of Endometrial Diagnosis after Review of the Initial Sections and the 
Additional Embedded Endometrial Sections
In 12% (8/68) of women, the additional embedding of the entire endometrium resulted in the 
identification of more severe endometrial pathology. In 5 cases, the primary sections revealed 
atrophic or disordered proliferative endometrium, whereas after viewing the extra embedded 
endometrium, sampled in accordance with the SEE-End protocol, the diagnosis was changed 
to SH in 4 cases and atypical hyperplasia in 1 case. In 3 cases, there was SH in the initial 
sections. However, after viewing the additional sections, a diagnosis of CAH was made in 1 
case, and a focus of intramucosal endometrioid endometrial carcinoma with adjacent atypical 
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hyperplasia was identified in the 2 other cases. Both women with endometrial carcinoma were 
postmenopausal.
Note that in 1 case with a focus of intramucosal carcinoma, the preoperative ultrasound of 
the uterus showed an intracavitary abnormality. A biopsy was performed, and this abnormality 
was diagnosed as a benign polyp. When we reviewed this particular case, we confirmed the 
presence of a benign polyp. The CAH and focus of carcinoma in this case were identified in 
Characteristic Total (N=68) Premenopausal (N=20) Postmenopausal (N=48)
Endometrial diagnosis
     Proliferative 10 (14,7%) 10 (50.0%) -
     Secretory 5 (7.4%) 5 (25.0%) -
     Atrophic 31 (45.6%) 4 (20.0%) 27 (56.3%)
     Disordered proliferative 5 (7.4%) - 5 (10.4%)
     SH 10 (14.7%) 1 (5.0%) 9 (18.8%)
     CH 1 (1.5%) 0 (0.0%) 1 (2.1%)
     SAH 2 (2.9%) 0 (0.0%) 2 (4.2%)
     CAH 2 (2.9%) 0 (0.0%) 2 (4.2%)
     Endometrioid endometrial carcinoma 2 (2.9%) 0 (0.0%) 2 (4.2%)
Additional identified lesions
     Polyp
          No 51 (75%) 18 (90.0%) 23 (68.7%)
          Yes, benign 15 (22.1%) 2 (10.0%) 13 (27.1%)
          Yes, hyperplastic 2 (2.9%) 0 (0.0%) 2 (4.2%)
     Metaplasia
          No 52 (76.5%) 17 (85.0%) 35 (72.9%)
          Yes, tubal 13 (19.1%) 3 (15.0%) 10 (20.8%)
          Yes, clear cel 3 (4.4%) 0 (0.0%) 3 (6.2%)
     Adenomyosis
          No 56 (82.4%) 17 (85.0%) 39 (81.2%)
          Yes 12 (17.6%) 3 (15.0%) 9 (18.8%)
     Leiomyomas
          No 52 (76.5%) 16 (80.0%) 36 (75.0%)
          Yes 16 (23.5%) 4 (20.0%) 12 (25.0%)
Table 2: Pathologic characteristics after review
Abbreviations: CAH, complex atypical hyperplasia; CH, complex hyperplasia; SAH, simple atypical hyperplasia; SH, 
simple hyperplasia.
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the adjacent endometrium and not in the polyp. In other cases, including the second case with 
a focus of carcinoma, no abnormalities were reported on the preoperative ultrasound.
Comparison of Patients without and with Endometrial Pathology
Women with and without endometrial pathology were compared with respect to clinical 
and pathologic characteristics (Table 4). Women with endometrial pathology were revealed 
to be significantly older and more often postmenopausal compared with the cases without 
endometrial pathology. Furthermore, the mean number of deliveries was higher in patients with 
endometrial pathology. The mean body mass index of patients with endometrial pathology was 
not significantly higher compared with the patients without endometrial pathology (27.8 kg/m2 
[range, 23.1-39.8 kg/m2] versus 25.3 kg/m2 [range, 19.6-36.8 kg/m2]; p=0.114). Preoperative 
ultrasound results showed no difference between women identified with or without endometrial
pathology. In only 1 case, an endometrial thickness above the threshold level of 4 mm was 
measured on preoperative ultrasound and was diagnosed as proliferative after histologic 
assessment. Available results of preoperative ultrasound of women in which endometrial 
pathology was identified are shown in Table 3.
Furthermore, no difference was found between endometrial thickness of pathologic and 
nonpathologic endometrial lesions measured in histologic sections. The mean endometrial 
thickness of areas with (cystic) atrophic endometrium, (disordered) proliferative, simple 
(atypical) hyperplasia, complex (atypical) hyperplasia, and carcinoma was 1.3 mm (range, 
0.3-4.0 mm), 0.8 mm (range, 0.5-1.3 mm), 1.2 mm (range, 0.6-2.2 mm), 1.3 mm (range, 0.7-
2.2 mm), and 1.2 mm (range, 1.0-3.0 mm), respectively.
 
Figure 2: The nature of the endometrium in this prospective cohort of uterovaginal prolapsed cases was diagnosed in 
the following categories: 
A) Atrophic endometrium. 
B) Cystic atrophic. 
C) Proliferative endometrium. 
D) Secretory endometrium. 
E) Disordered proliferative. 
F) Simple hyperplasia (SH). 
G) Complex atypical hyperplasia (CAH). 
H) Identical area with CAH, as in picture G, but at a higher level of magnification to show the atypia. 
I) Focus of intramucosal carcinoma. 
J) Overview of endometrium with identical area with focus of intramucosal carcinoma as in image I, but at a lower level 
of magnification. Adjacent to the focus of intramucosal carcinoma, areas with cystic atrophic endometrium to CAH (A-G 
and I, x10; H, x20; J, x2). 
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Characteristic No pathology (N=51) Pathology (N=17) p value
Age (y), mean (range) 57.7 (33-89) 68.9 (51-85) 0.002a
BMI (kg/m2), mean (range) 25.3 (19.6-36.8) 27.8 (23.1-39.8) 0.114a
Parity, mean (range) 2.5 (1-8) 3.5 (1-7) 0.028a
Menopausal status, N (%)
     Premenopausal 19 (37.3) 1 (5.9) 0.015c
     Postmenopausal 32 (62.7) 16 (94.1)
Diabetes mellitus, N (%)
     No 45 (91.8) 13 (86.7) 0.618c
     Yes 4 (8.2) 2 (13.3)
Hypertension, N (%)
     No 38 (77.6) 11 (73.3) 0.737c
     Yes 11 (22.4) 4 (26.7)
Use contraceptives, N (%)
     No 14 (70.0) 4 (100.0) 0.539c
     Yes 6 (30.0) 0 (0.0)
Use HRT, N (%)
     No 43 (87.7) 13 (86.7) 0.645c
     Yes 6 (12.3) 2 (13.3)
Additional identified lesions
     Polyp, N (%)
          No 41 (80.4) 10 (58.8) 0.075b
          Yes 10 (19.6) 7 (41.2)
     Metaplasia, N (%)
          No 40 (78.4) 12 (70.6) 0.509b
          Yes 11 (21.6) 5 (29.4)
     Adenomyosis, N (%)
          No 46 (90.2) 10 (58.8) 0.003b
          Yes 5 (9.8) 7 (41.2)
     Leiomyomas, N (%)
          No 40 (78.4) 12 (70.6) 0.509b
          Yes 11 (21.6) 5 (29.4)
Thickness myometrium (mm; N=46), mean (range) 12.38 (8.0-19.0) 11.63 (8.0-14.0) 0.598a
Thickness endometrium (mm; N=67), mean (range) 1.23 (0.2-4.0) 1.16 (0.7-2.5) 0.196a
Table 4: Comparison of clinicopathologic characteristics between women with and without endometrial pathology
Abbreviations: BMI, body mass index; HRT, hormone replacement therapy.
 a Mann-Whitney U test.
 b Pearson’s Chi square.
 c Fisher’s exact test.
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Discussion
In the current prospective study, we systematically sampled the entire endometrium 
of women who underwent a hysterectomy for uterovaginal prolapse. A surprisingly high 
prevalence of endometrial abnormalities was identified in these asymptomatic women. In 25% 
of the women, endometrial pathology was found: hyperplasia was shown to be present in 
16%, atypical hyperplasia in 6%, and a small focus of intramucosal endometrioid endometrial 
carcinoma in 3%. The endometrial thickness measured in the endometrial sections was 
not increased if endometrial pathology was present, indicating that it is unlikely to find this 
pathology preoperatively with ultrasound. 
Few studies analyzed the endometrium in asymptomatic women and reported a prevalence 
of endometrial abnormalities in only 5%. In studies examining curettage material in 
asymptomatic women, a prevalence of hyperplasia was found in 0.6% to 4.9%, hyperplasia 
with atypia in 0.5% to 0.6%, and adenocarcinoma in 0.5%8,11,12. When analyzing the pathology 
reports of hysterectomy specimens removed for benign reasons, hyperplasia was found to be 
present in 1.2% to 5.5%, atypical hyperplasia in 0.5% to 1.1%, and adenocarcinoma in 0.3% 
to 0.5%9,10,13,16,17. Restricted endometrial sampling and not performing a review of the histologic 
assessment are both important limitations that can putatively explain the large difference in the 
prevalence of endometrial lesions found in comparison with the current prospective study.
The current study demonstrates the heterogeneity of the endometrium. Endometrial 
abnormalities can easily be missed when performing only standard sampling of the endometrium 
of around 2 sections. In 8 women (12%), the more extended embedding of the endometrium 
resulted in a more severe diagnosis, which was exclusively present in the additional embedded 
sections. In 2 women, we found a small focus of intramucosal endometrioid carcinoma, which 
was not present in the standard embedded sections. Noteworthy is that in these 2 women, 
a diagnosis of hyperplasia was already made on the primary endometrial sections. This 
indicates that more extended review of the endometrium might be preferable in the uteri of 
(asymptomatic) women in whom hyperplasia is found in the primary embedded slides.
An important strength of this observational study is that it is prospective and multicenter. 
Limitations of the study are that the collection of the clinical data was retrospective and 
therefore sometimes incomplete. Furthermore, 8 patients did use hormone replacement 
therapy. However, estrogen supplementation in these patients was opposed with progesterone, 
and the number of patients using hormone replacement therapy was equal in the group 
with and without endometrial pathology. All patients underwent a hysterectomy, so follow-
up of the endometrial lesions was not possible. The aim of the study was to analyze the 
appearance of the endometrium in hysterectomy tissue of a general population. However, it is 
not investigated if hysterectomy tissue of women with prolapse uteri is comparable with tissue 
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from asymptomatic women in the general population.
Moreover, the diagnosis of simple and complex hyperplasia with or without atypia is 
moderately reproducible. It has been proposed by several authors to use the hyperplasia–
endometrial intraepithelial neoplasia classification system for the diagnosis of pathologic 
endometrial proliferation18. However, the reproducibility of the endometrial intraepithelial 
neoplasia system is a matter of debate, as well19. Therefore, we used the World Health 
Organization classification system that is in widespread use, well understood, and based on 
the classification system of Kurman and colleagues4. 
The current study provides more insight into the appearance of the endometrium in 
hysterectomy tissue of asymptomatic women. The patients included in our study
already underwent a hysterectomy, making the clinical importance of exactly identifying all 
types of endometrial lesions for these cases questionable. However, based on the results, 
we might conclude that endometrial lesions are more common in asymptomatic women than 
thought until now. These results are in line with a study on tubal epithelial lesions in healthy 
women, reporting the common presence of hyperplasia and minor atypia in the tubal epithelium, 
as well20. Moreover, Horwitz et al21,22, in 1981, already observed a rate of endometrial cancer 
at autopsy 4 times greater than during when the patient was alive, indicating that a proportion 
of endometrial cancers may exist without symptoms.
The clinical significance of (focal) hyperplasia has not yet been determined14. We considered 
the endometrium hyperplastic if at least 10% of the endometrium met the
criteria for hyperplasia, but the definition and impact of focal hyperplasia remain a gray area. 
Atypical hyperplasia diagnosed in endometrial curettings develops into carcinoma in about 
25%4. However, if and in which percentage focal atypical hyperplasia needs to be present 
before it might progress to malignant disease is unclear. 
Furthermore, it is suggested in the literature that a state of weak proliferation can be found 
in the endometrium in up to half of postmenopausal women7. A plausible explanation for this 
phenomenon is the gradually declining estrogen stimulation without the opposition of ovulation 
in the first years after menopause. The results of our study confirm that a significant percentage 
of the postmenopausal patients has some form of weak proliferative endometrium. Disordered 
proliferation is stated to be a clinically benign process because progression to hyperplasia 
may occur, but progression to carcinoma is extremely rare14. In our study, we therefore did not 
consider disordered proliferative endometrium as a pathologic condition. 
Factors known to cause an increased risk of endometrial hyperplasia are all linked to 
unopposed, increased, or prolonged estrogenic stimulation, such as late menopause, obesity, 
nulliparity, anovulatory cycles, diabetes mellitus, use of hormonal replacement therapy, and 
treatment with tamoxifen2,23. In the cohort of this study, except for a significant more advanced 
age and fewer premenopausal patients in the group with endometrial pathology, there were 
no differences in clinical characteristics between the groups with and without endometrial 
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pathology. An explanation for why some of the postmenopausal patients developed hyperplasia 
and others did not cannot be given based on these results.
In conclusion, in this descriptive study on histologic assessment of the entire endometrium 
of premenopausal and postmenopausal asymptomatic women, we found a high number of 
women with endometrial pathology in, especially, the postmenopausal group. If hyperplasia 
is identified in primary endometrial sections, additional sampling of the endometrium is 
recommended to exclude the presence of (pre)malignancy. Probably, there is a higher 
prevalence of endometrial pathology in asymptomatic women than we know of, based on the 
existing literature, and endometrial pathology may frequently exist without symptoms.
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Abstract
Serous ovarian cancer is suggested to develop from epithelium embryologically derived from the 
Müllerian ducts. The aim of the current study is to thoroughly, analyze the epithelium derived from the 
Müllerian ducts (cervix, endometrium and fallopian tubes) in serous ovarian cancer patients. Sixty 
women diagnosed with serous ovarian carcinoma were included in this multicenter, observational 
study. Tissues were embedded completely for histological assessment, in accordance with the SEE-
Fim and SEE-End protocol (Sectioning and Extensively Examining of the Fimbriated end; and—
Endometrium), and prevalence of cervical, as well as endometrial and tubal pathology was analyzed. 
In 31 (52%) cases, a pathologic lesion was identified, and in 16 (27%) of these cases coexistence of 
pathologic lesions. In 1 case, severe dysplasia was found in the cervix, in 9 (15%) cases endometrial 
intraepithelial carcinoma, in 19 (32%) cases atypical hyperplasia, and in 23 (43%) cases serous 
tubal intraepithelial carcinoma. Serous tubal intraepithelial carcinoma was seen significantly more 
often concurrent with endometrial atypical hyperplasia or endometrial intraepithelial carcinoma than 
with benign endometrium (64% vs 28%; p=0.01). To conclude, histological assessment of epithelium 
derived from Müllerian ducts of serous ovarian cancer patients resulted in the identification of 
endometrial intraepithelial carcinoma, serous tubal intraepithelial carcinoma and/or endometrial 
atypical hyperplasia in more than half of cases. Coexistence of these pathologic lesions was common, 
and might represent an effect of field carcinogenesis or tumor implantation of migrating cells.
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Introduction 
Epithelial ovarian cancer has the highest mortality rate of gynecologic malignancies. It 
was diagnosed with an incidence of 1400 women in The Netherlands in 2010, whereas 1065 
women died from this disease1,2. The vast majority of epithelial ovarian cancers are high-grade 
serous carcinomas, accounting for 70% of cases. High-grade serous carcinomas are mostly 
diagnosed in an advanced stage of disease due to non-specific symptoms and a tendency for 
early peritoneal spread3. The overall survival of patients with ovarian carcinoma has improved 
only minimally, and one of the reasons is that its route of development has not been totally 
clarified yet. 
It is thought that ovarian carcinoma develops from tissues that are embryologically derived 
from the Müllerian ducts and that the ovaries are involved secondarily4,5. Müllerian ducts 
develop in early embryogenesis into the upper part of the vagina, uterus, and fallopian tubes5. 
In the tubes the in situ carcinoma, serous tubal intraepithelial carcinoma (STIC), has been 
identified6,7. A STIC is found in 41% of patients diagnosed with serous ovarian carcinoma6,8-10. 
However, in a significant part of serous ovarian cancer patients, no STIC or predisposition for 
serous carcinoma has been found. Recently, endometrial intraepithelial carcinoma (EIC), was 
suggested as an alternative source for serous ovarian cancers, but its prevalence in ovarian 
cancer patients is unknown11.
The standard surgical treatment of serous ovarian carcinomas includes bilateral salpingo-
oophorectomy and hysterectomy. The most important reason to perform a hysterectomy is that 
the uterine serosa is one of the most frequent sites of peritoneal spread12. Moreover, double 
primary endometrial carcinomas are identified in 10% of endometrioid ovarian carcinomas 
and in 2–5% of other ovarian carcinoma types13-15.
The current study was performed to analyze the cervix, endometrium and tubal epithelium 
thoroughly in serous ovarian cancer patients. Therefore, structural embedding of the entire 
endometrium and fallopian tubal epithelium was performed and extensive histological 
assessment of tissue for all cases.
Materials and methods
Study Design and Case Selection
In this prospective, multicenter, cohort study, all women with high-grade serous ovarian 
cancer undergoing a primary or interval debulking surgery that included hysterectomy and 
bilateral salpingo-oophorectomy were identified. Women were operated at the Radboud 
University Nijmegen Medical Centre and Canisius Wilhelmina Hospital, Nijmegen, from 
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September 2010 to December 2012. Surgery was performed by a gynecologic oncologist. 
Clinical parameters, such as age, menopausal status, body mass index, BRCA-mutation 
status, treatment protocol, and medical history, were retrieved from medical records and 
pathology reports. Patients were classified and staged in accordance with the WHO 
classification and FIGO surgical staging adopted in 198816,17. Carcinomas were classified as 
primary ovarian if the largest tumor bulk was located in the ovaries. In case of simultaneous 
carcinoma involvement of the endometrium, additionally depth of myometrial invasion, ovarian 
tumor pattern, lymfovascular invasion and presence of STIC or EIC were used to differentiate 
primary ovarian from endometrial carcinoma18.
Histological Examination of Tissues Derived from the Müllerian Duct: Endocervix, 
Endometrium and Fallopian Tubes
All tissues were macroscopically assessed and described before formalin fixation overnight. 
The anterior side of the uterus was once cut several centimeters in longitudinal direction, from 
cervix toward fundus, to enable optimal fixation. The uterus was sampled using a systematic 
protocol with complete embedding of the endometrium, the SEE-End (Sectioning and 
Extensively Examining of the Endometrium) protocol (Figure 1). First of all, the uterus was cut 
longitudinally into two equal parts. Routine sections of the cervix uteri anterior and posterior 
were embedded, followed by a section of the isthmus region. A representative section of the 
fundus region was cut in longitudinal direction. Remaining endometrium was sectioned in 
transverse direction at intervals of 2–3 mm. For practical reasons, redundant myometrium 
was excised from additionally sampled sections to enable embedding of multiple endometrial 
samples in one paraffin block (Figure 1). In case of an endometrial polyp, it was embedded in 
toto. Representative sections were embedded for histological examination, such as polyps of 
the cervix or isthmus, leiomyomas, or other lesions.
The fallopian tubes were completely embedded for histological examination, in accordance 
with the SEE-Fim protocol (Sectioning and Extensively Examining of the Fimbriated end)19. 
The fimbriated end was amputated at the infundibulum and cut longitudinally in four sections 
to maximize exposure and optimize histological view of the tubal plicae. The fallopian tube 
was cross-sectioned at intervals of 2–3 mm19.
All histological sections were stained with hematoxylin and eosin and reviewed by two 
gynecopathologists. In case of discrepancies, consensus was reached between pathologists. 
The columnar epithelium of the cervix was examined for atypia, presence of adenocarcinoma 
in situ, or carcinoma. The nature of the endometrium was classified in the following categories: 
atrophic endometrium, proliferative, secretory, disordered proliferative, hyperplasia, atypical 
hyperplasia, EIC, or invasive carcinoma.
The classification system for endometrial hyperplasia outlined by the World Health Organization 
(WHO) in 2003 was used in the current study17,18. Hyperplasia was defined as proliferating 
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Figure 1: The entire endometrium was sampled and embedded following the SEE-End protocol (Sectioning and 
Extensively Examining the Endometrium). After sectioning the routine diagnostic samples, the remaining endometrium 
was sectioned in transverse direction at intervals of 2–3mm. Redundant myometrium was removed from additionally 
sampled endometrium to enable the display of several endometrial sections in one paraffin block. (A) Cervix uteri anterior 
and posterior. (B) Isthmus.(C) Representative section of fundus region of the endometrium, including an endometrial 
polyp. (D) Representative slide of small leiomyoma. (E–H) Remaining endometrium and endometrial polyp were 
embedded in accordance with the SEE-End protocol.
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endometrium with architectural abnormalities such as budding and branching. Cells are mostly 
enlarged and exhibit nuclear pseudostratification, with an increased number of mitotic figures. 
An increased gland-to-stroma ratio (3:1) is required for diagnosis of hyperplasia, and it can 
present with or without atypical cells20. In case of proliferative features, in absence of increased 
gland-to-stroma ratio, the endometrium was diagnosed as proliferative. The endometrium of 
postmenopausal women with proliferative features was considered disordered proliferative. 
Endometrial intraepithelial carcinoma was proposed by Ambros et al21, and described as 
noninvasive, serous carcinoma resembling cells, that replace the endometrial surface 
epithelium and glands. An example of atypical hyperplasia and EIC is shown in Figure 2.
Figure 2: 
A) An example of serous carcinoma located in an ovary (level of magnification: x100). The following 
pathologic lesions were identified in this cohort of women with serous ovarian carcinoma (level of 
magnification: x100).
B) Serous tubal intraepithelial carcinoma located in the tubal epithelium, with adjacent benign tubal 
epithelium. 
C) Endometrial intraepithelial carcinoma. 
D) Atypical hyperplasia located in endometrial glands.
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The tubal sections were classified as follows: normal tubal epithelium, hyperplasia, minor 
epithelial atypia, STIC, or invasive carcinoma22. Tubal hyperplasia was defined as cellular 
crowding in absence of atypical nuclei, and minor epithelial atypia as cellular crowding, with 
slight cellular atypia and nuclei with small nucleoli, but without loss of polarity. Serous tubal 
intraepithelial carcinoma is defined as noninvasive, serous carcinoma resembling cells that 
replace the tubal epithelium23-25. They are characterized by a high nuclear-to-cytoplasm ratio, 
nuclear pleomorphism, stratification, and a high mitotic index. Further, the presence of STIC in 
the fimbrial part of the fallopian tube, the non-fimbrial part, or in both locations was recorded. 
Histological Examination of the Ovaries
The ovaries were embedded following standard protocol and sections were scored for 
histological carcinoma type, the location and extent of the tumor, and the tumor differentiation 
grade (low or high grade)26,27. Furthermore, concurrent borderline tumors in the ovaries or 
other abnormalities were scored.
Immunohistochemistry
Immunohistochemical staining was performed for all cases identified with an EIC, and 
coexisting STIC and/or atypical hyperplasia. Representative sections of 4 mm were sliced 
from formalin-fixed paraffin-embedded samples and incubated with monoclonal antibodies 
against p53 (dilution 1:250; Clone DO-7; Neomarkers, Fremont, CA, USA), Ki-67 (dilution 
1:100; Clone MIB-1; Dako, Glostrup, Denmark), and WT1 (dilution 1:20; Clone WT49, NCL-
L-WT1-562, Leica Biosystems, Newcastle Upon Tyne, UK). Antigen retrieval was processed 
according to the manufacturers’ guidelines. Immunohistochemical stainings were interpreted 
by two of the authors (JB, AAGvT). Staining was scored as the percentage of positive nuclear 
tumor cells and classified as follows: 0%, <5%, 5–25%, 26–50%, 51–75%, >75%. Intensity of 
staining was scored as weak, moderate or strong.
Statistical Analysis
Statistical analyses were performed using SPSS software version 20.0 (SPSS Inc., Chicago, 
IL, USA) and p<0.05 (two-sided test) was considered statistically significant. For comparison 
of groups of women with or without serous tubal and/or EIC, the Pearson’s Chi square test was 
used, or when appropriate, the Fisher’s exact test. For comparison of continuous variables 
between both groups, the Mann-Whitney U test was used.
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Table 1: Clinical characteristics of the serous ovarian cancer patients (N=60)
Characteristics N/mean (%/range)
Age (years) 63 (42–79)
Parity 2 (0–5)
Menopausal status
     Premenopausal 7 (12%)
     Postmenopausal 51 (88%)
Body mass index (kg/m2) 24 (17–40)
Tubal ligation
     No or unknown 56 (93%)
     Yes 4 (7%)
Hormonal substitutive treatment
     No or unknown 56 (93%)
     Yes 4 (7%)
BRCA-mutation
     No or unknown 56 (93%)
     Yes (BRCA 1 mutation) 4 (7%)
Prior diagnosis of cancer
     No 49 (82%)
     Yes, 11 (18%)
          Breast cancer 8 (13%)
          Colon cancer 2 (3%)
          Melanoma 1 (2%)
FIGO stage
     I 3 (5%)
     II 4 (7%)
     III 47 (80%)
     IV 5 (8%)
     Unknown 1
Treatment management
     Primary debulking 15 (25%)
     Interval debulking after chemo 45 (75%)
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Results
Clinical Characteristics
The study cohort included 60 women diagnosed with high-grade serous ovarian cancer. 
Clinical characteristics of these women are shown in Table 1. Mean age was 63 years, 
the majority were postmenopausal (88%) and mean body mass index was 24 kg/m2. The 
FIGO stage distribution was as follows: 3 (5%) women had a FIGO stage I, 4 (7%) a stage 
II, 47 (80%) a stage III, and 5 (8%) a stage IV. Seventy-five percent of patients received 
chemotherapy before debulking surgery.
Eleven (18%) patients had another cancer diagnosed before their diagnosis of ovarian 
carcinoma: eight were diagnosed with breast carcinoma, two with colon carcinoma and one 
with melanoma. In four cases, the breast carcinoma was diagnosed within 6 months from the 
ovarian carcinoma, and they were considered double primary carcinomas. In four (7%) cases 
of the study population, a BRCA1 mutation was identified, but analysis was not performed for 
all included women. Three BRCA1 mutation carriers also had a diagnosis of breast carcinoma.
Overview of Tissues Derived from the Müllerian duct in Patients with Serous Ovarian 
Cancer
In three cases, the cervix was not available for histological examination, because a 
supravaginal hysterectomy was performed at debulking surgery. No pathology could be found 
in the endocervix of women with serous ovarian carcinoma, except for one case with serous 
carcinoma expanding towards the cervix, and another case with severe dysplasia (CIN 3).
In Table 2, results are shown of the histological examination of the endometrial sections. 
The endometrium was diagnosed as benign endometrium in 38 (63%) cases: in 29 (48%) 
cases the endometrium was atrophic, or (disordered) proliferative or secretory, and in 9 cases 
(15%) hyperplastic. In 13 (22%) cases the endometrium showed atypical hyperplasia, in 3 
(5%) cases an EIC was identified, and in 6 (10%) cases EIC and atypical hyperplasia. In total, 
EIC was found in 9 (15%) cases and atypical hyperplasia in 19 cases (32%).
Concurrent invasive serous endometrial carcinoma was found in five cases, and all occurred 
in cases diagnosed with additionally EIC and/or atypical hyperplasia. Invasive endometrial 
carcinoma was present in 23% (5/22) of cases diagnosed with EIC and/or atypical hyperplasia. 
All invasive endometrial carcinomas were of serous type. In one case it was seen concurrent 
to atypical hyperplasia, in one case concurrent to EIC, and in three cases concurrent to both 
EIC and atypical hyperplasia. In one of the latter, the endometrial and ovarian carcinoma 
were interpreted as double primaries, with the largest primary carcinoma located in the 
endometrium and a second focus of carcinoma located adjacent to borderline carcinoma in 
the left ovary. Four cases were classified as primary ovarian carcinoma with metastasis in the 
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endometrium, as the largest carcinoma mass was located in the ovary and diffuse ovarian 
involvement was seen.
Results of histological assessment of the tubal epithelium were shown in Table 3. In 18 (33%) 
cases the tubal epithelium was normal, in 2 (4%) cases hyperplasia was found, in 11 (20%) cases 
Endometrial entities N (%)
60 (100%)
Benign endometrium 38 (63%)
     Atrophic 11 (18%)
     Cystic atrophic 9 (15%)
     Secretory 1 (2%)
     Proliferative 4 (7%)
     Disordered proliferative 4 (7%)
     Non-atypical hyperplasia 9 (15%)
Atypical hyperplasia 13 (22%)
Endometrial intraepithelial carcinoma 3 (5%)
Endometrial intraepithelial carcinoma + atypical hyperplasia 6 (10%)
Table 2: Results of histological assessment of the endometrium in a cohort of serous ovarian 
cancer patients, sampled in accordance with the SEE-End (Sectioning and Extensively Exa-
mining of the Endometrium) protocol
Table 3: Results of histological assessment of the fallopian tubal epithelium in a cohort of 
serous ovarian cancer patients, sampled in accordance with the SEE-Fim (Sectioning and 
Extensively Examining of the Fimbriated end) protocol
Tubal entities N (%)
54 (100%)
Normal tubal epithelium 18 (33%)
Hyperplasia 2 (4%)
Minor epithelial atypia 11 (20%)
Serous tubal intraepithelial carcinoma 23 (43%)
Missing 6*
*Fallopian tubes were removed in previous surgery or could not be
identified in the tumor mass.
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minor epithelial atypia, and in 23 (43%) cases STIC was identified. Serous tubal intraepithelial 
carcinoma was identified in the fimbrial region of the fallopian tubes in 15 (65%) cases, in the 
non-fimbrial region in 4 (17%) cases, and in both fimbrial and non-fimbrial regions in 4 (17%) 
cases. In six (8%) cases the tubal epithelium was not available for histological assessment: 
in four cases the tubes could not be identified in the tumor mass, and in two cases the tubes 
were already removed during incomplete debulking surgery in another hospital.
In 50% (30/60) of cases with serous ovarian carcinoma, also invasive carcinoma was found 
in the tubal epithelium. The carcinoma was restricted to the fimbrial part of the tube in 28% 
(17/60) of cases. In 60% (18/30) of cases with serous invasive tubal carcinoma, additionally a 
serous intraepithelial carcinoma was found in the tubal epithelium, whereas STIC was found 
in only 17% (5/30) of cases without serous tubal carcinoma.
Characteristics of Serous Ovarian Carcinoma with EIC and/or STIC
Clinical and pathological characteristics were compared between groups of women 
diagnosed with EIC and/or STIC, and women diagnosed without these intraepithelial 
carcinomas (Table 4). None of the characteristics were significantly different between the 
two groups of women, except that the diagnosis of cancer before the ovarian carcinoma was 
more common in cases diagnosed with STIC and/or EIC (p=0.004). Cases who underwent 
chemotherapy before debulking surgery did not show significantly more often STIC and/or EIC 
(p=0.872). Further, bilateral ovarian carcinoma involvement, enlarged ovaries, presence of 
additional ovarian lesions as cysts, or type of ovarian carcinoma pattern (diffuse/multinodular/
mainly surface) was not significantly different for cases diagnosed with or without STIC and/
or EIC.
Coexisting EIC and STIC in Müllerian-Derived Tissues of Serous Ovarian Cancer 
Patients
In Table 5, an overview is given of the histologically examined tissue of all cases in which 
a STIC, EIC, and/or atypical hyperplasia was found concurrent to serous ovarian carcinoma. 
In 31 (52%) cases one or more of these lesions were identified in the analyzed tissues, in 
9 (15%) cases STIC was found, in 5 (8%) atypical hyperplasia, in 1 (2%) EIC, and in 16 
(27%) cases multiple pathological lesions were found. In eight (13%) cases STIC and atypical 
hyperplasia, in five (8%) cases EIC, as well as atypical hyperplasia and STIC, in two (3%) 
cases EIC and atypical hyperplasia, and in one (2%) case STIC and EIC (Table 5).
Immunophenotypes of EIC were compared with phenotypes of coexisting STIC and/
or atypical hyperplasia (Table 6). Six cases analyzed with STIC and EIC, showed almost 
comparable p53 as well as Ki-67 expression in coexisting lesions. WT1 showed a difference 
in expression of more than one expression class in three cases, and was comparable in 
two. In one of these cases, tissue of the STIC was not available for additional incubation 
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Characteristics No EIC or STIC (N=28) EIC or STIC (N=26) p value
N/mean, %/range N/mean, %/range
Clinical characteristics
     Age (years) 63 (42–79) 63 (47–77) 0.822a
     Parity 2 (0–4) 2 (0–5) 0.139a
     Menopausal status 1.000b
          Premenopausal 3 (11%) 3 (12%)
          Postmenopausal 25 (89% 21 (88%)
     Body mass index (kg/m2) 24 (17–30) 25 (18–40) 0.920a
     BRCA-mutation 2 (7%) 2 (8%) 1.000b
     Prior diagnosis of cancer 
          Yes 1 (4%) 9 (35%) 0.004b
               Breast cancer 1 (4%) 7 (27%)
     Treatment management 0.872c
          Primary debulking 7 (25%) 7 (27%)
          Interval debulking 21 (75%) 19 (73%)
Pathological characteristics
     Ovarian tumor pattern 0.329c
          Diffuse 15 (56%) 12 (48%)
          Multinodular 7 (26%) 4 (16%)
          Bulk on surface 5 (19%) 9 (36%)
     Bilateral ovarian carcinoma 24 (86%) 18 (69%) 0.196b
     Enlarged ovaries (>5cm) 11 (39%) 8 (31%) 0.449c
     Borderline tumor 1 (4%) 2 (8%) 0.604b
     Cyst (simple) 6 (21%) 5 (19%) 0.841b
     Endometriosis in the ovary 0 (0%) 1 (4%) 0.481b
aMann–Whitney U test. bPearson’s Chi square test. cFisher’s exact test.
Abbreviations: EIC, endometrial intraepithelial carcinoma; STIC, serous tubal intraepithelial carcinoma.
Table 4: Comparison of characteristics between serous ovarian cancer patients with or without EIC and/or STIC 
(N=54)
5M
üllerian precursor lesions in serous ovarian cancer patients, using the S
E
E
-Fim
 and S
E
E
-E
nd protocol
97
Endometrium Fallopian tube
Case Cervic premalignancy Premalignancy Malignancy Premalignancy Malignancy
1 - EIC + AH - STIC Yes
2 - EIC + AH - STIC (fimbrial) -
3 - EIC + AH Yes STIC Yes
4 - EIC + AH Yes STIC (fimbrial) Yes
5 - EIC + AH - - -
6 - EIC + AH Yes - -
7 - EIC Yes STIC (fimbrial) Yes
8 - EIC - STIC (fimbrial) Yes
9 - EIC - - -
10 - AH Yes STIC (fimbrial) Yes
11 - AH - STIC (non-fimbrial) Yes
12 - AH - STIC (fimbrial) Yes
13 - AH - STIC (fimbrial) Yes
14 - AH - STIC (fimbrial) Yes
15 - AH - STIC Yes
16 - AH - STIC (fimbrial) Yes
17 - AH - STIC (fimbrial) -
18 CIN 3 AH - - -
19 - AH - - -
20 - AH - - -
21 - AH - - Yes
22 - AH - - Yes
23 - - - STIC (fimbrial) -
24 - - - STIC (fimbrial) -
25 - - - STIC (fimbrial) Yes
26 - - - STIC (non-fimbrial) Yes
27 - - - STIC (non-fimbrial) Yes
28 - - - STIC (fimbrial) -
29 - - - STIC (fimbrial) Yes
30 - - - STIC (non-fimbrial) Yes
31 - - - STIC Yes
Table 5: Overview of Müllerian derived tissues in serous ovarian cancer patients in which a STIC, EIC, and/or endome-
trial atypical hyperplasia was found
Abbreviations: AH, atypical hyperplasia; EIC, endometrial intraepithelial carcinoma; STIC, serous tubal intraepithelial 
carcinoma, located in the fimbrial part of the tube, non-fimbrial part or both locations; CIN3, cervical intraepithelial neo-
plasia 3, severe dysplasia.
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with monoclonal antibody against WT1. Immunophenotypes of coexisting EIC and atypical 
hyperplasia showed lower expression for p53 and Ki-67 in atypical hyperplasia compared with 
EIC, and WT1 was negative in all atypical hyperplasia, regardless of the WT1 expression in 
the EIC. 
STIC, EIC and/or Atypical Hyperplasia Occur Significantly more often Synchronously
In Table 7, the prevalence of STIC is analyzed in concurrence to the different entities 
identified in the endometrium. STIC was significantly more often found in concurrence to 
EIC, atypical hyperplasia, and/or invasive endometrial carcinoma compared with normal 
endometrium (p=0.010; Pearson’s Chi square). In 64% of cases identified with STIC, an EIC 
and/or atypical hyperplasia was found in the endometrium, whereas in 28% of cases with 
STIC the endometrium was benign. Of the latter, in four cases non-atypical hyperplasia was 
found in the endometrium.
Discussion
High-grade serous ovarian carcinoma is suggested to originate from tissues embryologically 
derived from the Müllerian ducts, followed by spread into the abdominal cavity by exfoliation 
and migration of loose cohesive cells23,28. The fallopian tubes have been extensively examined 
Table 7: The coexistence of STIC and EIC and/or endometrial atypical hyperplasia in 
serous ovarian cancer patients (N=54)
STIC
Endometrium N N (%)
Benign 32 9 (28%)
Premalignancy 22 14 (64%)
     Atypical hyperplasia 13 8 (62%)
     EIC 3 2 (67%)
     EIC + atypical hyperplasia 6 4 (67%)
Malignancy 5 3 (60%)
p=0.010 (Pearson’s Chi square test)
Abbreviations: EIC, endometrial intraepithelial carcinoma; STIC, serous tubal intraepithe-
lial carcinoma.
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in the last decade and STIC has been found in serous ovarian carcinomas in a mean overall 
prevalence of 41%6,8-10. The current study is unique, as the entire epithelium of the endometrium 
and the tubal epithelium were extensively assessed, as well as representative sections of the 
cervix. In 52% of cases, a STIC, EIC, and/or endometrial atypical hyperplasia was found. In 
the endocervical tissue, one CIN3 lesion was found. In the fallopian tubes, STIC was present 
in 43%, and in the endometrium an intraepithelial carcinoma was found in 15% of cases and 
atypical hyperplasia in 32%. In a quarter of cases, a lesion was found in the tubes as well as 
in the endometrium. Serous tubal intraepithelial carcinoma occurred significantly more often 
in women diagnosed with an EIC and/or atypical hyperplasia compared with women with a 
benign endometrium, regardless of the type of endometrial lesion (p=0.010).
To the best of our knowledge, the surprisingly high prevalence of atypical hyperplasia and 
EIC in serous ovarian cancer patients has not been previously described. The few studies that 
investigated the endometrium in pathology reports of asymptomatic women, reported a much 
lower prevalence of atypical hyperplasia (0.5–1.1%) and no EIC29-31. We recently reported the 
prevalence of atypical hyperplasia in 6% of women who underwent a hysterectomy because 
of uterovaginal prolapse, after embedding the endometrial tissue in accordance with the SEE-
End protocol32. In none of these women, EIC was found.
The prevalence of STIC in the current study was comparable to other studies that extensively 
examined the fallopian tubes in accordance with the SEE-Fim protocol6,9. In these studies, 
STIC was found restrictive to ovarian cancers of serous histology type, which supports its 
suggested role in the development of serous carcinoma10,33. Tubal hyperplasia and minor 
epithelial atypia were equally present in women at risk of ovarian carcinoma compared 
with women from normal populations and considered as variants of normal tubal epithelial 
proliferation22.
Recently, the introduction of the SEE-Fim protocol resulted in a significant increase of 
the identification of STIC, as it enabled optimal microscopic view of the tubal plicae19. The 
endometrium is not particularly difficult to visualize microscopically, but its heterogeneous 
aspect and the small size of some lesions necessitates meticulous screening20. The 
introduction of the SEE-End protocol might contribute to a more accurate identification of 
endometrial pathology, as shown by the higher prevalence of endometrial pathology found in 
asymptomatic women after introduction of the new protocol32. Especially for the identification 
of EIC, the SEE-End protocol is recommended, as it can occur only unifocal and can be easily 
missed with routine sampling.
Further, identification of invasive endometrial carcinoma seems slightly increased in the 
current study (8%), compared with the prevalence reported after routine sampling (2–5%)15,34. 
This might be because of the introduction of the SEE-End protocol. In half of the cases 
additional serous tubal carcinoma was found and in one case even a lesion in the endocervix. 
Prevalence of extensive carcinoma is high and we cannot exclude that some of these cases 
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might be misclassified as primary ovarian instead of primary tubal or endometrial. However, 
diagnostic criteria for extensive serous carcinoma have not been well defined.
The high prevalence of endometrial atypical hyperplasia in this group of serous ovarian 
cancer patients is remarkable, as atypical hyperplasia is known as a precursor of endometrioid 
endometrial carcinoma and its development is influenced by genetic predisposition and 
increased, unopposed, estrogen35. Some endometrioid ovarian cancers have been described 
to cause increased estrogen levels, and this has even been reported for a few cases with 
serous ovarian cancer36-38. However, we have no information on estrogen levels from cases 
included in the current study.
Endometrial intraepithelial carcinoma is involved in the development of serous endometrial 
carcinoma, and is occasionally found concurrent to serous ovarian or extra-ovarian carcinoma, 
without presence of invasive endometrial carcinoma11,39-41. An EIC has the capability of 
disseminating throughout the peritoneal cavity, and could putatively be responsible for 
a proportion of serous epithelial ovarian cancers42,43. Interestingly, we often identified 
simultaneous prevalence of STIC, EIC, and/or atypical hyperplasia in patients with serous 
ovarian carcinoma. Several hypotheses can be put forward to explain their coexistence. 
Endometrial atypical hyperplasia represents most likely a synchronous precursor of 
endometrioid endometrial carcinoma in these women with serous ovarian carcinoma, instead 
of a lesion involved in the development of serous ovarian cancer. This is supported by the 
different immunophenotypes for atypical hyperplasia and coexisting EIC. However, STIC and 
EIC are both involved in the development of serous carcinoma, and their coexistence is in 
contrast with the assumption that serous carcinoma develops from one location, from where 
it can develop into invasive carcinoma or spread to other locations in the peritoneal cavity. 
An explanation for coexisting STIC and EIC is that one lesion represents the primary 
location from where the tumor spreads, and that the other lesion is a direct product of 
implantation of migrating cells. Spread of tumor cells from an EIC into the uterine cavity, 
through the tubes, toward the peritoneal cavity seems a plausible explanation, as it follows 
the route of retrograde menstruation11,43,44. However, as suggested by Jarboe et al40, STIC 
might also represent the primary location, as cells may exfoliate toward the peritoneal cavity 
as well as toward the uterine cavity45. They reported on a few cases diagnosed as endometrial 
serous carcinoma with coexistence of STIC and EIC40. However, most cases were without 
invasive endometrial carcinoma, but with tumor involvement of both ovaries. Therefore, cases 
seem comparable to the ones diagnosed in the current study as serous ovarian cancer with 
coexisting STIC and EIC. Jarboe et al40, analyzed the tumor origin of four cases with coexisting 
intraepithelial carcinomas with immunohistochemical Wilms tumor 1 (WT1) staining. Results 
were inconclusive and comparable to ours, as two cases showed strong expression in both 
lesions, whereas one case showed heterogeneous expression and another one none40.
Another intriguing explanation for the coexistence of STIC and EIC is that carcinoma 
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development does not occur in only one specific area of the Müllerian duct, but that the 
entire tract is susceptible for tumor development in these women. This could explain for the 
discordant WT1 staining in some of the coexisting STIC and EIC. A similar mechanism of 
field carcinogenesis has been described in many cancers, as for example in colonic and 
head and neck cancers, and has occasionally been described for ovarian cancers46-48. This 
mechanism could also explain that gynecologic carcinomas, of comparable or different 
histological subtypes, are often identified synchronously. Additional molecular genetic studies 
are necessary to differentiate primary carcinomas from metastases and to elucidate the route 
of carcinogenesis in these women.
Clinical and pathological characteristics were almost comparable for women with and 
without a STIC and/or EIC in the current study. However, clinical variables were retrieved 
retrospectively and not always complete. The majority of women included in this study 
underwent chemotherapy before debulking surgery. Although, no significant difference 
in prevalence of EIC, STIC or atypical hyperplasia was found between both groups, we 
cannot exclude that chemotherapy might have an impact on the prevalence of pathologic 
lesions. Another limitation of the current study is that the cervical tissue was not completely 
embedded.
In conclusion, the current study provided an overview of pathology in tissues derived from 
the Müllerian duct in women with serous ovarian cancer, embedded in accordance with 
the SEE-Fim and SEE-End protocol. Atypical hyperplasia, STIC, and EIC were commonly 
identified in these women, and often occurred simultaneously. The clinical significance and 
biological potential of these lesions in women diagnosed with serous ovarian carcinoma may 
be of utmost importance in understanding tumor development of ovarian cancers. 
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Abstract
Introduction: In cases with widespread serous carcinoma it can be difficult to determine the 
primary carcinoma. Immunohistochemical WT1 expression is considered as a discriminative marker 
for uterine papillary serous carcinoma (UPSC) and ovarian serous carcinoma (OSC). The aim of 
this study was to analyze histological characteristics and WT1 expression in widespread serous 
carcinoma involving the ovaries as well as the endometrium.
Materials & Methods: Histological characteristics and expression levels of WT1 (Clone WT49) were 
assessed of 15 extensive serous carcinomas involving ovaries as well as endometrium, 12 OSCs 
with coexisting endometrial intraepithelial carcinoma (EIC), and control groups of 16 UPSCs and 15 
OSC. TP53 mutations in exon 5 to 8 were analyzed to support tumor clonality. 
Results: Main histological characteristics to assign primary tumor site are location of the carcinoma 
mass and intraepithelial carcinoma. Extensive serous carcinomas showed concordant WT1 
expression in the entire carcinoma. The histologically assigned primary site was confirmed by 
expression levels in all but one case. In six cases histological classification was inconclusive and 
WT1 classified them as OSC in four, and UPSC in two cases. Cases with OSC and coexisting EIC 
showed concordant WT1 staining in 75%, suggestive of primary OSC in four and UPSC in five, but 
were inconclusive in 25%.  
Discussion: Concordant WT1 expression in widespread serous carcinomas suggests one primary 
site. Expression levels are thought of value in delineating primary carcinoma in case of involvement 
of ovaries as well as the endometrium. Its use is recommended in addition to histological criteria for 
classification. 
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Introduction
Serous carcinoma represents the majority of ovarian carcinomas, but can occur throughout 
the whole genital tract. The World Health Organization (WHO) subdivided serous carcinoma 
as primary ovarian, endometrial, fallopian tube, peritoneal and rarely cervical1. Intraepithelial 
carcinomas have been identified for some of the primary serous carcinomas. Endometrial 
intraepithelial carcinoma (EIC) is found adjacent to 90% of uterine papillary serous 
carcinomas (UPSC)2-4. Ovarian serous carcinoma (OSC) is thought to arise from serous tubal 
intraepithelial carcinoma (STIC) and is identified in around 40% of cases5-8. Occasionally the 
serous carcinoma is not specific for one primary site. In these cases there is often extensive 
involvement of the ovaries as well as the endometrium and assigning a primary site can be 
complicated. 
The primary carcinoma site is mainly determined by the location of the bulk of the tumor 
and, if present, the location of a precursor lesion1,9,10. Criteria to classify these extensive 
serous carcinomas have not been well defined. Scully and Ulbright et al. developed criteria to 
classify primary endometrial and primary ovarian carcinomas in case of simultaneous tumor 
involvement, but focused on endometrioid carcinomas instead of the serous histology type11,12. 
Histologically, OSC and UPSC are indistinguishable. Furthermore, they share a genetic 
phenotype and are characterized by the presence of a TP53 mutation13,17. Only slight genetic 
differences have been reported for OSC and UPSC16,17. However, the immunohistochemical 
detection of Wilms tumor 1 (WT1) antigen shows noticeable differences in expression for OSC 
and UPSC and is recognized as a valid discriminator between both tumors18,20. 
Wilms tumor 1 is a tumor suppressor gene, located on the short arm of chromosome 11. 
It plays a role in the embryonic development of the urogenital system and other tissues 
originating from the mesoderm, such as the kidney, ovary, testis, spleen and mesothelium18,21. 
Primary OSC exhibits strong, positive nuclear expression for WT1, whereas UPSC is expected 
to be negative for WT119,22,23. WT1 expression in OSC and UPSC cases has been analyzed 
in several studies, but its expression has not been analyzed for cases with extensive serous 
carcinomas involving the ovaries as well as the uterus. 
In the current study we analyzed histological criteria to classify widespread serous 
carcinomas as primary OSC or UPSC, and the expression pattern of WT1 in these cases. 
In control groups of women with OSC and UPSC a threshold level for WT1 expression was 
defined. Further, TP53 mutation analysis was performed to support clonality in multifocal 
lesions of widespread serous carcinoma. 
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Methods
Case Selection 
The Dutch nation-wide network and registry of histo- and cytopathology, PALGA 
(Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief), was used to identify the 
following cases: a control group of UPSC cases, a control group of high-grade OSC cases, 
and a group of high-grade ‘unclassified’ serous carcinomas with extensive involvement of the 
ovaries as well as the endometrium. In addition, a group of cases with OSC and coexisting 
EIC were analyzed. All patients underwent debulking surgery, including a hysterectomy and 
salpingo-oophorectomy, in the Radboud University Nijmegen Medical Centre (RUNMC) in the 
time period 1996 to 2012. Ovarian, tubal and endometrial tissues were extensively examined 
to analyze spread of disease and presence of intraepithelial carcinoma. An overview of 
included cases is shown in Table 1.
The control group of UPSC cases included sixteen cases. They were randomly selected 
from a cohort of UPSC cases24. The tubes and ovaries of these cases were examined to 
exclude tumor involvement in these locations. In twelve cases the endometrial tumor was of 
pure serous histology and in four of mixed histology, but with only a minor part of the tumor 
consisting of non-serous histology: endometrioid carcinoma in three cases, and clear cell 
carcinoma in one case. 
In the control group of OSC cases, fifteen cases were included. They were randomly 
selected from a cohort of women diagnosed with OSC25. The endometrium was embedded 
entirely in accordance with the SEE-End protocol (Sectioning and Extensive Examining of 
the Endometrium)25. Cases with endometrial tumor involvement were excluded for selection. 
Serous carcinoma Carcinoma (N) Intraepithelial carcinoma (N)
Ovaries Endometrium EIC STIC
Control group of UPSC (N=16) - 16 11 -
Control group of OSC (N=15) 15 - - 4
Widespread serous carcinoma (N=15) 15 15 12 5
(involving the endometrium as well as the ovaries)
OSC and EIC (N=12) 12 - 12 3
Abbreviations: OSC, ovarian serous carcinoma; UPSC, uterine papillary serous carcinoma; EIC, endometrial intraepit-
helial carcinoma; STIC, serous tubal intraepithelial carcinoma.
Table 1: Overview of the selected cases
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Fifteen cases were included with widespread serous carcinoma involving the ovaries as well 
as the endometrium extensively. Tissues were embedded in accordance with the SEE-Fim 
protocol or at least in total if diagnosed since 2006, and in accordance with the SEE-End 
protocol since 2010. Otherwise tissue was embedded according to standard protocol. All 
tissues were extensively examined for (intraepithelial) carcinomas. 
Additionally, twelve cases were analyzed with OSC and concurrent intraepithelial carcinoma 
in the endometrium, but without synchronous invasive endometrial carcinoma. 
Histological Classification
All cases were reviewed by a gyneco-pathologist (JB) to confirm histological diagnosis and 
to screen for histological criteria to assist in determining primary site. Main histological criteria 
to assign the primary carcinoma are the location of the largest tumor mass and, if present, 
the location of an intraepithelial carcinoma. Furthermore, the following histological criteria 
were analyzed as well because of their potential value in histological classification: depth 
of myometrial invasion, lymphovascular space invasion (LVSI) in the myometrium, enlarged 
ovaries (>5cm), ovarian tumor pattern (multinodular/diffuse/mainly on surface) and uni- or 
bilateral ovarian tumor9-12. The characteristics that were thought suggestive for a primary 
endometrial site were: presence of EIC, deep myometrial invasion, LVSI in the myometrium, 
surface carcinoma implants on the ovaries, or a multinodular ovarian carcinoma. Suggestive 
for a primary ovarian site were: presence of STIC, location of the largest tumor mass in the 
ovaries, none or less than one half of the myometrium invaded, and no LVSI in the myometrium 
or LVSI restricted to the outer half of the myometrium. 
Immunohistochemistry
Representative sections from the serous (intraepithelial) carcinomas were selected for 
further analyses. Paraffin embedded blocks were retrieved from the pathology archive of the 
RUNMC for all selected sections. Sections of 4 µm were sliced from these formalin-fixed, 
paraffin embedded samples. Sections were floated onto SuperFrostPlus slides, and dried 
in a stove at 56°C for 45 minutes, before they were deparaffinized in xylene and rehydrated 
through graded ethanol series. Sections were steamed in 0.01mol/L sodium citrate buffer 
(pH 6.0) for 20 minutes and endogenous peroxidase activity was blocked by 3% hydrogen 
peroxidase in methanol. Incubation with WT1 monoclonal antibody (dilution 1:20; Clone 
WT49, NCL-L-WT1-562, Leica Biosystems, Newcastle Upon Tyne, UK) was done overnight 
and visualization was carried out using a peroxidase envision method. Diaminobenzidine was 
used as chromogen and sections were counterstained with haematoxylin before coverslipped. 
Kidney tissue was included as positive control in each batch of staining. 
Immunohistochemical staining was interpreted by three of the authors (JB, AvT, and 
MM). The extent of nuclear staining of the entire tumor tissue present on the section was 
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recorded semiquantatively by estimating the percentage of positive stained tumor cells, and 
classified as follows: 0%, <5%, 5-25%, 26-50%, 51-75%, or >75%. The intensity of staining 
was subjectively assessed as weak, moderate or strong. An example of positive nuclear WT1 
expression is shown in Figure 1. In case of discrepancy in interpretation, this was resolved by 
simultaneous viewing of the sections. A difference in WT1 expression between the endometrial 
and ovarian tumor within one case was considered discordant if expression differed more than 
one percentage class.
Analysis of TP53 Mutation 
In the group of cases with widespread high-grade serous carcinomas and the group of 
cases with OSC and coexisting EIC, TP53 mutation analysis were performed to confirm 
tumor clonality in the endometrial and ovarian part of the tumor. Tumor cells were isolated by 
macroscopic dissection from sliced sections of 5 µm and for intraepithelial carcinomas clusters 
of cells were isolated with laser-capture microdissection (LMD6000, Leica Microsystems, 
Wetzlar, Germany). Methods for TP53 mutation analysis were published in detail before26. 
Genomic DNA was amplified by polymerase chain reaction using tailed M13 primers designed 
to amplify TP53 exons 5 to 8.
Figure 1: Positive nuclear expression of WT1 in serous ovarian carcinoma  (level of 
magnification: x200)
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Statistics
All statistical analyses were performed using SPSS software version 20.0 (SPSS Inc, 
Chicago, IL) and p<0.05 (two-sided test) was considered statistically significant.  
Results
Histological classification of widespread serous carcinoma 
An overview of histological characteristics for all cases with high-grade serous carcinoma 
extensively involving the endometrium as well as the ovaries is shown in Table 2. In routine 
practice, primary site is mostly based on location of tumor mass and, if present, the location of 
an intraepithelial carcinoma. In eight out of fifteen cases with widespread serous carcinoma, 
the location of the bulk of the tumor as well as an intraepithelial carcinoma were suggetive for 
one specific primary site (Case No. 1 to 8). Case No. 1 to 8 were considered primary UPSC as 
the largest tumor mass was located in the uterus and in Case No. 3 to 8 a primary endometrial 
site was supported by the presence of an EIC. In Case No. 1 and 2 the endometrial carcinoma 
was extensive, whereas the ovaries showed only nodular deposits of carcinoma in one case, 
and a single solitary deposit in the other. 
In the remaining seven cases tumor mass and intraepithelial carcinoma were not specific 
for one primary site (Case No. 9 to 15) (Table 2). Case No. 9 was considered primary OSC 
because of a large carcinoma bulk in the ovary compared to only a small focus of carcinoma 
in the endometrium, but coexisting EIC was present. In Case No. 15 the primary site was 
considered inconclusive, as the carcinoma was massive and did not show preference for one 
site. In Case No. 10 to 14 coexistence of EIC as well as STIC was found. In Case No. 11, 
13 and 14 the largest carcinoma mass was located in the ovaries suggestive for a primary 
ovarian origin, whereas in Case No. 10 and 12 tumor mass is inconclusive for one site. 
Results on other analyzed histological criteria are also summarized in Table 2. In case of 
a conclusive primary site based on location of tumor mass and intraepithelial carcinoma, 
additional histological criteria were supportive for that specific primary site. Cases classified 
as primary UPSC, showed myometrial invasion of more than half of the myometrium in all but 
two cases (6/8), and in all but one case (7/8) LVSI was found in the myometrium (Case No. 1 
to 8). Seven out of eight cases showed bilateral ovarian carcinoma, with diffuse involvement 
of the ovaries in five cases and mainly involvement of the epithelial surface in two. In the one 
case with unilocular ovarian involvement the carcinoma was located multinodular.
In case of inconclusive classification of widespread serous carcinomas by location of tumor 
mass and intraepithelial carcinoma, additional histological criteria were not specific for one 
specific primary carcinoma as well (Table 2). For example, in Case No. 9 diffuse ovarian 
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carcinoma was found in one enlarged ovary with additional endometrial carcinoma without 
myometrial invasion or LVSI, but with coexisting EIC. 
WT1 (clone WT49) expression in more than half of tumor cells is suggestive for OSC
WT1 expression was analyzed for a control group of OSC and UPSC cases to define a 
threshold level to discriminate both primary carcinomas (Table 3). All fifteen OSC cases 
showed strong expression for WT1 in more than 50% of tumor cells, with an intensity ranging 
from moderate to strong. The sixteen cases included in the UPSC group showed completely 
negative staining in eleven (69%) cases, expression in 5-25% of tumor cells in four (25%) 
cases, and in 26-50% in one (6%) case. The latter showed weak expression of WT1 in thirty 
per cent of tumors cells. Concluding, all primary OSC cases showed moderate to strong WT1 
expression in more than half of tumor cells, whereas none of the primary UPSC cases did. 
Based on these results, nuclear WT1 expression in >50% of tumor cells is suggestive for a 
OSC, whereas expression in <50% of tumor cells is suggestive for a UPSC, regardless of 
the intensity of staining. Nuclear staining of >50% of tumor cells was considered as positive 
expression. 
An overview of studies reporting on WT1 reactivity in OSC and UPSC cases is shown in 
Table 4. Details of WT1 clones used and their definitions of positive WT1 expression were 
included. Definitions of positive reactivity ranged from any type of staining to nuclear staining 
in >50% of tumor cells. WT1 expression was analyzed in 296 OSC cases and in 195 UPSC 
cases. Overall, OSC was positively expressed for WT1 in 89% (range 47-100%) and for 
UPSC in 23% (range 0-67%).
Concordant WT1 expression in widespread serous carcinomas 
Results of WT1 expression in cases with widespread serous carcinoma are shown in 
Table 5. In all fifteen cases WT1 immunoreactivity did not differ more than one percentage 
class in both the endometrial and ovarian part of the carcinoma and staining was considered 
concordant in the entire carcinoma.
TP53 mutation analysis for exon 5 to 8 was performed to confirm clonality of the ovarian 
and endometrial location of the widespread serous carcinoma. In Case No. 6 and 14 (13%) an 
identical TP53 mutation could be found in the endometrial as well as the ovarian carcinoma 
location. In eight (53%) pairs a unique TP53 mutation was identified in only one of the tumor 
locations, which was located in the endometrial carcinoma in four cases (Case No. 7, 8, 12 
and 13) and in the ovarian carcinoma in the other four (Case No. 3, 4, 9 and 15). In five pairs 
no TP53 mutation could be found in both carcinoma parts (Case No. 1, 2, 5, 10 and 11).
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Concordant histological classification and WT1 classification in cases with wide 
spread serous carcinoma 
The primary carcinoma site based on histological classification was compared with the 
primary site based on WT1 expression. In all but one case the WT1 expression level was 
supportive for the same primary carcinoma in the endometrial as well as the ovarian carcinoma 
location. Cases histologically classified as UPSC showed negative WT1 expression, supportive 
for a primary endometrial origin (Case No. 1, 2, and 4 to 8), apart for one case (Case No. 3). 
Concluding, in those cases in which we were able to determine a primary carcinoma based 
on histological criteria, WT1 classification confirmed the primary site in 89% (8/9), and was 
inconclusive in one case. In all seven cases with inconclusive histological classification WT1 
expression was supportive for one specific primary location. 
Two-third of serous ovarian carcinomas with concurrent EIC show concordant WT1 
staining
WT1 expression was analyzed in twelve cases with OSC and an EIC located in the 
endometrium, without invasive endometrial carcinoma. In Case No. 1, 10 and 11 a STIC was 
found as well. 
Nine out of twelve (75%) cases showed identical WT1 expression in both the OSC and EIC 
location (Case 1, 3, 5 to 8, 10 to 12). Four (33%) cases showed positive expression for WT1 
in both lesions, and five (42%) cases were completely negative for WT1 or expression was 
below the threshold. Case No. 2,4 and 9 (25%) showed discordant staining patterns for WT1 
in the ovarian carcinoma and concurrent EIC. In these cases the EIC showed no reactivity for 
WT1, whereas the ovarian carcinoma showed positive WT1 expression. 
An identical TP53 mutation was found in both OSC and EIC in three (25%) cases (Case 
No. 1, 3 and 7). In two (17%) cases a TP53 mutation was only identified in the EIC, but the 
mutation could not be confirmed in the concurrent ovarian carcinoma (Case No. 4 and 6). In 
seven (58%) cases no TP53 mutation was found in both lesions, including the three cases 
with discordant WT1 expression in the OSC and EIC. 
Discussion
In cases with widespread serous carcinoma, involving the endometrium as well as the 
ovaries, it can be difficult to determine the primary site using morphology alone. Accurate 
classification of UPSC and OSC is crucial in order to enable optimal treatment management, 
determine prognosis and route of tumor development. 
Main histological criteria to classify widespread serous carcinomas are the location of the 
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largest tumor mass and presence of an intraepithelial carcinoma. Other histological criteria 
were administered in the decisive process as well. In the nine out of fifteen cases with 
widespread serous carcinoma that could be classified based on the main criteria, presence 
of LVSI in the myometrium, and carcinoma invasion of more than half of the myometrium 
seemed supportive for a primary UPSC. No myometrial LVSI and involvement of less than 
half of the myometrium seemed supportive for a primary OSC. Characteristics of the ovarian 
carcinoma were less informative, as the majority of cases with widespread serous carcinoma 
had bilateral and diffuse carcinoma involvement of the ovaries. In cases in which the main 
histological criteria were inconclusive for a specific primary site, the additional histological 
characteristics were not able to delineate the primary location clearly in all cases. The adjusted 
FIGO staging for ovarian carcinoma in 2014 added a specific category for these cases and 
suggested to list them as ‘undesignated’27,28.
In the current study we showed that WT1 expression can have value in discriminating OSC 
and UPSC in case of widespread serous carcinoma. Evidence for the discriminative ability of 
WT1 has already been provided for cases with solitary primary OSC and UPSC19,22,23,29. The 
discriminative ability of WT1 between OSC and UPSC was confirmed in the current study for 
clone WT49. An optimal threshold level was defined in these control cases. Expression of 
WT1 in >50% of tumor cells is supportive for a OSC. In widespread serous carcinomas the 
WT1 expression was comparable in the entire carcinoma and expression levels were almost 
always in concordance with the primary site assigned by histological classification. Moreover, 
in cases in which histological classification was inconclusive, WT1 expression was suggestive 
for one specific primary site. 
Results for WT1 expression are comparable with expression levels reported in other 
studies7,19,22,23,29-34. Further, the defined WT1 threshold level is comparable with levels 
suggested by others20,23. The range in WT1 expression for OSC and UPSC in the literature is 
large, but can be explained by the use of different definitions for positive staining, incomparable 
scoring systems, different types of antibodies used, variations in the embedding and fixation 
of the tissue, or different staining protocols. Definitions for positive staining ranged from any 
reactivity, including expression located in the nucleus and/or cytoplasm, to expression in more 
than half of tumor cells. In the current study, we scored the percentage of positive tumor 
cells and performed immunohistochemical staining with monoclonal antibody, clone WT49, 
instead of the more commonly used conventional clones 6F-H2 and C19. The WT49 clone is 
a newer monoclonal antibody that has the advantage that it is restricted to the nucleus without 
cytoplasmic staining, as is seen for some other WT1 antibodies35. 
A proportion of UPSC cases has been reported to show WT1 expression as well23,29. Results 
from the current study confirm that some UPSC cases show WT1 expression. However, WT1 
expression in UPSC cases was most often less intense and heterogeneous compared with 
the diffuse staining that is commonly found in serous carcinomas arising elsewhere in the 
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genital tract20,23. 
WT1 expression was concordant for both carcinoma locations in all investigated cases with 
widespread serous carcinoma, including those with coexisting EIC and STIC. Findings suggest 
that these cases likely originate from one primary carcinoma instead of two synchronous 
primaries. Euscher et al. reported on WT1 expression in similar cases, but with primary 
peritoneal serous carcinomas and coexisting UPSC30. Only one out of nine cases showed 
positive WT1 expression and the UPSC stained concordantly, whereas 80% of primary 
peritoneal serous carcinomas showed positive WT1 expression30. Results suggest different 
pathogenic pathways for cases showing concordant positive or negative WT1 staining. 
In the current study, clonality of the endometrial and ovarian carcinoma location in cases 
with widespread serous carcinoma could be confirmed by an identical TP53 mutation in 
13% (2/15) of cases. In 53% (8/15) of cases a TP53 mutation was found in only one of the 
carcinoma locations and we cannot exclude synchronous primaries in these cases, despite of 
concordant WT1 staining. 
TP53 mutation analysis was limited to exon 5 to 8, and a mutual TP53 mutation could be 
present in one of the other exons not examined. Further, not all carcinoma tissue was isolated 
with laser microdissection, and tissue collection with macrodissection might have been not 
sensitive enough to detect all mutations present in the carcinoma tissue. Other limitations of 
the study are the relatively small cohorts and that not all tissue was embedded in accordance 
with the SEE-Fim and SEE-End protocol. Therefore, presence of additional intraepithelial 
carcinoma cannot be excluded for all cases and could be responsible for some misclassified 
primary carcinomas. Furthermore, in this study we assume that the WT1 expression level in 
widespread serous carcinomas is related to the expression levels shown in solitary OSC and 
UPSC cases.
In addition, we investigated WT1 expression in cases with OSC and EIC. Four cases 
showed positive WT1 expression suggestive for a primary OSC, whereas in five cases both 
the OSC and EIC showed negative expression of WT1 suggestive for a UPSC, and in three 
cases WT1 expression was inconclusive. In the latter, the ovarian carcinoma showed positive 
expression, whereas the EIC was negative for WT1. No TP53 mutation could be found in the 
OSC or the EIC of cases with discordant WT1 expression to enable conclusions on clonality 
of the tumor. Discordant WT1 expression in some cases with OSC and EIC could be because 
of two synchronous primaries. Another explanation is that TP53 mutations are present in the 
non-analyzed TP53 exons. 
In conclusion, histological classification is not always able to assign the primary site in 
widespread serous carcinomas simultaneously involving the endometrium as well as 
ovaries. WT1 expression is valuable in differentiating OSC and UPSC. WT1 classification 
is recommended in addition to histological classification to determine primary carcinoma in 
cases with widespread serous carcinoma. 
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Abstract
Introduction: Ovarian serous carcinomas (OSC) and uterine papillary serous carcinomas (UPSC) 
are thought to arise from different carcinogenetic pathways, but are histologically highly comparable 
and share their genetic denominators. The aim of this study was to analyze if their methylation 
profiles have discriminative capacity. 
Materials & Methods: Methylation specific multiplex ligation-dependent probe amplification 
(MS-MLPA, probe mix ME001-C2) was used to analyze the methylation status of 24 commonly 
hypermethylated tumor suppressor gene (TSGs) promoters in 15 high-grade ovarian serous 
carcinomas (OSC), 15 uterine papillary serous carcinomas (UPSC), and in 13 widespread serous 
carcinoma with involvement of both the endometrium and ovaries. 
Results: The CDH13 methylation levels were significantly higher in UPSC cases compared to OSC 
cases. Methylation levels of other TSGs showed comparable profiles in the OSC and UPSC cases. 
A cut-off level for CDH13 methylation was determined to support in classifying primary origin of 
the carcinoma, and a level of ≥ 0.32 was suggestive of an endometrial origin. The mean CDH13 
methylation level confirmed the histological classification in 7 widespread serous carcinomas. In 
another six cases histological classification was inconclusive; the mean CDH13 methylation was 
supportive for primary UPSC in 4 cases, and OSC in 2 cases.
Discussion: CDH13 methylation has discriminative capability between OSC and UPSC and might 
have value in determining the primary carcinoma location in cases with widespread serous carcinoma 
and inconclusive histological classification.
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Introduction
Various histological subtypes of carcinoma can arise from the epithelial tissue of the genital 
tract. High-grade serous carcinoma is one of the main histological subtypes of ovarian 
carcinoma, but can also occur in the tubes, the peritoneum, endometrium, and rarely the 
cervix. 
High-grade ovarian serous carcinoma presents mostly in an advanced stage at diagnosis, 
as it is rapidly progressive and without specific symptoms at onset of disease. It is diagnosed 
with extra-ovarian disease in 70% of cases, with often spreads towards the uterus. In case of 
widespread serous carcinoma it can be complicated to reliably determine the primary tumor 
site based on only gross histological characteristics, as different primaries are histologically 
indistinguishable. However, different primaries of serous carcinoma are thought to develop 
following different pathways of carcinogenesis1. It is necessary to be able to discriminate them 
in order to individualize their treatment management. 
Molecularly, high-grade serous carcinomas also share genetic denominators. They are 
characterized by the presence of TP53 mutations in 70-97%, regardless of the primary site of 
the carcinoma2-4. Although, one study assessing comparative genomic hybridization in serous 
carcinomas of the ovaries and endometrium suggested that these two primaries represent 
different entities5, the latest genome-wide copy number and mutation studies suggest a highly 
similar molecular profile for serous ovarian and endometrial tumors6.
Less focus has been given to epigenetic changes in the various serous carcinomas. Putatively, 
epigenetic research shows discriminative features between primary serous carcinomas. DNA 
methylation has an important role in silencing promoters of tumor suppressor genes commonly 
altered in cancers7. It has been speculated that epigenetic changes, like methylation, might be 
an earlier event than genetic changes7. Hypermethylation of CpG island is found to be cancer 
type specific and several reports showed that histological subtypes of ovarian carcinoma 
can be differentiated by their methylation profiles3,8-13. A few studies focused on methylation 
profiles to differentiate histological subtypes of endometrial carcinoma14-17. Only one study 
focused on methylation profiles of different primary carcinomas of a specific histology type 
and found highly similar methylation phenotypes18. However, the analyzed cohort was small 
(nine ovarian and six endometrial samples) and the study only focused on the endometrioid 
histological subtype of primary ovarian and primary endometrial carcinomas. 
We wanted to determine whether or not serous primary endometrial or ovarian carcinomas 
showed DNA methylation events specific for the primary anatomic site. If so, methylation 
profiling might be of use in discriminating primary serous ovarian cancer (OSC) from serous 
endometrial cancer (UPSC (uterine papillary serous carcinoma)) in cases with widespread 
serous carcinoma, synchronously involving the endometrium and ovaries. We studied the 
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methylation status of a series of 24 promoter regions of known tumor suppressor genes 
(TSGs) and oncogenes in OSC and UPSC cases, and in cases with widespread serous 
carcinoma with the tumor bulk located in the ovaries as well as in the endometrium.  
Materials and Methods
Patients were identified with the search terms ‘serous ovarian’ and ‘serous endometrial’ 
carcinoma, using the Dutch nation-wide network and registry of histo- and cytopathology, 
PALGA (Pathologisch anatomisch landelijk geautomatiseerd archief). All included patients 
were selected from the Radboud University Medical Centre, Nijmegen, and were reviewed by 
a gyneco-pathologist (JB) to confirm their serous histology and determine primary carcinoma. 
Sample Collection of UPSC and OSC Cases 
Fifteen high-grade OSC cases were randomly selected from a study cohort of women 
diagnosed with OSC in the time period October 2010 until December 201219. All endometrial 
and tubal tissue of patients who underwent debulking surgery for ovarian carcinoma within 
this time period was embedded in accordance with the SEE-Fim and SEE-End protocol 
(Sectioning and Extensive Examining of the Fimbriated end; and -of the Endometrium)19,20. 
Fifteen solitary UPSC cases were randomly selected from a study cohort of UPSC cases21, 
who underwent surgery for endometrial carcinoma in the time period 1992 until 2009. The 
mean age of OSC cases was 62 years (range 43-79 years), and mean age of UPSC cases 
was 72 years (range 64-79 years).
Sample Collection of Widespread Serous Carcinoma Cases
Thirteen cases were identified with widespread serous carcinoma, synchronously involving 
the endometrium and ovary extensively, from the time period 1996 until 2012. Classification of 
their putative primary site was based on the following histological criteria: location of the largest 
tumor bulk, presence of a carcinoma in situ, extent of myometrial invasion, lymfovascular 
space invasion (LVSI) in the myometrium, and ovarian tumor pattern22,23. In Table 1 histological 
features are specified for widespread serous carcinomas and suggested primary carcinoma. 
Seven cases were classified as primary endometrial (patient ID 2 to 4, 7, 10, 11 and 13). In six 
cases we were not able to determine a primary carcinomas, because the tumor bulk and/or 
intraepithelial carcinoma was not specific for one primary site (Patient ID 1, 5, 6, 8, 9 and 12). 
DNA Preparation
Paraffin embedded blocks of selected sections were retrieved from the pathology archive 
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of the Radboud University Medical Centre. For the widespread cases two tissue blocks were 
included, one for the endometrial part and another one for the ovarian part of the carcinoma. A 
hematoxylin & eosin stained slide was made to confirm tumor presence in the tissue block and 
to assess the percentage of carcinoma in it. If sections covered areas of high tumor cellularity 
(>75%), 8 µm sections were included in total for DNA isolation, otherwise, sections were 
placed on slides and dried overnight, before areas with serous tumor were scraped from the 
tissue sections with a scalpel. DNA was isolated with TET-lysis buffer (10 mmol/L Tris-HCl, pH 
8.5; 1 mmol/L EDTA, pH 8; 0.1% Tween-20) containing 5% Chelex-100 (Bio-Rad, Hercules, 
CA). Protein digestion was performed by adding 20 µL of proteinase K to each sample and 
incubation at 56°C for 48 hours. Fresh proteinase K of 10 µL was added after 24 hours. 
Next, DNA was denatured by heat inactivation at 95°C for ten minutes. The samples were 
centrifuged for ten minutes at 14.000 rpm (RT) and the DNA concentration of the supernatant 
was measured on a Nanodrop ND-1000 (NanoDrop Technologies, Wilmington, DE) before 
storage at 4°C.
Methylation-Specific Multiplex Ligation-Dependent Probe Amplification
The methylation specific multiplex ligation-dependent probe amplification (MS-MLPA®) 
probe mix ME001-C2 (MRCA Holland, Amsterdam, The Netherlands) was used to detect the 
methylation status of 24 different tumor suppressor gene promotors. The mix contained 26 
probes, with two probes for RASSF1 and MLH1. All 24 genes are known to be frequently 
silenced by methylation in several cancers, and a proportion is commonly methylated in 
ovarian and endometrial cancers. The protocol of the manufacturer was followed for the 
experimental procedure and the description can be found at their website (http://www.mlpa.
com). 
This MS-MLPA reaction uses the methylation sensitive HhaI restriction enzyme that 
selectively digests unmethylated sequences. Fifteen reference probes were included that are 
not influenced by the HhaI digestion and undigested tumor DNA samples served as a control. 
Aliquots of 1.0 µL of the PCR reaction product were combined with 8.8 µL formamide and 
0.2 µL LIZ500. Samples were analyzed by electrophoresis on an ABI 3730 DNA Analyzer 
(Applied Biosystems, Paisley, UK) and analyzed using the Genescan software (Applied 
Biosystems). 
The peak height of each probe was normalized by dividing it by the combined heights of 
the control probes. Each normalized peak height from a digested sample was compared with 
that obtained in the undigested sample. The peak heights and areas were exported to Excel, 
and the normalized heights from the digested and undigested samples were compared to 
determine the methylation ratio. Non malignant tissue that was identically treated as the tumor 
tissue and a negative control without DNA were included in each experiment. 
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Statistical Analysis 
Values were reported as the proportion of peak height arising from the methylated probe 
from 0 (all DNA unmethylated) to 1 (all DNA methylated). A cumulative methylation index 
(CMI) was calculated as the sum of the methylation levels for all genes analyzed for each 
sample24. The data were imported in Excel and SPSS 20.0 (SPSS Inc, Chicago, IL) for further 
analysis. Results were considered statistically significant if the p-value was ≤0.05 (two-sided 
test). Mean methylation levels or CMI between groups of solitary serous ovarian and serous 
endometrial carcinomas were compared using the Mann-Whitney U test and Kruskal-Wallis 
test. Threshold levels were determined for each tumor suppressor gene by adding one 
standard deviation (SD) to the mean methylation level per probe found in the normal tissues. 
This was done in order to identify those cases with hypermethylation of the specific gene. 
Frequency of a methylation level above the threshold was compared between the types of 
serous carcinoma using the Pearson’s Chi square or Fisher’s Exact Test if appropriate. An 
optimal methylation level was determined, by calculation a ROC curve for tumor suppressor 
genes with significantly different methylation levels in the group of solitary OSC compared to 
the group of solitary UPSC. The spearman correlation coefficient² (r²) was calculated for pairs 
with serous ovarian carcinoma and endometrial carcinoma. 
Results
Solitary UPSC Show More Often Hypermethylation of CDH13
Putative differences in methylation of OSC and UPSC for 24 tumor suppressor genes that 
are known to be frequently hypermethylated in several cancers were analyzed. In Figure 1 an 
overview is shown of methylation levels for all probe amplifications in both groups. Overall, 
the methylation profile for OSC and UPSC was very similar for the analyzed tumor suppressor 
genes. Average methylation level and mean CMI were comparable in the UPSC and OSC 
cases (0.19 vs 0.21 for OSC and UPSC, respectively; 5.07 vs 5.44, p=0.87). A complete list of 
the mean methylation levels of tumor suppressor genes is available at Supplementary Table 
1. The OSC group showed an average of 5.3 genes hypermethylated and UPSC an average 
of 8.9 genes, but this difference was not significant (p=0.30).
The tumor suppressor gene CDH13 was significantly hypermethylated in UPSC cases 
compared to OSC cases in the current study (0.40 vs 0.28, respectively, p=0.001; Figure 
1), whereas other analyzed tumor suppressor genes showed comparable methylation levels 
in both groups. The frequency of CDH13 methylation above the threshold level was also 
significantly higher in UPSC cases compared to OSC cases (13/15 vs 4/15, p=0.003). A 
complete list of the frequency of hypermethylated tumor suppressor genes is available at 
134
Figure 1: Mean tumor suppressor gene methylation percentage in solitary serous 
carcinomas. Only CDH13 is significantly hypermethylated in UPSC
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Supplementary Table 2. 
The optimal CDH13 methylation level to discriminate solitary UPSC cases from solitary OSC 
was analyzed by performing an ROC curve analysis. A methylation level of ≥0.32 appeared 
to be the most optimal level to distinguish solitary UPSC from OSC in the current study, with 
a positive predictive value (PPV) of 76% and a negative predictive value (NPV) of 85% (Table 
2). CDH13 methylation has a good discriminative power to classify UPSC and OSC in this 
study population, with an area under the curve of 0.84 (95% CI=0.70-0.99). 
Widespread Serous Carcinomas Show Resemblance in CDH13 Methylation Level 
with Solitary UPSC
We decided to see whether CDH13 could give us information about the primary location 
of widespread serous tumors. Therefore, CDH13 methylation was analyzed in widespread 
serous carcinomas synchronously involving the endometrium and ovaries. The optimal cut-off 
level to discriminate solitary UPSC from OSC in this study of ≥0.32 methylated was applied to 
assign their primary carcinoma location.
First, we analyzed if CDH13 methylation levels were comparable in the different locations 
within the carcinoma, and if a CDH13 methylation level is representative for the specific 
carcinoma. In each case, CDH13 methylation was measured twice, once in the endometrium 
part of the carcinoma and once in the ovarian part, to analyze differences between endometrial 
and ovarian carcinoma location and the range between measurements. The range was 
relatively small in the majority of cases with a difference of <0.15 in CDH13 methylation 
levels, in four cases a difference of 0.26-0.37 was found between the two CDH13 methylation 
measurements (Patient ID 4, 8, 10, and 12). Mean CDH13 methylation levels were calculated 
to assign primary carcinoma location in cases. Next, the threshold was applied to assign the 
primary carcinoma location. Only two cases showed a mean CDH13 methylation level below 
Table 2: The optimal CDH13 methylation level was determined to discriminate solitary serous 
ovarian carcinoma from solitary serous endometrial carcinoma
Abbreviations: PPV: positive predictive value; NPV: negative predictive value. 
Area under the curve (AUC) = 0.84 (95% CI, 0.70 - 0.99).
CDH13 methylated level (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
26 100 53 68 100
28 93 53 67 89
30 87 67 72 83
32 87 73 76 85
34 67 80 71 69
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the threshold and were suggestive for a primary ovarian carcinoma location (Patient ID 1 and 
5). All other cases showed CDH13 methylation levels suggestive for primary UPSC. 
Primary carcinoma based on histological criteria was compared with the assigned primary 
carcinoma based on CDH13 methylation. All patients histologically classified as putative 
primary UPSC, showed CDH13 methylation above the discriminative level (Patient ID 2-4, 
10, 11, and 13), supporting a primary endometrial carcinoma. In 6 cases we were not able to 
determine primary carcinoma based on histological criteria (Patient ID 1, 5, 6, 8, 9, 13). Two 
of these cases were suggested primary OSC based on CDH13 methylation levels (Patient ID 
1, 5), and four cases primary USPC (Patient ID 6, 8, 9, 12). 
Counterparts of Widespread Serous Carcinomas Show Correlation in Their Overall 
Methylation Measurements 
Correlation in methylation levels between the endometrial and ovarian part of the carcinoma 
was confirmed by their overall 24-gene methylation measurements. Twelve carcinoma pairs 
showed strong to very strong correlation between methylated genes in tumor pairs (r²=0.69-
97), and one carcinoma pair showed moderate correlation (Patient ID 9, r²=0.45). Therefore, 
we concluded that methylation in the ovarian location of widespread serous carcinomas was 
highly correlated to its endometrial counterpart. 
The average methylation of the 24-gene set was a bit higher in the ovarian location of 
the widespread serous carcinoma (0.28 vs 0.21), as was the CMI (for ovarian 7.15, for 
endometrial 5.45 (p=0.047)). This was also reflected in the number of genes methylated 
above the threshold (for ovarian 9.8, for endometrial 4.9). 
Discussion
Methylation levels for CDH13 are significantly different between OSC and UPSC cases 
and the optimal level of CDH13 to discriminate OSC from UPSC was ≥0.32. Other analyzed 
promoter regions of commonly methylated tumor suppressor genes did not have discriminative 
capability in assayed samples and showed highly identical methylation levels in the OSC and 
UPSC cases.
The tumor suppressor gene, CDH13, or cadherin 13 (T-cadherin) is suggested to be involved 
in various cancers, including ovarian and endometrial cancer25. In comparison to normal 
endometrial or ovarian tissue CDH13 methylation is significantly increased in endometrial and 
ovarian carcinomas10,26. The CDH13 protein is a cell surface transmembrane protein, and has 
a role in cell adhesion. Silencing of T-cadherin expression by aberrant promoter methylation 
in cancers is associated with metastatic potential, and may play a role in tumor cell invasion 
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and progression of cancers25,27. 
Methylation levels for CDH13, as found in the current study, were comparable with levels 
reported by others, using a similar MS-MLPA probe mix9,10,17. Seeber et al.17, found frequent 
hypermethylation of CDH13 in UPSC cases with mean methylation levels of 0.44, which is 
comparable to the 0.40 as found in the current study. Bol et al.9, used the MS-MLPA probe 
mix to investigate methylation profiles within a cohort of ovarian carcinoma, consisting of OSC 
in 88%. They reported a mean methylation level for CDH13 of 0.22, which is comparable 
to the 0.28 we reported for solitary OSC9. Studies using other methods to analyze CDH13 
methylation in OSC reported hypermethylation in 9-24%12,13. 
We compared results for the 24 tumor suppressor genes of UPSC and OSC in the study 
cohort with results obtained from the publicly available ‘The Cancer Genome Atlas Research 
Network (TGCA)’ data3,6. Data included results from 17 cases diagnosed with UPSC and a 
large number of cases with OSC. A total of 65 OSC cases were selected from this database, 
based on the following criteria: bilateral disease, high FIGO stage, serous histology type and 
Caucasian. Average methylation levels were similar to results from the current study (0.19 vs 
0.21 for serous ovarian and endometrial cancer, respectively). Their CMI was slightly lower 
with a mean level of 4.89 for UPSC and 4.38 for OSC, compared to 5.44 and 5.07 in the 
current study.
Interestingly, the mean methylation levels from the UPSC and OSC cases of the TGCA 
database differed significantly in more than half of analyzed tumor suppressor genes between 
both groups, including methylation levels for CDH13. However, compared to the current study 
different probes and methods for DNA methylation measurements were used. Moreover, the 
UPSC and OSC data had to be retrieved from two digital TGCA databases and comparing 
their results might not be correct because of putative differences in analysis, other than DNA 
methylation platforms. Finally, the number of UPSC cases analyzed is relatively small. 
In this study, we also tested the value of CDH13 methylation to support in classifying 
widespread serous carcinoma, involving the endometrium and ovaries as primary endometrial 
or ovarian. Primary carcinoma location determined by histological criteria was confirmed by 
CDH13 methylation levels when applying the cut-off level of ≥0.32. All widespread serous 
carcinomas histologically suggestive for primary UPSC, showed a CDH13 methylation level 
of >0.32. In those cases with inconclusive primary location, 2 out of 6 cases showed a CDH13 
methylation below this cut-off level suggestive for a primary ovarian origin, and four were 
suggestive for a primary endometrial origin. 
The CDH13 methylation levels were not significantly different between locations within 
carcinoma pairs, and one level was thought representative for the entire carcinoma. However, 
in four cases the range between CDH13 methylation levels was a bit larger, compared to 
the other cases. In three of them both endometrial and ovarian CHD13 methylation levels 
were located above the cut-off level. Though, in the case with the widest range between both 
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locations, only the endometrial part of the carcinoma showed a methylation level suggestive 
for a primary ovarian location (Patient ID 12). In the latter, a double primary carcinoma could 
be one explanation for this wider range in CDH13 methylation levels. 
Most widespread serous carcinomas included in this study were classified as primary 
endometrial in origin (UPSC). Remarkably, the 24-genes methylation profile of the ovarian 
location of the widespread serous carcinoma shows significantly higher methylation levels 
compared to their endometrial counterpart, or compared to the solitary OSC and UPSC 
cases. Although, the correlation for methylation in the endometrial and ovarian location within 
cases was high, higher methylation levels in the ovarian counterpart could represent an effect 
needed for spread of disease or metastasis of the primary carcinoma. 
Further, in all analyzed groups of cases relatively high, as well as relatively low methylation 
levels were found. These DNA methylation clusters have been reported before in OSC and 
were attributed to significant differences in age at diagnosis and overall survival3. Our current 
results do not show a correlation between the cumulative methylation index and age at 
diagnosis, but sample sizes are relatively small, and data on 5-year overall survival were not 
available yet in most cases. 
Another limitation of the current study is the restricted number of genes analyzed. Ideally 
methylation profiling of both primary carcinoma would be performed by analyzing promoter 
regions of a much larger set of genes to identify a panel of discriminative markers. We 
were unaware of studies specifically looking at methylation differences between serous 
carcinomas, and since it has been speculated that methylation might even be an earlier event 
than mutation, we chose to look at promoter regions of TSGs and oncogenes commonly 
altered in carcinomas.
Besides methylation levels for CDH13, levels for the other frequently silenced promoter 
regions in cancers were highly identical for OSC and UPSC in the current study. Total genome-
wide studies already provided evidence for highly similar genetic profiles of OSC and UPSC, 
and the current study suggests that these serous carcinomas also have highly comparable 
methylation profile. Kolbe et al., compared gynecologic carcinomas of endometrioid histology 
type and also found highly comparable methylation levels in solitary endometrial and ovarian 
endometrioid carcinoma18. A common methylation phenotype for endometrioid ovarian and 
endometrial carcinomas is in line with the hypothesis that all endometrioid carcinomas might 
originate following a similar pathway involving the malignant development of endometriosis, 
originally arising from endometrial cells. However, OSC and UPSC are thought to develop 
following different pathways of carcinogenesis28. 
Comparable histological and (epi-)genetic tumor characteristics for UPSC and OSC support 
that UPSC is more and more treated as OSC in the last decade. Despite of highly similar 
profiles, immunohistochemical staining for Wilms tumor 1 has been suggested to show 
different expression in serous endometrial and serous ovarian carcinomas, and for example 
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the frequency of PPP2R1A mutations has been reported as a potential molecular distinction 
between UPSC and OSC5,29-31. Possibly, CDH13 methylation levels might represent another 
discriminative feature between both serous carcinoma. Although, efforts still need to be made 
to elucidate the biology of these serous subtypes and to personalize treatment management 
further. 
In conclusion, OSC and UPSC are not only genetically highly similar, but also their methylation 
profiles are comparable. However, CDH13 methylation might have discriminative capability 
between OSC and UPSC and might have value in determining the primary carcinoma location 
in cases with widespread serous carcinoma.  
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OSC (N=15) UPSC (N=15) Paired OSC (N=13) Paired UPSC (N=13)
Genes Mean SD Mean SD Mean SD Mean SD
APC 0.28 0.15 0.31 0.21 0.44 0.12 0.36 0.23
ATM 0.17 0.13 0.19 0.16 0.27 0.07 0.19 0.14
BRCA1 0.17 0.16 0.16 0.14 0.22 0.07 0.16 0.11
BRCA2 0.16 0.12 0.18 0.15 0.25 0.07 0.17 0.10
CASP8 0.23 0.21 0.22 0.16 0.26 0.07 0.20 0.12
CD44 0.27 0.16 0.25 0.13 0.32 0.07 0.26 0.09
CDH13 0.28 0.09 0.40 0.10 0.44 0.17 0.39 0.13
CDKN2A 0.14 0.07 0.15 0.08 0.18 0.05 0.14 0.06
CDKN1B 0.18 0.11 0.22 0.14 0.29 0.09 0.21 0.14
CDKN2B 0.33 0.21 0.31 0.21 0.43 0.08 0.34 0.16
CHFR 0.12 0.12 0.15 0.14 0.20 0.07 0.13 0.12
DAPK1 0.12 0.11 0.13 0.11 0.17 0.05 0.12 0.08
ESR1 0.26 0.16 0.25 0.17 0.35 0.08 0.27 0.10
FHIT 0.07 0.07 0.09 0.09 0.09 0.04 0.06 0.05
GSTP1 0.20 0.12 0.21 0.13 0.28 0.08 0.23 0.10
HIC1 0.19 0.15 0.20 0.18 0.29 0.07 0.25 0.17
IGSF4 0.15 0.13 0.17 0.15 0.22 0.07 0.17 0.09
MLH1 0.17 0.14 0.17 0.14 0.24 0.06 0.17 0.13
MLH1b 0.09 0.08 0.10 0.11 0.14 0.06 0.09 0.08
PTEN 0.25 0.15 0.26 0.17 0.32 0.07 0.25 0.12
RARB 0.15 0.11 0.18 0.13 0.23 0.06 0.17 0.11
RASSF1a 0.29 0.24 0.29 0.19 0.38 0.23 0.28 0.15
RASSF1b 0.37 0.30 0.36 0.18 0.44 0.23 0.35 0.23
TIMP3 0.16 0.14 0.20 0.17 0.30 0.16 0.21 0.13
TP73 0.17 0.08 0.23 0.13 0.29 0.10 0.22 0.09
VHL 0.07 0.06 0.08 0.07 0.10 0.04 0.07 0.06
CMI 5.07 5.44 7.15 5.45
Supplementary Table 1: Mean tumor suppressor gene methylation level in solitary and paired serous tumors
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OSC UPSC Paired OSC Paired UPSC
Genes N=15 % N=15 % p value N=13 % N=13 % p value
APC 4 27% 6 40% 0.700 11 85% 4 31% 0.015
ATM 3 20% 5 33% 0.682 8 62% 2 15% 0.041
BRCA1 3 20% 4 27% 1.000 1 8% 2 15% 1.000
BRCA2 3 20% 4 27% 1.000 5 39% 2 15% 0.378
CASP8 4 27% 5 33% 1.000 4 31% 2 15% 0.645
CD44 3 20% 4 27% 1.000 5 39% 2 15% 0.378
CDH13 4 27% 13 87% 0.003 12 92% 10 77% 0.593
CDKN2A 3 20% 6 40% 0.427 8 62% 2 15% 0.041
CDKN1B 2 13% 3 20% 1.000 3 23% 1 8% 0.593
CDKN2B 5 33% 5 33% 1.000 6 46% 2 15% 0.202
CHFR 3 20% 5 33% 0.682 5 39% 2 15% 0.378
DAPK1 2 13% 4 27% 0.651 2 15% 1 8% 0.480
ESR1 3 20% 4 27% 1.000 5 39% 2 15% 0.378
FHIT 2 13% 2 27% 1.000 0 0% 0 0% 1.000
GSTP1 2 20% 4 27% 0.651 3 23% 1 8% 0.593
HIC1 3 20% 4 27% 1.000 5 39% 3 23% 0.673
IGSF4 3 20% 5 33% 0.682 4 31% 1 8% 0.322
MLH1 4 27% 4 27% 1.000 6 39% 2 15% 0.202
MLH1b 2 13% 4 27% 0.651 1 8% 1 8% 1.000
PTEN 3 20% 5 33% 0.682 5 39% 2 15% 0.378
RARB 3 20% 6 40% 0.427 6 46% 2 15% 0.202
RASSF1a 6 40% 8 53% 0.464 7 54% 8 62% 0.691
RASSF1b 4 27% 8 53% 0.264 6 39% 3 23% 0.411
TIMP3 4 27% 5 33% 1.000 10 67% 3 23% 0.017
TP73 1 7% 6 40% 0.080 4 31% 1 8% 0.322
VHL 1 7% 4 27% 0.330 1 8% 1 8% 1.000
Total; mean 80; 5.3 20% 133; 8.9 34% 0.296 133; 10.2 38% 62; 4.8 19% 0.110
Supplementary Table 2: Frequency of methylation above the threshold compared between serous carcinomas located 
in the ovaries or endometrium
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In this thesis we focus on the most common type of ovarian cancer which is high-grade 
serous ovarian carcinoma. In our search for its precursor, the tubal epithelium is analyzed in 
women diagnosed with serous ovarian carcinoma, in a large cohort of BRCA-mutation carriers 
and in control cases of women without an increased risk of developing ovarian carcinoma. 
Furthermore, the entire endometrium is examined for potential premalignancies in women 
diagnosed with various histological subtypes of ovarian carcinoma, and in a control group 
of asymptomatic women. In the last two chapters of this thesis we focus on the challenges 
of determining the origin of widespread serous carcinoma and methods to facilitate its 
classification.
The Prevalence of Serous Tubal Intraepithelial Carcinoma (STIC) and Its Location 
within the Fallopian Tube in BRCA-Mutation Carriers and Serous Ovarian Cancer 
Patients
After complete embedding of the fallopian tubes, we identified STIC in 6% of BRCA-mutation 
carriers who underwent pBSO (prophylactic bilateral salpingo-oophorectomy) (chapter 2). 
The fimbriated end of the fallopian tube is the favored localization of STIC, as is confirmed in 
chapter 21,2. However, in our study presence of STIC is not limited to this part of the fallopian 
tube. In one-third of cases STIC was identified only in the isthmus or ampulla of the tubes.
The presence of STIC in the isthmus or ampulla might explain the 19% risk reduction to 
develop serous ovarian carcinoma after tubal ligation3. The ligation in itself may prevent 
spreading of tumor cells from the ampulla or tubal isthmus. Reduced flow of carcinogenic or 
inflammatory agents through the fallopian tube, or altered blood flow to the ovary could also 
possibly explain the decrease in development of ovarian cancer3-8.
The presence of STIC in the ampulla or isthmic part of the fallopian tube contradicts that 
a ‘radical fimbriectomy’ would be sufficient in preventing ovarian carcinoma, as has been 
suggested as an alternative solution for pBSO9. We recommend a total tubectomy when 
performing risk reductive surgery in BRCA-mutation carriers. A promising alternative for 
pBSO in mutation carriers seems the two step procedure in which the bilateral tubectomy is 
performed when the childbearing is completed with second step removal of the ovaries at a 
higher age. This method could overcome the adverse effects of early menopause because 
of ovariectomy at the age of 40. Trials are currently carried out in France by Leblanc et al. 
(NCT01608074), in Texas, USA, by Nebgen et al. (NCT01907789) and in our own institution. 
First results are expected in 2019 (www.clinicaltrials.gov)9,10.
At the moment pBSO is performed around the age of 40. In chapter 2, STIC was identified in 
two out of the 84 women included in this study with an age of 40 years or younger. Treatment 
management of STIC and whether STIC is a reason to perform pBSO or tubectomy at an 
earlier age in BRCA-mutation carriers is still a matter of debate. The study that was carried 
out cannot provide conclusive answers to these questions. Powell et al. and Wethington et 
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al. reported on the follow up of 29 BRCA-mutation carriers in which STIC was identified at 
the time of pBSO11,12. In one patient a recurrence was detected in the omentum on routine 
surveillance, at 43 months after pBSO11,12. This woman was successfully treated and remained 
disease free 16 months later. There is no hard evidence to include surgical staging or adjuvant 
chemotherapy in treatment management of women diagnosed with STIC, when invasion has 
been thoroughly ruled out by rigorous pathological sampling. However, sample sizes in these 
studies are small and optimal treatment management needs to be re-evaluated in the near 
future. 
In chapter 5 we show that STIC can be found in 43% of high-grade serous ovarian 
carcinomas after embedding the fallopian tubes in accordance with the SEE-Fim protocol. This 
prevalence is in agreement with findings reported by others who used the identical protocol to 
meticulously examine the entire tubal epithelium13-16. Even if a proportion of STIC is missed, 
it is not likely that STIC is present in all women diagnosed with serous ovarian carcinoma. 
Furthermore, it is strongly questioned whether STIC has to be classified as a malignancy 
instead of a premalignancy, as it has the potential of metastasizing in rare cases12,17,18. The 
ability of cancer cells to invade and metastasize is central in the progression of carcinoma 
and involves a biological process during which immotile epithelial cells are converted into 
motile mesenchymal cells (epithelial-mesenchymal transition (EMT))19,20. The development 
of tubal intraepithelial carcinoma towards carcinoma is thought to be a rapid process, as the 
overall prevalence of STIC in BRCA-mutation carriers is relatively low with 1-8% compared 
to 40-60% in BRCA-mutation carriers diagnosed with serous ovarian carcinoma11,13,17,21-25. To 
improve prognosis it is important to detect the disease when it is still in a premalignant state.
Normal Tubal Epithelial Variation in Women without an Increased Risk of Developing 
Ovarian Carcinoma
A wide variety of potential tubal precursor lesions has been reported in the literature, but 
there exact impact is still discussed. For example, dysregulation of PAX2 and/or p53 signatures 
are hypothesized to represent early steps in serous carcinogenesis. They have however also 
been described regularly in control cases, though less extensively as in BRCA-mutation 
carriers22,26. To identify potential tubal epithelial lesions it is essential to have knowledge on 
normal tubal epithelial variation, its extent and location.
In chapter 2 the tubal epithelium of a large control group of women who underwent BSO for 
non-malignant reasons was meticulously examined for microscopically visible tubal epithelial 
changes. Although the tubal epithelium was not embedded in accordance with the SEE-Fim 
protocol for these control cases, tubal hyperplasia and minor epithelial atypia were frequently 
found. They did not have a marked preference for the fimbriated end, and were even more 
commonly found than in BRCA-mutation carriers. STIC was found in none of the control 
cases. These results suggest that it is unlikely that tubal epithelial hyperplasia or minor atypia 
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represent direct steps in serous carcinogenesis. Further research is strongly recommended 
to enable comparison of results.
Normal Endometrial Variation and Pre-neoplastic Lesions in the Endometrium of 
Women Diagnosed with Ovarian Carcinoma or Control Cases
As pointed out in the introduction of this thesis, it is not clear that all high-grade serous 
ovarian carcinomas are derived from a premalignant lesion of the fallopian tube. The origin of 
serous ovarian carcinoma might be multicentric and it is indicated that some high-grade serous 
ovarian carcinomas may arise from the ovary27. Our research group even suggested that the 
endometrium might be a potential origin for a proportion of serous ovarian carcinomas28,29.
Women diagnosed with ovarian carcinoma are mostly postmenopausal. The endometrium 
of asymptomatic postmenopausal women is expected to be atrophic instead of the cyclic 
pattern as is seen in premenopausal women. Sivridis et al. reported that occasionally 
weak proliferation of the endometrium can be found in asymptomatic postmenopausal 
women as well30. We extensively examined the endometrium in asymptomatic women and 
in women diagnosed with ovarian carcinoma to improve knowledge on the appearance of 
the endometrium in these women. The SEE-End protocol was developed to enable optimal 
interpretation of the entire endometrium. 
Using this protocol, the entire endometrium can be histologically examined in a relatively 
limited amount of sections. Redundant myometrium was removed to enable the display of 
several endometrial parts in one section. Time to assess the entire endometrium, compared to 
only standard endometrial sections, was not significantly longer given the ordered arrangement 
of the endometrial parts (SEE-End protocol).
In chapter 4 we showed that the endometrium of asymptomatic postmenopausal women 
is indeed atrophic, but that hyperplasia with or without atypia is regularly found. Atypical 
hyperplasia was found in 6% of women who underwent a hysterectomy because of uterovaginal 
prolapse, and hyperplasia without atypia in 17%. In none of these asymptomatic women an 
endometrial intraepithelial carcinoma (EIC) was found, but occult endometrial carcinoma was 
identified in two. Presence of endometrial atypical hyperplasia was confirmed in 24% of women 
diagnosed with serous, endometrioid, clear cell or mucinous ovarian carcinoma (chapter 3). 
In the prospective cohort of women diagnosed with serous ovarian carcinoma in which the 
endometrium was embedded in accordance with the SEE-End protocol, endometrial atypical 
hyperplasia was found in a comparable prevalence of 22% (chapter 5).
We may conclude that endometrial atypical hyperplasia is more commonly found in women 
diagnosed with ovarian carcinoma than in asymptomatic women. The prevalence of atypical 
hyperplasia is different for the various histological subtypes of ovarian carcinoma, being 
highest in the endometrioid cancer type. In these women it is identified in almost half of cases. 
This finding may suggest a causal relationship in this ovarian carcinoma subtype. Though, 
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its mechanism has not yet been clarified. Body mass index (BMI) is the only clinical variable 
in ovarian cancer patients that is associated with atypical hyperplasia (chapter 3). Under 
the influence of relatively high levels of unopposed oestrogenic stimulation postmenopausal 
endometrium may develop into atypical hyperplasia, and/or endometrioid carcinoma31,32. 
Endometrial intraepithelial carcinoma (EIC) was only found in women diagnosed with the 
serous histological subtype of ovarian carcinoma, and not in those diagnosed with other 
subtypes. When embedding the endometrium in accordance with the SEE-End protocol, EIC 
was found in 15% of these women (chapter 5) instead of in 5% after routine endometrial 
sampling (chapter 3). Therefore, specifically in the detection of EIC sampling of the entire 
endometrium seems mandatory. 
Endometrial pathology, as EIC or occult endometrial carcinoma, can easily be missed if only 
one or two endometrial sections are taken. In most cases the endometrium is heterogeneous 
and lesions are not present in the entire endometrium. To ensure the detection of endometrial 
pathology in women suspected for ovarian carcinoma, we recommend to embed the 
endometrium in accordance with the SEE-End protocol. The high prevalence of endometrial 
pathology in these women also stresses the importance of performing hysterectomy in case of 
staging or debulking procedure. If conservative surgery is considered with preservation of the 
uterus at least endometrial sampling should be performed to screen for additional endometrial 
pathology33.
Challenges in Determining Primary Origin of Serous Carcinoma
Endometrial intraepithelial carcinoma is detected in 15% of serous ovarian carcinomas and 
might account for the origin of part of these malignancies (chapter 5). Yet, in two-third of the 
women in which EIC was identified, also STIC was found in the fallopian tubes. The fallopian 
tubes are generally accepted as a plausible origin of ovarian cancer. Most likely the primary 
origin in these cases is located in the fallopian tubes with the EIC representing a metastic 
site34. However, tumor cells from EIC can also spread through the tubes towards the ovaries 
and peritoneal cavity, and in this case STIC could represent a metastatic deposit18,29,35,36.
Multiple locations of (intraepithelial) serous carcinomas are most likely of clonal origin13,29,37-39. 
We were able to confirm clonality of STIC, EIC and concurrent serous ovarian carcinoma in 
some cases, but in the majority of cases we identified a TP53 mutation in only one or in none 
of the locations. This might be due to the method of TP53 mutation analysis, as not all tissue 
was gathered with laser microdissection. Multiple intraepithelial lesions could also represent 
an effect of field carcinogenesis, and develop at multiple loci within the genital tract, therefore 
lacking identical TP53 mutations. 
Until the origin of serous carcinoma is entirely understood, assigning primary location 
of serous malignancy can be complicated. In 2013 the FIGO (International Federation 
of Gynecology and Obstetrics) revised staging for ovarian cancer40,41. Despite of general 
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agreement that the fallopian tubes are a likely origin of serous ovarian carcinoma, there is 
no consensus yet on the classification of carcinomas identified with STIC as primary tubal or 
ovarian16,36. One of the changes in staging for ovarian cancer concerned the fact that serous 
ovarian, tubal, and primary peritoneal carcinomas are designated where possible, but they are 
all gathered in one single system40. ‘Undesignated’ primary carcinoma is added as a category 
to this system in case it is not possible to delineate the primary site.
Differentiating Primary Serous Ovarian Carcinoma and Uterine Papillary Serous 
Carcinoma (UPSC)
Precursor lesions assist in determining primary origin of serous carcinoma, but are not 
always very specific for one site. Determining primary origin of serous carcinoma can be 
very complicated in case of widespread disease or multiple intraepithelial carcinomas. Other 
promising molecular markers of the carcinoma may assist in the differentiation of primaries. 
Serous ovarian carcinomas and UPSC (serous endometrial carcinoma) show highly similar 
molecular profiles, with only minor discriminative molecular features including somatic 
mutations of PPP2R1A and PIK3CA in UPSC cases and BRCA1 and BRCA2 mutations in a 
proportion of serous ovarian cancer patients42-48.
Results in chapter 6 support that WT1 immunohistochemistry (clone WT49) shows 
significantly different expression patterns in cases with solitary primary serous ovarian 
carcinoma compared to UPSC, as has previously been suggested by others 49-52. In addition, 
we tested the discriminative ability of WT1 expression in ‘undesignated’ serous carcinomas with 
extensive involvement of the ovaries as well as the endometrium (chapter 6). In the majority 
of cases with ‘undesignated’ serous carcinoma, WT1 expression is supportive for one primary 
origin. In case of serous ovarian carcinoma and coexisting EIC, two synchronous primaries 
could not be excluded in some cases because of discordant WT1 expression. Concluding, 
WT1 staining is a practical marker to classify serous carcinoma with a strong discriminative 
power, and is advised to be used in addition to extensive histological examination.
Future Perspectives
The interpretation of EIC as well as STIC in women diagnosed with serous ovarian 
carcinoma needs further analysis. STIC is an essential step in serous carcinogenesis, but while 
examining tubal epithelium we noticed a strong variety in the degree of STIC. Discriminating 
various degrees of STIC might be an interesting addition to the classification system as they 
might differ in their ability to metastasize. Immunohistochemical expression patterns of the 
various degrees of STIC might be added to screen for early steps in serous carcinogenesis. 
In addition, large, multicentre studies are needed to assess prognosis of women in which the 
various degrees of STIC are identified and to assess their optimal treatment.
Whether endometrial intraepithelial carcinoma is responsible for a proportion of serous 
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ovarian carcinomas, or just represents one out of multiple intraepithelial foci has not yet 
been solved. Further research is needed to unravel this matter. Methods should include laser 
microdissection of tissue from all different foci of the carcinoma, and a panel of discriminative 
markers including WT1 staining, CDH13 methylation or other promising features.
Common presence of atypia and hyperplasia in the genital tract epithelium of women 
diagnosed with ovarian carcinoma suggests that they are subjected to micro environmental 
factors causing carcinogenic changes5,53-55. Models should be developed to study the effect 
of induced inflammation of the Müllerian derived tissue of the genital tract, for example by 
estrogens, to search for an effect of field carcinogenesis.
A remaining challenge will be to detect these carcinomas in an earlier stage of disease. 
Apart from histological examination exploration of other effective detection strategies need to 
be assessed. 
Suggestions for Clinical Practice
• we recommend that a total tubectomy is performed in case of risk reductive surgery in 
BRCA-mutation carriers, instead of a ‘radical’ fimbriectomy.
• a generally used classification method is advised for the interpretation of the different 
types of tubal pathology.
• if preservation of the uterus is considered in women diagnosed with early stage ovarian 
carcinoma, at least endometrial sampling is recommended given the high prevalence of 
endometrial pathology.
• the endometrium is recommended to be embedded in accordance with the SEE-End 
protocol in ovarian carcinoma cases to reveal additional intraepithelial abnormalities.
• WT1 staining is recommended, in addition to extensive histological examination, to 
determine primary origin in cases with ‘undesignated’ high-grade serous carcinoma with 
involvement of the ovaries and endometrium.
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Ovarian carcinoma is one of the most common types of gynecologic cancer and the one 
with the highest mortality. At diagnosis it is often already in an advanced stage as symptoms 
of disease are non-specific and knowledge of the origin of ovarian carcinoma is poor. 
Ovarian carcinoma is a collective term for carcinomas with different histological subtypes, 
differentiation grades, clinicopathological characteristics and prognosis. High-grade serous 
ovarian carcinoma is the most common type of ovarian carcinoma and the majority of the 
thesis is focused on this specific subtype. 
Despite of decades of diligent examination of the ovaries, no potential precursor lesions for 
serous ovarian carcinoma were revealed in the ovaries. Nowadays it is thought that ovarian 
carcinomas arise from tissues that are embryologically derived from the Müllerian ducts 
instead of the Wolffian ducts that develop into the ovary. The Müllerian ducts develop into 
the upper part of the vagina, uterus and fallopian tubes. The normal epithelial lining of the 
fallopian tubes resemble histological characteristics of the serous carcinoma subtype. Serous 
tubal intraepithelial carcinoma has been identified in the fallopian tubes and is a potential 
premalignancy of serous ovarian carcinoma. Though, there is no evidence that all serous 
ovarian carcinomas arise from the fallopian tubes and/or from STIC. In this thesis the entire 
Müllerian derived epithelium was meticulously assessed for (potential) premalignancies 
in women at high risk of developing serous ovarian carcinoma, in women diagnosed with 
(serous) ovarian carcinoma, and in controls.
In chapter 2 we examined the tubal epithelium of a large cohort of BRCA-mutation carriers 
and of control cases without an increased risk of developing ovarian carcinoma. We analyzed 
the prevalence and localization of serous tubal intraepithelial carcinoma (STIC), hyperplasia 
and minor epithelial atypia in the tubal epithelium of these women. STIC was found in 6% 
of BRCA-mutation carriers and in none of the control cases. Tubal hyperplasia and minor 
epithelial atypia were frequently found in both BRCA-mutation carriers as well as in control 
cases, in 42% and 58% respectively. The high prevalence of hyperplasia and minor epithelial 
atypia in control cases suggests that they represent normal tubal epithelial variation. STIC 
was found in two-third of cases in the fimbriated end. Tubal hyperplasia and minor epithelial 
atypia displayed more variation in localization within the tubal epithelium. However, still one-
third of STIC were identified in the non-fimbriated end of the fallopian tube instead of the 
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favored fimbriated end, and we recommend to perform total salpingectomy at risk reducing 
surgery for BRCA-mutation carriers.
Apart from the presence of a double primary carcinoma in the endometrium, little is known 
about concurrent endometrial pathology in women diagnosed with ovarian carcinoma. In 
chapter 3 we reviewed all hematoxylin and eosin stained endometrial and ovarian sections of 
a cohort of women diagnosed with epithelial ovarian cancer: 136 serous ovarian carcinomas, 
19 endometrioid, 7 clear cell and 15 mucinous carcinomas. Furthermore, medical records, 
surgical and pathology reports were analyzed for pertinent clinical and pathological data. 
Atypical hyperplasia was found in a significant amount of women diagnosed with epithelial 
ovarian cancer, but it was most common in concurrence to endometrioid ovarian carcinoma. 
In the latter, endometrial atypical hyperplasia was found in 47% of cases, compared to 24% 
in case of serous ovarian carcinoma, 29% in clear cell, and 7% in mucinous. The presence of 
endometrial intraepithelial carcinoma (EIC) was limited to cases diagnosed with serous ovarian 
carcinoma, and EIC was found in 5% of them. Double primary endometrial carcinomas were 
identified in 3% of serous ovarian carcinomas and in 11% of endometrioid ovarian carcinomas, 
whereas in none of the clear cell or mucinous carcinomas. Population characteristics and 
potential endometrial proliferation risk factors revealed a significantly higher mean body mass 
index (BMI) in the women diagnosed with an atypical endometrium compared to those with a 
normal endometrium. 
Serous ovarian carcinoma is the most common ovarian carcinoma. Immunohisto-chemical 
staining patterns for serous ovarian carcinoma were compared with staining patterns for the 
coexisting endometrial lesions: atypical hyperplasia, or EIC. Immunohistochemical expression 
patterns for EIC and concurrent serous ovarian carcinoma were highly comparable, with 
strong exhibition of Ki-67, p16 and ER, weak exhibition of PR, and strongly positive or 
completely negative p53 staining. The expression pattern of atypical hyperplasia was more 
distinctive, showing strong exhibition of ER and PR, and negative to moderate Ki-67, p16 
and p53 expression in the majority of cases. Concluding, coexisting endometrial pathology, 
including (intraepithelial) carcinoma, is present in a significant number of women diagnosed 
with ovarian carcinoma. If conservative surgery is considered with preservation of the uterus, 
attention should be given to the possibility of concurrent endometrial pathology.
In standard routine practice only a selection of the endometrium is embedded for histological 
assessment. The SEE-End (Sectioning and Extensively Examining the Endometrium) 
protocol was developed to enable structural embedding of the entire endometrium. In chapter 
4 the SEE-End protocol was used to gain more insight in normal epithelial variation of the 
endometrium in asymptomatic women. We included women who underwent a hysterectomy 
on indication of uterovaginal prolapse. If symptoms of postmenopausal vaginal blood loss or 
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premenopausal disordered vaginal bleeding were present, these cases were excluded from 
the study. We included 68 women from 3 hospitals in the South of the Netherlands, 48 women 
were postmenopausal and 20 were premenopausal. The following endometrial pathology 
was identified in these women: hyperplasia in 12%, atypical hyperplasia in 6%, and a small 
focus of intramucosal endometrioid endometrial carcinoma in 3%. In general, the lesions 
were not present in the entire endometrium. This study demonstrates the heterogeneity 
of the endometrium in premenopausal women as well as in postmenopausal women. The 
prevalence of endometrial pathology in these women was remarkably high, but its clinical 
relevance is not yet clear. 
In chapter 5 the endometrium and fallopian tubes of women who underwent debulking 
surgery because of high-grade serous ovarian carcinoma were embedded in accordance 
with the SEE-End and SEE-Fim protocol to examine the presence of premalignancies in 
these Müllerian derived tissues. Sixty women which were diagnosed with serous ovarian 
carcinoma were included in this multicenter, observational study. In more than half of these 
cases intraepithelial carcinoma and/or endometrial atypical hyperplasia was found: in 32% 
of cases endometrial atypical hyperplasia, in 15% EIC, and in 43% STIC. In 27% of women 
multiple types of pathologic lesions were found within one case. For example, in five cases 
EIC, atypical hyperplasia as well as STIC was found. Interestingly, if STIC was identified in 
the tubal epithelium, the concurrent endometrium showed significantly more frequently an 
endometrial (pre)malignancy instead of a normal endometrium. The prevalence of coexisting 
intraepithelial carcinomas was surprisingly high. This is in contrast with the assumption that 
serous carcinoma develops from one intraepithelial carcinoma, from where it can develop into 
invasive carcinoma or spread to other locations in the peritoneal cavity.  
The SEE-End protocol enabled the identification of a much higher prevalence of EIC in 
serous ovarian cancer patients compared to the standard protocol of endometrial embedding. 
EIC was identified in 15% compared to 5%, respectively. 
In chapter 6 and 7 we discussed the similarities of serous endometrial carcinoma (uterine 
papillary serous carcinoma (UPSC)) and ovarian serous carcinoma (OSC). In cases with 
extensive serous carcinoma it can be difficult, or even impossible, to assign its primary site. 
Determining the primary site is based on histological criteria, but these criteria are not well 
defined or specific and promising markers to assist in the classification of serous carcinomas 
are needed.  
In chapter 6 the value of WT1 immunohistochemical expression was analyzed in the 
classification of widespread serous carcinomas as primary ovarian or primary endometrial. 
Different WT1 expression levels have been shown in cases with OSC or UPSC and WT1 is 
thought to be a discriminating marker for both primaries. 
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The discriminative ability of WT1 expression (clone WT49) was confirmed in control cases 
diagnosed with serous endometrial or serous ovarian carcinoma. A threshold level was defined 
to discriminate between OSC and UPSC. WT1 expression was suggestive for a primary 
ovarian origin in case of expression in >50% of tumor cells and for a primary endometrial 
origin in case of expression in <50% of tumor cells. 
Primary site was analyzed for 15 cases with widespread serous carcinoma involving the 
ovaries as well as the endometrium. The level of WT1 staining was found comparable in the 
endometrial as well as the ovarian carcinoma location within cases. Primary carcinoma site 
determined by histological criteria was confirmed by WT1 classification in all but one case. In 
six cases histological criteria were not able to determine a primary site and WT1 classification 
was suggestive for one primary site in all of these cases. Finally, WT1 expression was 
analyzed in 12 cases with OSC and coexisting EIC. WT1 expression was supportive for a 
primary OSC in four cases, primary UPSC in five, and was inconclusive for a specific primary 
site in three cases. WT1 immunohistochemistry is recommended to be used in addition to 
histological classification in cases with undesignated serous carcinoma, involving the ovaries 
as well as endometrium.
In chapter 7 we analyzed if methylation profiles of UPSC and OSC have discriminative 
capacity. Putative differences in methylation levels of promotor regions of 24 tumor suppressor 
genes, frequently hypermethylated in cancers, were analyzed for OSC and UPSC. Apart from 
methylation levels for CDH13, levels for the other tumor suppressor genes were highly identical 
for UPSC and OSC in the current study. CDH13 showed significantly higher methylation levels 
in UPSC compared to OSC cases. The optimal CDH13 methylation level to distinguish UPSC 
from OSC was ≥0.32, with a positive predictive value of 76% and a negative predictive value 
of 85%. 
The discriminative capacity of CDH13 methylation was analyzed in widespread serous 
carcinomas with involvement of the endometrium as well as the ovaries. In the majority of 
cases CDH13 methylation levels were relatively comparable in the endometrial and ovarian 
part of the carcinoma. Histological classification of these extensive serous carcinomas was 
supported by CDH13 methylation levels. Therefore, CDH13 methylation levels might be of 
value in determining primary carcinoma in cases with widespread serous carcinoma.
In chapter 8 the results of the studies in this thesis are discussed and the main findings are 
summarized. 
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Eierstokkanker is een van de meest voorkomende typen van gynaecologische kanker en 
degene met de hoogste mortaliteit. Op het moment van diagnose is de tumor vaak al in een 
vergevorderd stadium aanwezig. Dit komt mede doordat de ziekte geen specifieke symptomen 
kent en doordat de kennis over het ontstaan van eierstokkanker beperkt is. Eierstokkanker, 
oftewel ovariumcarcinoom, is een verzamelnaam voor diverse histologische typen van 
eierstokkanker met verschillende mate van tumor differentiatie, klinische kenmerken en 
prognose. Het hoog-gradig sereuze type van eierstokkanker is veruit het meest voorkomende 
type en het merendeel van dit proefschrift is op dit type eierstokkanker gefocust.
Ondanks decennia van uitvoerig onderzoek van de eierstokken werd hier geen voorloper 
stadium van kanker gevonden die een goede verklaring vormt voor het ontstaan van het 
sereuze type eierstokkanker. De huidige gedachte is dat het ontstaat uit epitheel dat zich 
in de embryogenese ontwikkelt uit de buizen van Müller, in plaats van uit de buizen van 
Wolff waaruit de eierstokken gevormd worden. De buizen van Müller ontwikkelen zich tot 
het bovenste deel van de vagina, de baarmoeder en de eileiders (tubae). Het epitheel 
van de eileiders toont sterke histologische overeenkomsten met het sereuze subtype van 
eierstokkanker. In het epitheel van de eileiders werd eveneens een mogelijk voorstadia van 
het sereuze subtype van eierstokkanker gevonden, namelijk het sereus tubair intraepitheliaal 
carcinoom (STIC). Echter niet in alle gevallen van het sereuze type eierstokkanker kan in de 
eileiders een dergelijke voorloper gevonden worden. 
In dit proefschrift hebben we het epitheel dat zich in de embryogenese ontwikkelt uit de 
buizen van Müller uitgebreid onderzocht op de aanwezigheid van (potentiële) voorstadia 
van kanker. Dit hebben we gedaan voor een cohort van vrouwen die een verhoogd risico 
hebben op het ontwikkelen van (sereuze) eierstokkanker of hiermee waren gediagnosticeerd. 
Hetzelfde werd gedaan voor een controlegroep zonder een verhoogd risico op krijgen van 
gynaecologische kanker.  
In hoofdstuk 2 zijn we op zoek gegaan naar microscopische zichtbare epitheliale 
veranderingen in de eileiders van een groot cohort vrouwen die drager zijn van een bewezen 
BRCA1/2 gen-mutatie en van een controlegroep vrouwen zonder een verhoogd risico op het 
ontwikkelen van eierstokkanker. De epitheliale veranderingen in het tuba epitheel werden 
geclassificeerd als hyperplasie, atypie en STIC. In maar liefst 6% van de BRCA1/2 gen-
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mutatie dragers werd STIC geïdentificeerd. In geen enkele casus van de controlegroep werd 
STIC gevonden in het tuba epitheel. Hyperplasie en atypie werden zowel in de BRCA1/2 
gen-mutatie dragers als in de controlegroep regelmatig gevonden, namelijk in 42% en in 58% 
van deze vrouwen. De hoge prevalentie van hyperplasie en atypie in het tuba epitheel van de 
controle groep suggereert dat deze epitheliale verandering past binnen de normale variatie 
van tuba epitheel. STIC is bij voorkeur gelegen in het fimbriële uiteinde van de tuba en dit 
werd ook in deze studie bevestigd. In twee-derde van de gevallen was STIC in het fimbriële 
uiteinde gelokaliseerd. Tubaire atypie en hyperplasie was veel meer verspreid aanwezig in het 
gehele tuba epitheel. Ondanks de voorkeurslokalisatie van STIC voor het fimbriële uiteinde 
van de tuba werd het in maar liefs een-derde van de gevallen in de ampulla en isthmus van de 
tuba geidentificeerd. Op basis van deze gegevens adviseren we dan ook om de gehele tuba 
te verwijderen indien er een profylactische salpingo-ovariectomie wordt verricht bij BRCA1/2 
gen-mutatie dragers in plaats van alleen het fimbrieel uiteinde.
Afgezien van het regelmatig vaststellen van een dubbele primaire tumor in het endometrium 
is er slechts weinig bekend over histologische veranderingen van het endometrium bij 
vrouwen gediagnosticeerd met eierstokkanker. In hoofdstuk 3 werden alle coupes van het 
endometrium en ovarium van vrouwen gediagnosticeerd met eierstokkanker nauwkeurig 
onderzocht op de aanwezigheid van premaligne afwijkingen: 136 sereuze ovarium carcinomen, 
19 endometrioide, 7 clear cell en 15 mucineuze carcinomen. Overige pathologische en 
klinische gegevens werden verkregen uit de medische dossiers, chirurgie en pathologie 
verslagen. In een significant deel van deze vrouwen werd atypische hyperplasie vastgesteld 
in het endometrium. In het geval van het endometrioid type eierstokkanker betrof dit zelfs 47% 
van de vrouwen. Atypische hyperplasie werd bij 24% van de vrouwen gediagnosticeerd met 
het sereuze type eierstokkanker gezien, bij 29% van de vrouwen gediagnosticeerd met het 
clear cel type en bij 7% van de mucineuze. De premaligniteit, endometrium intraepitheliaal 
carcinoom (EIC), werd alleen bij het sereuze type eierstokkanker gevonden en wel in 5% 
van deze vrouwen. Een dubbele primaire tumor in het endometrium werd alleen gezien in 
vrouwen gediagnosticeerd met het sereuze of endometrioide type eierstokkanker, en wel 
in 3% en 11% van deze vrouwen. Van alle onderzochte populatiekenmerken en potentiële 
risicofactoren voor endometriumproliferatie is alleen het BMI (body mass index) significant 
hoger in de vrouwen gediagnosticeerd met atypische hyperplasie. 
Aangezien het sereuze type eierstokkanker veruit het meeste voorkomt, werden 
de endometriumafwijkingen in deze groep vrouwen nader bekeken met behulp van 
immunohistochemisch onderzoek. Immunohistochemische expressiepatronen van de 
sereuze tumoren werden vergeleken met de bijbehorend gevonden endometriumafwijkingen: 
atypische hyperplasie of EIC. Atypische hyperplasie wordt gezien als een voorstadium van 
het endometrioide subtype van endometriumkanker terwijl EIC een voorstadium betreft van 
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sereuze subtype endometriumkanker. De immunohistochemische expressiepatronen waren 
sterk vergelijkbaar voor EIC en bijbehorende sereuze ovariumcarcinomen waarbij sterke 
expressie werd gezien voor zowel Ki-67, p16 en ER, terwijl PR juist zwak kleurde en p53 
helemaal niet of heel sterk. Daarentegen liet atypische hyperplasie van het endometrium juist 
een ander expressiepatroon zien met sterke expressie voor ER en PR, en matige expressie 
voor Ki-67, p16 en p53. 
We kunnen hieruit concluderen dat een significant aantal van de vrouwen gediagnosticeerd 
met eierstokkanker ook (pre)maligne afwijkingen in het endometrium heeft. Indien men 
overweegt om de baarmoeder in situ te laten bij iemand die is gediagnosticeerd met 
eierstokkanker, dient men bedacht te zijn op mogelijke aanwezigheid van deze additionele 
endometrium afwijkingen. 
In de standaard praktijkvoering wordt slechts een selectie van het endometrium ingesloten 
voor histologische beoordeling, uiteraard mits hierin geen verdachte macroscopische laesies 
aanwezig zijn. Het SEE-End (Sectioning and Extensively Examining of the Endometrium) 
protocol is ontwikkelt om het endometrium op een structurele manier in zijn totaliteit in te 
kunnen sluiten voor histologische beoordeling. In hoofdstuk 4 is het bewuste SEE-End 
protocol gebruikt om meer inzicht te krijgen in de normale variatie van het endometrium in 
vrouwen. Voor deze studie werden vrouwen geïncludeerd die behandeld werden voor een 
verzakking door middel van het verwijderen van de baarmoeder. Indien symptomen van 
postmenopauzaal bloedverlies of premenopauzale menstruatiestoornissen aanwezig waren, 
werden deze vrouwen geëxcludeerd uit de studie. Er konden 68 vrouwen geïncludeerd 
worden in de studie, afkomstig uit 3 ziekenhuizen gelegen in het zuiden van Nederland. 
Van deze groep vrouwen waren 48 vrouwen postmenopauzaal en 20 premenopauzaal. 
De volgende endometriumafwijkingen werden vastgesteld: hyperplasie in 12%, atypische 
hyperplasie in 6%, en in 2 casus (3%) werd een gelokaliseerd intramucosaal endometrium 
carcinoom gevonden. De gevonden afwijkingen waren meestal niet aanwezig in het gehele 
endometrium. Deze studie demonstreert daarmee de heterogeniteit van het endometrium 
in niet alleen premenopauzale vrouwen, maar tevens in postmenopauzale vrouwen. De 
aanwezigheid van deze premaligne afwijkingen in het endometrium van een gezonde groep 
vrouwen is onverwacht hoog. De klinische relevantie van deze afwijkingen is vooralsnog niet 
duidelijk en verdient nadere aandacht. 
In hoofdstuk 5 werden zowel het endometrium als de eileiders volgens het SEE-End en 
SEE-Fim ingesloten bij vrouwen die een debulking operatie hadden ondergaan wegens een 
hoog-gradig sereus type eierstokkanker. Het gehele epitheel afkomstig van de buizen van 
Müller werd onderzocht op de aanwezigheid van potentiële premaligniteiten. Zestig vrouwen 
werden geïncludeerd in deze prospectieve, multicentrum studie. In meer dan de helft van 
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deze vrouwen werd een intraepitheliaal carcinoom en/of atypische hyperplasie gezien: in 
32% atypische hyperplasie van het endometrium, in 15% EIC en in 43% STIC. In 27% van 
de vrouwen werden zelfs meerdere typen van deze voorstadia gevonden. Bijvoorbeeld: in 5 
casus werd zowel een EIC, als atypische hyperplasie en ook STIC waargenomen. Met behulp 
van het SEE-End protocol werd vaker een EIC gevonden bij vrouwen gediagnosticeerd met 
het sereuze type eierstokkanker dan indien het endometrium volgens de standaard procedure 
werd onderzocht, namelijk in 15% versus 5%. 
Een opvallend gegeven is dat indien STIC aanwezig was in de eileider, er tevens  significant 
vaker afwijkingen in het endometrium werden gezien. Dit is opvallend aangezien de 
aanwezigheid van meerdere voorstadia indruist tegen de idee dat kanker zich ontwikkelt vanuit 
een enkele laesie van waaruit het invasief wordt en metastaseert. Mogelijke verklaringen 
hiervoor zijn dat sommige van deze laesies toch al metastasen betreffen in plaats van 
voorstadia, of dat het gehele epitheel aan carcinogene veranderingen onderhevig is waarvan 
een enkele de voorloper betreft van het invasief carcinoom. 
Het sereuze type kanker kan primair ontstaan in zowel de eierstokken, eileiders, 
baarmoeder, en zelfs heel zeldzaam ook in de baarmoederhals. Indien de kanker uitgebreid 
aanwezig is, kan het haast onmogelijk zijn om de primaire lokalisatie van de tumor vast te 
stellen. In hoofdstuk 6 en 7 werd de moeilijkheid van het onderscheiden van het sereuze type 
endometrium kanker (UPSC) en eierstokkanker (OSC) bij uitgebreide ziekte bediscussieerd. 
Dit wordt gedaan op basis van histologische criteria als de aanwezigheid van voorstadia en 
lokalisatie van de grootste tumormassa. Deze criteria zijn echter niet erg specifiek en andere 
markers zijn nodig om het onderscheid goed te kunnen maken. 
In hoofdstuk 6 werd de waarde van de immunohistochemische expressie van WT1 nader 
onderzocht om tussen sereus endometrium en eierstokkanker te differentiëren. WT1 wordt 
gezien als een potentiële discriminerende marker aangezien verschillende expressieniveaus 
worden beschreven voor de twee typen sereuze gynaecologische kankers. 
De verschillende expressies voor WT1 (clone WT49) werd bevestigd in een controlegroep 
van sereuze endometriumkankers en eierstokkankers. WT1 expressie in >50% van de tumor 
cellen is specifiek voor een primaire ovariële origine, terwijl WT1 expressie in <50% een 
primaire endometrium origine ondersteunt. De primaire tumor lokalisatie werd vervolgens 
geanalyseerd voor 15 casus waarbij sprake was van uitgebreide sereuze ziekte van zowel 
de ovaria als het endometrium. WT1 liet identieke expressie zien in de gehele tumor. Op 
één casus na liet WT1 een expressie zien die de histologisch veronderstelde primaire 
tumorlocatie bevestigde. In sommige casus was het echter niet mogelijk om met behulp van 
de histologische criteria een primaire tumor lokalisatie aan te wijzen. In al deze gevallen was 
de WT1 expressie echter wel suggestief voor een van beide primaire lokalisaties. 
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Tot slot werd de expressie van WT1 ook nog onderzocht in 12 casus waarbij sprake was 
van het sereuze type eierstokkanker, maar waarbij daarnaast ook nog een gelokaliseerd 
intraepitheliaal carcinoom in het endometrium werd gevonden. In vier van deze casus was 
de WT1 expressie in zowel de eierstok als het endometrium specifiek voor een primaire 
lokalisatie in de eierstok, in vijf casus in het endometrium, en in drie casus was de WT1 
expressie niet specifiek voor een van beide primaire lokalisaties. 
We bevelen aan om bij vrouwen met uitgebreide sereuze ziekte, van zowel de eierstokken 
als het endometrium, WT1 immunohistochemie te gebruiken naast de histologische criteria 
om de primaire lokalisatie van de tumor te achterhalen. 
In hoofdstuk 7 hebben we onderzocht of de methyleringsprofielen van het sereus type 
endometrium- en eierstokkanker een discriminerende waarde hebben voor beide primaire 
tumoren. De methyleringsniveaus van promotor regio’s van 24 tumorsuppressorgenen zijn 
onderzocht voor beide groepen tumoren. De geselecteerde tumorsuppresorgenen zijn genen 
die in diverse typen kankers vaak hypermethylatie laten zien. Afgezien van de mate van 
methylering voor CDH13, zijn de methyleringsniveaus van de onderzochte tumor suppressor 
genen sterk overeenkomstig in beide groepen kankers. CDH13 laat echter een significant 
hogere mate van methylering zien in de groep met de endometriumkanker. De waarde voor 
methylering van CDH13 waarbij het meest optimaal een onderscheid kan worden gemaakt 
tussen beide groepen betreft >0.32. De positief voorspellende waarde is hierbij 76% en de 
negatief voorspellende waarde 85%. Indien de mate van CDH13 methylering werd bekeken 
in vrouwen met uitgebreide sereuze ziekte in zowel het endometrium als de eierstokken, was 
het methyleringsniveau redelijk vergelijkbaar in de gehele tumor. De veronderstelde primaire 
lokalisatie op basis van histologische criteria werd ook ondersteund door het niveau van de 
CHD13 methylering. Mogelijk is CDH13 methylering ook van waarde in het classificeren van 
de primaire tumor in het geval van uitgebreide sereuze ziekte. 
In hoofdstuk 8 worden de resultaten van de verschilende studies in dit proefschrift 
bediscussieerd en worden de belangrijkste bevindingen samengevat.
 en de literatuur.
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Het moment is aangekomen dat ik jullie allemaal kan bedanken voor het mogelijk maken 
van dit proefschrift. 
Geachte professor dr. Massuger, beste Leon. Dank voor je verfrissende visie en je 
onuitputtelijke stroom aan nieuwe ideeën. Jij kon als geen ander mij helpen de hoofdzaken 
van de bijzaken te onderscheiden. Ondanks de vele promovendi die je begeleidt, wist je toch 
voor ons allemaal weer tijd vrij te maken en kon ik altijd bij je aankloppen. 
Geachte copromotoren, dr. Bulten, dr. van Ham en dr. van Tilborg. 
Beste Hans, dank voor je inzet en tijd om alle coupes voor dit proefschrift met mij te beoordelen. 
Ik ben me ervan bewust dat het er wel heel veel waren en dat niet alles op een coupe zich 
heel makkelijk laat classificeren. Veel heb ik van je mogen leren over jouw mooie vak, de 
pathologie, en ik heb het dan ook zeer leren waarderen. Maar ook dank voor de vele gezellige 
middagen en gesprekken. Zonder jou was dit proefschrift geenszins mogelijk geweest. Mijn 
dank hiervoor. 
Beste Maaike. Ook jij hebt een belangrijke rol gespeeld in de totstandkoming van 
dit proefschrift. Je klinische blik en praktische vragen wisten ervoor te zorgen dat het 
daadwerkelijke doel van dit onderzoek, namelijk het verbeteren van de zorg voor vrouwen 
gediagnosticeerd met eierstokkanker, altijd helder voor ogen bleef. 
Beste Angela. Wat was ik blij toen jij bij ons kwam tijdens de laatste fase van mijn onderzoek. 
Eindelijk lukte het nu om de plannen die in de loop van de tijd ontstaan waren ook echt te gaan 
uitvoeren. Ik kon met al mijn ideeën maar ook praktische vragen bij jou terecht en daarvoor 
ben ik je nog steeds heel dankbaar. 
Graag wil ik ook de vele mensen van de afdeling pathologie bedanken die gedurende de 
jaren hebben geholpen om mij wegwijs te maken op het laboratorium en de kneepjes van het 
vak te leren. In het bijzonder wil ik hier Jeroen van der Laak en Irene Otte-Höller bedanken. 
Dankzij jullie heb ik kennis mogen maken met vele technische hoogstandjes, als onder 
andere de immunofluorescentie. Dit leverde de meest schitterende plaatjes op die ook zeker 
niet hadden misstaan als kaft voor dit proefschrift. Dank ook aan Jeroen Dijkstra voor zijn 
hulp met de gen mutatie analyses. In dit rijtje mag Arie Maat echter ook zeker niet ontbreken. 
Samen met Hans Bulten hebben we druk gediscussieerd over de beste methode om al het 
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te beoordelen materiaal zo ëfficient en overzichtelijk mogelijk in de paraffine blokjes in te 
sluiten. Door jouw behulpzaamheid en enthousiasme hebben we dit kunnen doen en ik moet 
toegeven dat ik altijd met veel plezier op de uitsnijkamer van de pathologie te vinden was! Het 
is geweldig om te zien dat onze methode nog steeds wordt toegepast in de huidige dagelijkse 
praktijk. Tot slot natuurlijk ook mijn dank aan iedereen van de afdeling pathologie die ik nu 
niet met naam en toenaam heb benoemd maar zonder wie dit proefschrift zeker niet tot stand 
had kunnen komen.
Mijn dank gaat ook uit naar het Canisius-Wilhelmina Ziekenhuis, het St. Elisabeth Ziekenhuis 
en het TweeSteden Ziekenhuis. Beste dr. Snijders, dr. de Kievit, dr. Pijnenborg en dr. van der 
Wurff. Wat fijn dat jullie het mogelijk maakten om het onderzoek ook naar jullie kliniek uit te 
breiden en meedachten over de praktische uitvoerbaarheid hiervan. 
Ondanks dat ik veel bij de pathologie te vinden was, had ik mijn vaste werkplek in de 
‘kantoortuin’ van de afdeling gynaecologie samen met mijn mede onderzoeksmaatjes. Ik vond 
het heel bijzonder om hier met elkaar zoveel lief en leed te mogen delen. Niet onbelangrijk 
waren ook de congressen waar we samen naar toe zijn gegaan en de onderzoekersweekendjes 
met bijpassende thema’s. Speciale dank aan mijn maatjes aan de oncologie kant van de 
tuin: Yvette, Remko, Myrtille, Sabine, Loes, Kim M, Kim W, Thijs, Rafli, Pleun, Floor, Louis, 
Marieke, Fraukje en Sophieke (en natuurlijk ook Karin). Maar eigenlijk is deze lijst nog veel 
langer en horen hier nog veel meer namen bij. Yvette, jij hebt een hele periode van onze 
tijd in de kantoortuin tegenover mij gezeten en ook ik mis nog steeds de dagelijkse heerlijke 
gesprekken over vrijwel alles. Blij dat we nog steeds vrienden zijn en dat zal zeker ook zo 
blijven. 
Lieve collega’s uit Enschede. Lieve arts-assistenten, we vormden een super groep samen! 
Ik vond het heel bijzonder om zo hecht en intens alles samen te kunnen beleven en delen. 
Dank ook aan alle gynaecologen waarvan ik op zo’n prettige manier zo veel hebben mogen 
leren. En natuurlijk ook aan alle verloskundigen en verpleegkundigen. Het was een eer om 
met jullie te mogen werken. 
Het doet mij groot genoegen om nu in het Catharina Ziekenhuis te Eindhoven mijn opleiding 
te mogen starten. 
Lieve vrienden en familie. Jullie zijn met te veel om allemaal apart op te noemen, maar jullie 
weten dat ik jullie bedoel. Dank dat jullie me altijd in alles hebben gesteund en niet opkeken 
van alweer de volgende stap in mijn leven. Ik ga heel gauw jullie weer de aandacht geven 
die jullie verdienen! Lieve schoonfamilie, wat fijn dat er altijd tijd is voor een goed gesprek. 
Lieve zussen. Lieve Alma. Lieve Omayra. Met jullie twee in mijn leven is de keuze voor mijn 
paranimfen snel gemaakt. Blij dat we al zoveel samen in ons leven hebben mogen delen. 
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Alma, ik vond het een eer om jouw paranimf te mogen zijn en het lijkt me dan ook fantastisch 
wanneer jij die van mij bent. Omayra, dankzij jou is het gelukt om dit proefschrift tot een mooi 
boekwerk te maken! Zou het toeval zijn dat onze ‘mannen’ het ook zo goed met elkaar kunnen 
vinden..? Ik heb er twee broers bij gekregen, en Floran niet te vergeten! Lieve papa en mama, 
ik waardeer het enorm dat jullie mij altijd gesteund hebben in alle plannen in mijn leven en in 
plaats van mij te sturen, gekeken hebben hoe jullie me konden helpen en ondersteunen. Lieve 
Ruben, ik weet dat jij nog meer naar dit moment hebt uitgekeken dan ik! Ja, we gaan weer 
vaker samen op vakantie! En, ja, ik hou van je. 
174
175
C
urriculum
 vitae
Curriculum Vitae
Marjanka Mingels werd op 23 mei 1983 geboren te Sibbe, gemeente Valkenburg a/d 
Geul, in Zuid-Limburg. Zij voltooide in 2001 haar middelbare schoolperiode aan het S.G. 
Sophianum te Gulpen. Dit zelfde jaar startte zij met de studie Voeding en Gezondheid aan 
de Wageningen Universiteit en behaalde hier haar propedeuse. In 2002 werd zij ingeloot 
voor de studie geneeskunde aan de Radboud Universiteit te Nijmegen en volgde een mooie 
studietijd. In het 2e en 3e jaar van haar opleiding nam zij tevens deel aan het Interdisciplinary 
Honours Programme van de Radboud Universiteit Nijmegen. Naast haar studie was zij verder 
nog betrokken bij de IFMSA (International Federation of Medical Students’ Association) en 
de werkgroep voor sekse specifieke geneeskunde (WSSG) onder begeleiding van prof. dr. 
A.L.M. Lagro-Janssen. Alvorens te starten met haar coschappen ging zij naar Nepal om 
hier ervaring op de doen in de gezondheidszorg door middel van diverse korte stages. De 
coschappen werden afgesloten met een senior coschap gynaecologie in het Dr. Horacio 
E. Oduber Hospitaal te Aruba alwaar het enthousiasme voor het vak een feit werd. Tijdens 
haar coschappen was zij betrokken bij wetenschappelijk onderzoek naar het sereuze type 
endometrium kanker, onder begeleiding van dr. T. Roelofsen en prof dr. L.F.A.G. Massuger. 
Na het behalen van haar artsexamen in maart 2010 kon zij als fulltime arts-onderzoeker 
starten bij de pijler gynaecologische oncologie, in samenwerking met de afdeling pathologie 
van het Radboudumc te Nijmegen (promotor prof. dr. L.F.A.G. Massuger, en copromotoren 
dr. J. Bulten, dr. M.A.P.C. van Ham en dr. A.A.G. van Tilborg). Het laatste deel van haar 
promotietraject combineerde zij met een baan als arts-assistent (ANIOS) gynaecologie in 
het Medisch Spectrum Twente te Enschede alwaar zij vanaf november 2013 tot juni 2015 
met veel plezier gewerkt heeft. In juli dit jaar zal zij in opleiding gaan tot gynaecoloog in het 
Catharina Ziekenhuis te Eindhoven (opleider dr. S.M.I. Kuppens). Marjanka woont samen met 
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